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CHAPTER 1
GENERAL INTRODUCTION AND 
OUTLINE OF THE THESIS




Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the 
gastro-intestinal tract and encompasses Crohn’s disease (CD), ulcerative colitis (UC) and 
IBD-unclassified (IBDU). Even though these subtypes are considered separate entities, all 
are characterized by relapsing chronic inflammation with periods of active disease (flares) 
alternated with quiescent periods (remission). Over the past decades, the incidence and 
prevalence of IBD have increased worldwide, putting significant burden on both individuals 
and the health care system. IBD prevalence is highest in developed countries and currently 
estimated at 0.3% in Europe.1 Disease onset is typically in early adulthood, and most patients 
are diagnosed between 20-40 years of age. Although the exact aetiology of IBD remains 
unclear, current evidence indicates that it involves a complex interplay between the immune 
system, the gut microbiome, genetic susceptibility and environmental factors. The current 
hypothesis is that a genetically susceptible person (host) experiences an environmental trigger 
that causes an inappropriate and perpetuating immune response towards the intestinal 
microbiota, resulting in chronic immune activation and intestinal inflammation.2,3
Disease characteristics
IBD is diagnosed based on a combination of clinical, endoscopic, radiological and 
histological findings.4 UC was the first subtype of IBD to be characterized as a distinct 
entity and is characterized by inflammation extending from the rectum and limited to the 
colon. Inflammation in UC is continuous and typically involves the superficial mucosal and 
submucosal layers. Depending on the extent of inflammation in the colon, patients can be 
classified as having proctitis (inflammation limited to rectum), left-sided colitis (inflammation 
up to the splenic flexure), or extensive colitis (beyond the splenic flexure).5 In CD, inflammation 
can be present along the entire gastrointestinal tract from the oral cavity to the anal region, 
but the terminal ileum and colon are most commonly affected.6,7 Inflammation in CD is 
characterised by a patchy distribution and begins with small superficial aphtous ulcers that 
can develop into larger transverse linear ulcers.8-11 The inflammation involves all layers of the 
bowel wall (transmural). 12,13 In some cases it is impossible to distinguish between CD and 
UC and these patients are labelled as IBDU.14-16 When features of the colectomy specimen 
are insufficient to allow a definitive diagnosis, patients are labelled as IBD-indeterminate 
(IBDI).17
Symptoms and disease manifestations
Patients suffer from a variety of gastro-intestinal symptoms including abdominal pain, 
diarrhea, bloody stools and urgency. In addition, systemic symptoms like anemia, anorexia 
and weight loss are common. Most patients suffer from fatigue, especially during active disease 
periods, but also when disease seems inactive. A significant proportion of patients experience 
extra-intestinal manifestations like arthralgia, arthritis, uveitis, primary sclerosing cholangitis, 
and skin abnormalities such as erythema nodosum, hidradenitis suppurativa and pyoderma 
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gangrenosum. Both intestinal and extra-intestinal symptoms negatively affect the physical 
well-being and quality of life of IBD patients.18-20
Natural history
The course of IBD is difficult to predict because disease onset, severity and duration of flares 
vary widely among patients. IBD is usually characterized by alternating episodes of flares 
and remission and can follow various patterns, from aggressive to indolent types.21-23 The 
majority of patients present with moderate-to-severe symptoms at diagnosis, but disease 
activity tends to decrease over time.24 Nearly all patients have a disease flare after the initial 
clinical episode and over 50% experience a relapse within the first year after diagnosis.25,26 
Recurrent flares or untreated inflammation are associated with irreversible damage to the 
gastro-intestinal tract such as bowel perforation or formation of strictures, abscesses and 
fistulas. CD patients in particular are prone to develop these disease complications because of 
transmural inflammation.12,13 Fistulas are inflammatory tracts that form a connection between 
the intestine and the skin, bladder, vagina or other bowel segments. Disease complications 
develop in 70-75% of CD patients and are associated with significant morbidity and often 
require hospitalization and surgery.12,13,27-31 These disease complications are rare in UC because 
of superficial bowel inflammation. However, data suggest that a 10-15% of UC patients 
experience disease progression to extensive colitis and some patients do require surgery 
(colectomy).25,32 More importantly, IBD patients are at increased risk for colorectal cancer, a 
result of chronic (histological) inflammation in the colon, causing continuous regeneration 
of bowel cells.33
MEDICAL TREATMENT
Since IBD is a complex, multifactorial disease with a progressive natural history and 
invalidating symptoms, and a ‘cure’ has not been identified, most patients require long-
term medical therapy with anti-inflammatory drugs or surgery to treat disease flares and 
complications and to reduce the risk of a relapse. Over the years several new anti-inflammatory 
drugs targeting different aspects of the immune system, have become available. Classification 
and positioning of these different IBD drugs rely on their properties; induction therapies are 
characterised by a rapid onset of action to induce response and remission, and maintenance 
therapies to maintain remission are appropriate for long-term use. Some drugs are fit both 
as induction and maintenance therapies.
Corticosteroids were amongst the first drugs used in the treatment of IBD and have proven 
to be effective in induction of disease remission.34,35 These drugs bind to the glucocorticoid 
receptor and stimulate transcription of anti-inflammatory genes and inactivates pro-
inflammatory transcription factors (nuclear factor κβ, activator protein-1) thereby preventing 
activation of inflammatory mediators (e.g. leukotrienes and cytokines such as IL-1 and IL-
6).36,37Current treatment strategies limit the use of corticosteroids to induction courses. 
Moreover, corticosteroid-sparing strategies have been advocated over recent decades since 
glucocorticosteroids are insufficiently effective as maintenance treatment and associated with 
1
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serious side effects, especially in high dosages or long-term use. Side effects include infections, 
hyperglycemia, psychosis, osteopenia, growth failure and weight gain.38,39
Aminosalicylates, mainly 5-aminosalicylic acid (5-ASA) serve both as induction therapy and 
maintenance treatment and might reduce the risk of colonic cancer.40 Several mechanisms 
of action for 5-ASA have been proposed including reduction of prostaglandin synthesis via 
local inhibition of pro-inflammatory cytokines and oxygen-free radicals, and inhibition of 
T-cell proliferation and activation.41,42 It is an effective treatment in the majority of UC patients 
(90%), particularly in those with mild to moderate ulcerative colitis.43 5-ASA has a favourable 
safety profile and is well tolerated with subsequent high treatment adherence. 5-ASA can be 
administered orally or rectally (suppository or enema). Local treatment with suppositories 
or enemas is an appealing treatment option to manage patients with inflammation limited 
to the rectum and left-sided colon in certain patients. Although frequently prescribed in the 
past, the efficacy of 5-ASA in CD has been questioned and current guidelines advice against 
the use of 5-ASA for induction of remission.44,45 Cases of impaired renal function have been 
sparsely mentioned usually managed with drug withdrawal.46
Immunomodulators comprise purine analogues (azathioprine, mercaptopurine, tioguanine), 
folate antagonists (methotrexate) and calcineurin inhibitors (ciclosporin, tacrolimus). Purine 
analogues (i.e. azathioprine (AZA), mercaptopurine (MP) and tioguanine (TG) have been 
used in medical treatment of IBD with over 50 years of global experience.47 Thiopurines were 
considered after therapy failure of aminosalicylates and in steroid-refractory or steroid-
dependent IBD patients, but are nowadays applied as a maintenance strategy, and in 
moderate CD as a primary treatment. Advantages include a steroid-sparing effect, low costs 
and its association with a reduced risk of colorectal carcinoma.48,49 A recent study showed that 
thiopurine continuation in UC was associated with a lower rate of hospital admission and a 
reduced risk of progression of disease extent and colectomy.50 Also, in the past decades they 
have been used in combination treatment alongside a biologic agent with proven synergistic 
effects and reduction of antidrug-antibody formation (immunogenicity).51 AZA and MP are 
pharmacologically inactive pro-drugs, which are converted by three competing enzymatic 
pathways to produce, amongst others, the pharmacologically active metabolites 6-thio-
guanine nucleotides (6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMPR). TG 
undergoes direct enzymatic conversion towards the formation of 6-TGN (Figure 1).
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Figure 1. Simplified model of thiopurine metabolism.
6-MP, 6-mercaptopurine; 6-TGN, 6-thioguanine; 6-MMPR, 6-methylmercaptopurine ribonucleotides; 
6-TG, 6-thioguanine; HGPRT, hypoxantine-guanine phosphoribosyl transferase; TPMT thiopurine 
S-methyltransferase; 6-TGTP, 6-thioguanosine 5’ triphosphate.
The immunosuppressive effects and predominantly assigned to the metabolite 6-TGN (more 
specifically 6-thioguanine triphosphate) that inhibits the activity of Rac1, thereby inducing 
apoptosis of activated T lymphocytes.52,53 Another route of immunosuppression involves 
conversion of 6-TGN into deoxy-6-thioguanosine, which causes cytotoxicity by incorporation 
into DNA and RNA.54 Clinical effectiveness is correlated with 6-TGN, but high levels are 
associated with myelotoxicity. Conversely, the metabolites 6-MMPR have been associated 
with therapy refractory disease and adverse events such as hepatotoxicity.55-57 The therapeutic 
window of thiopurines is small and some patients withdraw from treatment because of lack 
of efficacy or adverse events.58 Both efficacy and toxicity of thiopurines are dependent on 
the extent to which 6-TGN and 6-MMPR metabolites are produced and often varies between 
patients because of large inter-individual variation in thiopurine metabolism.55-58 Genetic 
polymorphisms of the thiopurine metabolizing enzymes thiopurine S-methyl transferase 
(TPMT) and NUDT15 in part explain variable enzyme activity and have been associated with 
the development of myelotoxicity. Nowadays, genetic testing for TPMT mutations before the 
start of thiopurine treatment is suggested to avoid (early) myelotoxicity.59 Another strategy 
to avoid therapy withdrawal is therapeutic drug monitoring (TDM) using 6-TGN and 6-MMPR 
metabolite measurements to adjust thiopurine dose in patients with inadequate response or 
adverse events. Patients with a ‘skewed metabolism’ produce high levels of the potentially 
1
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toxic 6-MMPR, whereas favourable 6-TGN levels remain below therapeutic range and are 
therefore particularly at risk of thiopurine withdrawal. Two important optimization strategies 
can be considered in patients on AZA or MP with 6-MMPR associated intolerance or treatment 
failure. First, the addition of allopurinol, a xanthine oxidase inhibitor, to a reduced thiopurine 
dose redirects the thiopurine metabolism towards 6-TGN formation, resulting in increased 
6-TGN levels and decreased 6-MMPR levels.60,61 Second, switching treatment to TG bypasses 
several intermediate metabolites associated with the majority of adverse events.62-65 Both 
strategies improve effectiveness and tolerability of thiopurines.66
The folate antagonist methotrexate (MTX) affects survival of immune cells by inhibition of 
cell proliferation, suppression of pro-inflammatory cytokine production and induction of 
apoptosis.67,68 MTX has moderate efficacy in CD as a steroid-sparing induction therapy, but 
mainly as a maintenance therapy. MTX is largely inneffective in UC.69-71 As with thiopurines, MTX 
can be used as monotherapy or in combination with biologics to reduce immunogenicity. Up 
to one third of patients discontinue MTX because of intolerance, and cases of myelotoxicity, 
hepatotoxicity and interstitial pneumonitis have been described.72
Although less frequently prescribed, systemically applied calcineurin inhibitors are an 
established therapeutic option for steroid-refractory ulcerative colitis.73 Calcineurin inhibitors 
bind to specific intracellular receptors and act by blocking the activation of transcription 
factor nuclear factor of activated T-cells and thereby inhibit cytokine gene transcription and 
promote T-cell apoptosis.74,75 Ciclosporine-A has been used as an intravenous rescue therapy 
for acute severe colitis.73,76 Tacrolimus was also studied as a local therapy and found to be safe 
and effective as an induction therapy.77,78
The introduction of biologics in the late nineties has brought substantial advances in the 
medical treatment of IBD. The first biologics were directed towards the pro-inflammatory 
cytokine ‘tumor necrosis factor α’ (i.e. anti-TNF) produced in various cells in the inflamed 
gut of IBD patients.79,80 Anti-TNF agents are large protein molecules and consist of solely 
human (adalimumab, golimumab and certolizumab) or both human and mouse (infliximab) 
monoclonal antibodies. These drugs have a rapid onset of action and are potent for both 
inducing remission, maintaining remission and reduce the need for hospitalization and 
surgery.81,82 Despite the proven benefit of these therapies, a significant number of patients 
(30%) will not respond to anti-TNF or fails to maintain response (40%).83-87 The development 
of anti-drug antibodies with neutralizing properties that reduce the efficacy of the drug 
(immunogenicity), play an important role in treatment failure.88 Concomitant use of 
immunomodulators has a beneficial effect, both synergistic in effectiveness as well as in 
decreasing the risk of immunogenicity.89 Years later, new groups of biologics have entered the 
market such as selective anti-integrins (vedolizumab, natalizumab) some with gut-selective 
anti-inflammatory effects, and anti-interleukins (ustekinumab). Another drug group that has 
been explored concerns new small molecules including Janus kinase inhibitors (tofacitinib).90-93 
At the time of writing this thesis, a plethora of new drugs are being tested in clinical trials 
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in IBD. Many of these new therapeutic approaches have been developed on the basis of 
studies in IBD mouse models, genetic studies, analyses of IBD tissues and new insights into 
inflammatory pathways in other chronic inflammatory disorders, such as rheumatoid arthritis 
and psoriasis.94-96
THERAPEUTIC APPROACH
The therapeutic approach in IBD management has evolved considerably over the years 
since treatment goals have shifted, and are facilitated by the increasing number of available 
therapies. In the past, treatment in IBD focussed primarily on symptom relief induction and 
maintenance of clinical remission and ultimately corticosteroid-sparing management and 
avoiding surgery. Patients were treated following a “step-up” approach where the different 
medication classes are successively introduced after failure of a previous drug, starting with 
the least aggressive therapy (Figure 2). 97Therapeutic approaches driven only by symptomatic 
control of disease activity failed to change the natural disease course.98,99 Therefore, the 
therapeutic paradigm changed to an ‘accelerated step-up’ approach’ in which more aggressive 
medication is initiated early in the treatment combined with more stringent assessment of 
disease activity and rapid therapeutic escalation to achieve tight control of inflammation and 
prevent “bowel damage”. 100,101 Current treatment goals comprise clinical and steroid-free 
remission, mucosal healing, and prevention of hospital admission, surgery, inflammatory-
related malignancy and improvement of quality of life.100-108 Another strategy is the ‘top-down’
approach in which biologics are introduced early in the disease course, usually combined with 
an immunomodulator (Figure 2).
Figure 2. IBD treatment pyramid
These strategies are mostly applied in patients presenting with severe disease characteristics, 
disadvantageous prognostic factors or early signs of therapeutic failure. It has been 
shown that the top-down approach was more effective for induction of remission than the 
1
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conventional step-up approach.109 The precise efficacy of the top-down approach in the long 
term is not completely clear, although some studies report reduced complications and surgical 
rates.110,111
RISKS IN MEDICAL TREATMENT
IBD is a chronic disease requiring long-term medical treatment in most patients. Although 
these therapies have a clear benefit in IBD, certain treatment-associated risks need to 
be considered when choosing a therapeutic strategy. While disease-related morbidity is 
feared in step-up strategies, the risk of overtreatment with top-down strategies is almost 
inevitable. Patients are exposed to drug-specific adverse events as discussed above but the 
risk of infections and certain types of cancer is also increased. On the one hand, treatment 
of IBD aims for mucosal healing and deep remission, thereby decreasing the risk of intestinal 
infections related to intestinal lesions and reducing the risk of cancers associated with chronic 
mucosal inflammation. On the other hand, immunosuppressive treatments have been shown 
to promote (opportunistic) infections and certain types of cancer in IBD patients.112 The nature 
and magnitude of the increased risk of infections and cancer vary with patient sex, age and 
immunosuppressive drug class.
Infections
The severity of infections varies among patients and can present as mild infections, serious 
infections that require hospitalization and life-threatening opportunistic infections that only 
occur in immune-compromised patients.113-115 The majority are mild viral infections, usually 
related to immunomodulator exposure, but cases of fatal infections in young patients have 
been described.116,117 There is an excess risk of all types of infections in patients exposed to 
corticosteroids, immunomodulators and/or anti-TNF agents, particularly older patients.114,118 
The risk of opportunistic infections is highest in the setting of combination therapy with 
immunomodulators and anti-TNF agents, or exposure to corticosteroids.114,119,120 Myelotoxicity, 
a known adverse event of thiopurine therap, further increases the risk of opportunistic 
infections.113,121 To timely detect myelotoxicity, frequent monitoring of the full blood count 
(FBC) is performed throughout therapy with thiopurines or methotrexate. Also, patients 
are usually vaccinated before initiation of immunomodulators or biologics for viruses like 
hepatitis B, and also screened for latent infections that can reactivate in the setting of 
immunosuppressive treatment such as tuberculosis.
Cancer
IBD patients are 2–6 times more likely to develop colorectal cancer (CRC) than the general 
population.122 The risk of CRC is higher in UC than in CD patients, and increases with disease 
duration.123,124 Persistent histological inflammation is also a prerequisite for the development 
of CRC and therefore the risk is particularly high in patients with chronic active disease.125,126 
In addition, IBD patients are at increased risk of extra-intestinal cancers including skin cancer 
and lymphoproliferative disorders and cervical neoplasia.14,127,128 Immunomodulators and 
anti-TNF agents have been associated with hematologic and dermatologic malignancies.102 
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Thiopurines and MTX appear to increase the risk of non-melanoma skin cancer both during 
active use of the drug and possibly after the medication is discontinued.129-132 Patients exposed 
to anti-TNF agents may be at increased risk of melanoma.131 To detect skin cancer, IBD patients 
on maintenance treatment with immunomodulators and/or biologic agents are yearly referred 
to a dermatologist for full body examination.
Patients treated with thiopurines have a three- to fivefold increased risk of developing 
lymphoma, which is probably the most feared complication.129 This increased risk of lymphoma 
is also related to longer disease duration and older age, particularly in men.129 Also, anti-
TNF treatment and in particular combination treatment with anti-TNFs and thiopurines have 
also been associated with lymphoma development.133,134 In addition, combination treatment 
with thiopurines and anti-TNFs has been associated with the hepatosplenic T-cell lymphoma, 
especially in young males.129,135 There is no specific prevention of immunosuppressive induced 
hematologic malignancies and the only preventative strategy is to limit the use and duration of 
immunosuppressive drugs, especially in high risk patients (men older than age 65 years).112
Several studies suggest that IBD women are at increased risk of cervical dysplasia and cervical 
cancer caused by the human papillomavirus (HPV), but the role of disease characteristics and 
immunosuppression in the pathogenesis is unclear.136-140 Female patients are encouraged to 
adhere to cervical screening programs.
CLINICAL DECISION MAKING
Many new IBD drugs targeting different immunological pathways have been, and still are 
being, developed to increase the chance of patients responding to a treatment. The majority of 
health-care costs for IBD are explained by medical therapies and thus there is a clear need for 
optimal use of different drugs to avert under treatment and overtreatment. There are multiple 
barriers to overcome, in order to achieve the ultimate goal: select the right drug for the right 
patient at the right time. Physicians prescribing immunosuppressive treatment to IBD patients 
are faced with several issues: 1) Selection of an appropriate and effective treatment strategy 
for the patient; 2) Avoid adverse events and (long-term) disease-related and treatment-related 
complications; 3) Health-care costs.
Clinical decision-making needs to be adapted to patients’ age, sex and disease characteristics 
and correct phenotyping of the patient before initiation, followed by re-evaluation and 
modification of the therapeutic strategy when treatment goals are not (yet) reached. 
Treatment escalation or optimization should be considered in patients with inadequate 
response or intolerance. These optimization strategies include dose increase, shortening of 
treatment interval, step-up from local to systemic treatment, addition of therapy or switch 
to a different treatment. Disease monitoring but also TDM has allowed for early detection 
and prevention of loss of response, thereby optimizing drug use and cost-effectiveness. In 
patients that achieve sustained remission, safety concerns like adverse events, infections and 
cancer but also health-care costs and quality of life prompt de-escalation strategies. These 
1
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strategies comprise dose-reduction, drug switch to local treatment or step-down treatment, 
drug withdrawal in combination treatment or complete cessation, but also less stringent 
monitoring. The risk of relapse and complications should be balanced against the risk of severe 
adverse events and different aspects of quality of life.
Standard treatment typically depends on the extent of involvement en disease severity. 
However, classification based on clinical symptoms does not always predict the disease course 
of the patient. Despite significant efforts, also in the genetic field, there is on-going uncertainty 
when it comes to predicting therapy response in the individual patient. Treatment response 
and (short-term) adverse events have been widely studied in randomized controlled trials 
(RCTs), performed under strict conditions and selection of patients. Therefore, their external 
validity is limited as the patient population in clinical practice is more heterogeneous with 
different disease characteristics, age categories, comorbidities, and less stringent monitoring. 
Studies in real-life clinical practice are essential in visualizing actual effectiveness, drug 
survival and (long-term) safety aspects of treatment. In addition, data from real-life clinical 
cohorts may also identify more rare risk factors for treatment failure and adverse events 
and thereby yield new targets for treatment optimization to improve IBD treatment in the 
future.
AIMS AND OUTLINE OF THIS THESIS
This thesis aims to provide insight into several safety aspects and opportunities with current 
immunosuppressive treatment in inflammatory bowel disease. The thesis is divided in three 
sections.
The first part of this thesis addresses monitoring efficacy and safety of immunosuppressive 
treatment in inflammatory bowel disease. To increase the chance of patients responding 
to a treatment, it is of crucial importance to identify patients that are prone to treatment 
failure and could benefit from treatment modification. TDM of drug metabolites as well as 
laboratory monitoring of leucocytes and liver enzymes both add to the success of thiopurine 
therapy, since optimization of dosing to achieve optimal disease response and avoidance 
of toxicity are essential components. Monitoring strategies need to balance the benefits 
of timely adjustment of therapy and limit the burden of monitoring. Chapter 2 describes a 
cohort study evaluating the clinical relevance and prognostic value of a routinely established 
skewed thiopurine metabolism. Continuing on this, in Chapter 3 we describe the uncommon 
adverse event of myelotoxicity related to extremely high concentrations of 6-MMPR in patients 
receiving conventional thiopurine derivatives. In Chapter 4 we investigate drug survival of 
low-dose thiopurine-allopurinol combination therapy. Furthermore, we explore risk factors for 
treatment cessation of this thiopurine optimization strategy. In Chapter 5 we assess incidence 
rates and clinical consequences of myelotoxicity and hepatotoxicity (i.e. laboratory toxicity) 
within current laboratory regimen in thiopurine maintenance therapy. Special consideration 
binnenwerk_joany.indd   16 7-12-2020   13:27:22
| 17
General introduction
is required in female IBD patients, as the sex of the patient can have profound influences on 
drug metabolism and efficacy. Chapter 6 focuses on drug survival of adalimumab and possible 
other sex differences in a cohort of patients with CD.
Part two of this thesis focuses on one of the extra-intestinal neoplastic complications in IBD 
patients: cervical dysplasia and cancer. Cervical cancer is the fourth most common type 
of cancer in women worldwide, caused by a persistent HPV infection. The risk of cervical 
dysplasia and cancer in IBD women has been studied, but results are conflicting and most of 
these cohorts lack details on drug exposure and longitudinal follow up. In Chapter 7 we assess 
prevalence and persistence of cervical dysplasia and cancer in a large cohort of IBD women 
from the Dutch IBD Biobank compared to the general population. We evaluate whether certain 
IBD disease characteristics are associated with cervical abnormalities. It is hypothesized that 
chronic use of immunosuppressive drugs is a risk factor for cervical dysplasia and cancer but 
the association is not well understood. Therefore, we aim to assess the role of exposure to 
immunosuppressive drugs in development of cervical dysplasia and cancer in large cohort 
of IBD women in Chapter 8.
In the third part of this thesis we investigate rectal tacrolimus as a new treatment option for 
ulcerative proctitis. The majority of UC patients present with proctitis and therefore local 
treatment with suppositories are an attractive treatment option as systemically administered 
drugs are often associated with adverse events and higher costs. In Chapter 9 we assess the 
efficacy of topical tacrolimus compared to topical beclomethasone as an induction therapy 
for ulcerative proctitis in a randomised controlled trial. Finally in Chapter 10 the main findings 
of this thesis are summarized and discussed.
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ROUTINELY ESTABLISHED SKEWED 
THIOPURINE METABOLISM 
LEADS TO A STRIKINGLY HIGH 
RATE OF EARLY THERAPEUTIC 
FAILURE IN PATIENTS WITH 
INFLAMMATORY BOWEL DISEASE
Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de 
Boer NK
Therapeutic drug monitoring 2015 Dec; 37(6):797-804.




Background: The conventional thiopurines azathioprine and mercaptopurine are considered 
maintenance immunosuppressive drugs of choice in the treatment of inflammatory bowel 
disease (IBD). Unfortunately, treatment is often discontinued due to adverse events or 
refractoriness, retrospectively associated with high levels of the thiopurine metabolites 
6-methylmercaptopurine ribonucleotides (6-MMPR). Patients with a clinically “skewed” 
thiopurine metabolism may be particularly at risk for therapy failure. We determined the 
predictive value of this pharmacological phenomenon in IBD patients during regular 
thiopurine therapy.
Methods: Clinical effectiveness and tolerability of weight-based thiopurine therapy 
were determined in all IBD patients displaying a skewed metabolism (ratio 6-MMPR/6-
thioguaninenucleotide (6-TGN) >20). All samples were routinely assessed between 2008-2012, 
as part of standard clinical follow-up after initiation of conventional thiopurine therapy.
Results: Forty-one (84%) out of 49 included IBD patients discontinued thiopurines (55% 
female, 53% with Crohn’s disease) with a median duration of 14 weeks (range 7-155). The 
majority of patients with a skewed metabolism discontinued thiopurines due to adverse events 
(55%) or refractoriness (12%). The most commonly observed adverse event was hepatotoxicity 
(18 patients, 37%). Median 6-TGN level was 159 pmol/8x108 RBC (range 46-419), median 6-MMPR 
level was 11020 pmol/8x108 RBC (range 3610-43670) and the median 6-MMPR/6-TGN ratio was 
72 (range 29-367). Thiopurine therapy failure was associated with a ratio above 50 (p<0.03). 
Hepatotoxicity occurred more frequently in patients with an extremely skewed metabolism 
(6-MMPR/6-TGN ratio >100) (p<0.01).
Conclusions: This study demonstrates that a routinely established skewed metabolism is a 
major risk factor for future thiopurine failure in IBD patients. These observations imply that 
routine thiopurine metabolite measurements may be used as a prognostic tool to identify 
those patients with an aberrant skewed metabolism at an early stage, possibly benefitting 
from therapy adjustments.
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INTRODUCTION
Conventional immune-modulating thiopurine therapy, consisting of azathioprine (AZA) 
and mercaptopurine (MP), has proven successful in the treatment of inflammatory bowel 
disease (IBD) for induction treatment, but primarily for maintenance of remission. It is 
therefore considered to be the immunosuppressive drug of choice.1-3 Unfortunately up to 
50 percent of patients discontinue thiopurine therapy within 2-years after initiation, mainly 
due to the development of intractable adverse events.1-4 Azathioprine and MP are both 
pharmacologically inactive pro-drugs, which are converted by three major competing 
enzymatic pathways to produce, amongst others, the metabolites 6-thio guanine nucleotides 
(6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMPR). In several studies and 
a meta-analysis, it has been demonstrated that 6-TGN are the pharmacologically active 
metabolites predominantly responsible for the immunosuppressive effects, and that these 
are correlating with clinical effectiveness.5-7 Conversely, the metabolites 6-MMPR have been 
associated with therapy refractory disease, induction of hepatotoxicity and other adverse 
events.7-9 Moreover, a 6-MMPR/6-TGN ratio above 20 is associated with therapeutic inefficacy.10 
Recent studies conclude that 15-30 percent of patients discontinue thiopurine therapy due to 
adverse events8, allegedly related to a skewed thiopurine metabolism profile.11 These so-called 
‘ultramethylators’ preferentially produce excessive amounts of the potentially toxic 6-MMPR 
metabolites, whereas favorable 6-TGN levels remain below therapeutic range.12-14 These 
patients are particularly at risk of thiopurine failure due to (hepato)toxicity or ineffectiveness. 
Although the enzymatic pathways leading to the formation of this grossly elevated 6-MMPR 
level have partly been unraveled, the prognostic clinical value of a skewed thiopurine 
metabolism for successful thiopurine therapy in IBD patients remains to be assessed.15 The aim 
of this study was to establish the clinical relevance of a routinely established aberrant skewed 
thiopurine metabolism in IBD patients by determining the tolerability and effectiveness of 
ongoing treatment in these patients.
METHODS
Study design
The data of this retrospective study were based on a 4-year inception cohort from January 
1st 2008 until December 31st 2011. The Pharmacy department of the VU University Medical 
Center (Amsterdam, The Netherlands) operates as the sole department for determination of 
metabolite concentrations of 6-TGN and 6-MMPR. Their database was searched to identify all 
patients demonstrating a skewed thiopurine metabolism, arbitrarily defined as a 6-MMPR/6-
TGN ratio above 20, within the predefined study period.12-14 These patients were cross-checked 
with the IBD databases and the patient registration system of our tertiary referral hospital (VU 
University Medical Center). This database was further scrutinized with ascertainment of (digital) 
chart review to identify only those IBD patients in whom conventional thiopurine therapy 
was initiated and displayed a skewed metabolism detected on initial routine determination, 
2
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generally 4 to 12 weeks after initiation of thiopurine therapy as part of our standard local 
protocol.1,12 So, essentially, all consecutive IBD patients showing a skewed metabolism of 
thiopurines were included for analysis. Patients were excluded from analysis who were 
referred for thiopurine metabolite measurements, during the study period, for specific 
therapy related problems (adverse events, clinical refractoriness or non-compliance), and 
therefore lacked the initial routine thiopurine determination. As per local treatment guidelines 
all patients were monitored by an IBD-specialized nurse in the first 3 months of thiopurine 
initiation as well as during follow up. The minimal follow-up time was 1 year (till December 31st 
2012). Through chart review, we retrospectively determined patient characteristics, treatment 
characteristics, effectiveness and tolerability of thiopurine therapy. Patients with a history 
of hepatitis B, C or D, history of severe pancreatitis, impaired hepatic function (>2 times the 
upper limit of normal of alkaline phosphatase (AP), gamma-glutamyltransferase (γ-GT), and/or 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) activities) at baseline and/
or persistent bone marrow suppression (leukocyte count <3.5x109/L or platelet count <100 x 
109/L) at baseline, were excluded from analysis. The upper limits for liver tests were defined 
as AP 120 U/L, γ-GT 55 U/L, ALT 45 U/L and AST 35 U/L.
Patient characteristics
Standard demographic and disease-related data were collected, including: gender, weight, 
age at diagnosis, duration of IBD in years at initiation of thiopurine treatment and surgical 
history. All patients were classified according to the Montreal classification.16,17
Treatment characteristics
Azathioprine and MP were prescribed according to Dutch IBD and ECCO guidelines, based 
on individual weight (targeted at 2-2.5 mg/kg for AZA, and 1-1.5 mg/kg for MP).16,18 The local 
start-up protocol for thiopurines includes low dose prescription in the first week, followed 
by full dose therapy following ascertainment of tolerance, clinically and in blood in order to 
avoid (severe) leukopenia in patients with non-functional thiopurine S-methyltransferase 
(TPMT) variants. Full blood count, renal function, ALT, AST, AP and/or γ-GT performed at 
initiation of therapy (baseline) and at the time of metabolite assessment were documented. 
The following variables regarding the use of thiopurines were collected: type of thiopurine 
(AZA or MP), dosage and age at initiation of thiopurine therapy. Furthermore, data regarding 
the use of concomitant IBD related medication such as 5-ASA (5-aminosalicylic acid), steroids 
and biologicals were documented in order to reflect the level of complexity of enrolled IBD 
patients. In particular the use of systemic corticosteroids prescribed for an IBD indication, 
that exceeded the estimated thiopurine induction of remission period of 3 months. Patients 
were excluded from the study design when thiopurines were primarily prescribed for a non-IBD 
indication. Patients that initiated 5-ASA compounds simultaneously at the time of thiopurine 
initiation were excluded from analysis. Patients with concomitant use of allopurinol at 
baseline, angiotensin converting enzyme-inhibitors, trimethoprim, cimetidin or indomethacin 
were excluded from analysis as these drugs may interact with thiopurine metabolism.3,19,20
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Thiopurine metabolite measurements
A skewed metabolism was defined as a 6-MMPR/6-TGN ratio above 20, which closely reflects 
the ratio of target concentrations for both metabolites, i.e. 6-MMPR <5700 pmol/8x108 red 
blood cells (RBC) and 6-TGN >235 pmol/8x108 RBC.5,14 The extent of ultramethylation was 
arbitrarily defined as mild (ratio 20-50), moderate (ratio 50-100) and severe (ratio >100). The 
measurements were performed in the laboratory for Clinical Pharmacology and Pharmacy 
at the VU University Medical Center. The levels of 6-TGN and 6-MMPR metabolites in RBCs 
were measured by a validated high performance liquid chromatography assay, according 
to the method described by Dervieux and Boulieu.21,22,23,24 This method has been used in the 
laboratory for more than 8 years to monitor thiopurine metabolites in more than 10.000 
samples from Dutch hospitals. The accuracy is 107%, the between-assay imprecision is 6,7%. 
The laboratory participates in the thiopurine proficiency testing program of the Association for 
Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology in the Netherlands. 
Blood samples for 6-TGN and 6-MMPR metabolite measurements were obtained at least 4 
weeks after initiation of AZA or MP in order to determine steady-state levels.25,26 As part of 
the local treatment protocol, metabolites were generally measured 8 weeks after therapy 
onset as a routine.
Effectiveness and tolerability
Clinical effectiveness was assessed by means of a global physician’s assessment, indicative 
of quiescent disease, supported by systemic steroid withdrawal for >3 months and the 
absence of inflammation on laboratory findings, such as C-reactive protein (CRP) and/or 
faecal calprotectin, and radiological, endoscopic and histopathological reports (if present). 
Refractoriness was defined as the inability to achieve the above mentioned criteria for 
clinical effectiveness and was subdivided into: primary non-response after 3 to 6 months of 
treatment or loss of therapeutic response after more than 6 months of treatment. Sustained 
clinical benefit was defined as ongoing use of the initiated thiopurine therapy at the time of 
data collection at the last outpatient contact before the end of study period, or intentional 
discontinuation of successful thiopurine therapy at patient’s request at any date before 
end of study. Failure was defined as cessation of thiopurine therapy due to refractoriness, 
or in consequence of the occurrence of any intolerable AE. Initiation of allopurinol and/
or biologicals therapy concomitant with a thiopurine was also considered therapy failure. 
An adverse event to thiopurine administration was defined as any reaction, side effect or 
untoward event that occurred during the course of thiopurine treatment. Adverse events 
were subdivided, according to Dutch IBD guidelines, into gastro-intestinal complaints like 
nausea and vomiting, general malaise, arthralgia, dermatological eruptions, hepatotoxicity, 
myelosuppression, pancreatitis, lymphomas, infectious complications and others such as 
alopecia or myalgia.16 Hepatotoxicity was defined as twice or more the upper limit of normal 
of ALT, AST, AP and/or γ-GT activities, supported by histopathological findings, if present. 
Furthermore, with retrospective ascertainment of chart review, patients were excluded in case 
the diagnostic work-up of the treating physician demonstrated signs of viral, auto-immune or 
steatotic causes of hepatotoxicity. Myelosuppression was defined as a leukocyte count <3.5 
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x 109/L and/or platelet count <100 x 109/L, according to the Common Terminology Criteria for 
Adverse Events (version 3.0).
Data analysis
Statistical analysis was performed using SPSS for Windows version 20.0. Quantitative 
data were expressed as means with standard deviations for continuous data, percentages 
for categorical data, or in case of non-normal distributions as medians with range. Group 
differences for categorical variables were assessed using Chi-square or Fisherman’s test. 
Group differences for continuous variables were assessed using the ANOVA, Mann-Witney 
or Students T-test for paired or individual data. Variables possibly predicting outcomes of 
thiopurine therapy discontinuation were investigated by multivariate regression analysis. 
For proper comparison with existing literature, which often utilizes the Lennard method to 
determine the metabolite levels, 6-TGN levels were recalculated by dividing the 6-TGN outcome 
by a converting factor of 2.6.24,27 The 6-MMPR metabolite outcomes are comparable in both 
methods. Multiple documented AEs in one patient were separately counted, due to which 




Of the estimated total IBD population of approximately 2000 patients treated at the VU 
University Medical Center, around 800 patients (i.e. 40%) were treated with thiopurine 
immunosuppression and 140 patients treated with conventional thiopurines displayed 
an aberrant thiopurine metabolism (6-MMPR/6-TGN ratio above 20) between January 1st 
2008 and December 31st 2011. Seventy-four patients (53%) were excluded due to alternative 
indicative factors for thiopurine metabolite assessment (i.e. suspected thiopurine induced 
AE or clinical refractoriness) or insufficient data to deduce the indication for metabolite 
assessment. Twelve patients were excluded from analysis based on uncertainty of definitive 
IBD diagnosis or concomitant use of ACE-inhibitors (n=2). One patient was formerly diagnosed 
with an autoimmune hepatitis with severe liver test abnormalities and was therefore excluded 
from analysis. Four patients were lost to follow up, leaving a total of 49 patients in which 
metabolite levels were determined as a routine for further analysis. Twenty-seven patients 
were female (55%) and the median age of diagnosis was 27 years (range 18-79). Twenty-six 
patients (53%) were diagnosed with Crohn’s disease (CD), mainly located in the terminal ileum 
and colon region. Twenty-three patients (47%) were diagnosed with ulcerative colitis (UC). 
The majority of UC patients (52%) had an extensive colitis. Baseline patient demographics 
and disease characteristics are depicted in Table 1.
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Table 1. Patient and Treatment Characteristics
N = 49
Gender M : F (n) (%) 22 : 27 (45 : 55)
CD Patients (n) (%) 26 (53)
UC Patients (n) (%) 23 (47)
Median age at diagnosis (years) [range] 27 [18-79]
Smoking status (active/former : never) 21 : 28























UC - Montreal classification: Extent
 ulcerative proctitis





History of IBD related surgery (n) (%) 14 (29)
AZA : 6-MP (%) 4 : 45 (8 : 92)
Median thiopurine dose (mg/kg)
 AZA (n = 3, 1 missing) [range]
 6MP (n = 45) [range]
1.98 [1.69-3.13]
1.20 [0.60-2.08]
Systemic steroids >3 months at induction of remission (n) (%)
 Median duration (weeks) [range]
10 (20)
41 [15-125]
5-ASA during thiopurines (n) (%) 26 (53)
Biological at induction (n) (%) 6 (12)
F, Female; M, Male ; CD, Crohn’s Disease; UC, Ulcerative colitis; 5-ASA, aminosalicylates.
Treatment characteristics
At the time of thiopurine metabolite measurement, 45 patients (92%) were treated with MP 
with a median dose of 1.20 mg/kg (range 0.6-2.08) and 4 patients (8%) with AZA with a median 
dose of 1.98 mg/kg (range 1.69-3.13). Prolonged use of systemic glucocorticoids prescribed 
for an IBD indication, at remission-induction that exceeded the estimated period of 3 months, 
occurred in 9 patients with a total median usage of 41 weeks (range 15-125). Twenty-six patients 
(53%) were using 5-ASA compounds as maintenance strategy alongside thiopurine therapy, 
generally in case of UC (20 patients, 77%). Twelve (24%) patients had documented use of AZA 
in the past. Ten of these patients switched to MP and two patients were re-challenged with 
AZA. Reasons for historical discontinuation of preceding AZA-therapy were ineffectiveness 
(n=6), intolerance (n=2), or issues of compliance (n=1). Two patients discontinued AZA at 
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their own initiative and two patients due to prolonged remission of disease. All therapeutic 
characteristics are also depicted in Table 1.
Routinely established thiopurine metabolite measurements
All metabolite concentrations are depicted in Table 2. Overall, routine metabolite level 
determination was performed after a median duration of 8 weeks (range 4-22) after initiation 
of thiopurine treatment. Nine patients with a skewed metabolism of MP showed metabolite 
levels during the previous weight-based AZA usage within normal ranges.
Table 2. Thiopurine Metabolites and Laboratory Results
6-TGN pmol/8x108 RBC (n=49) 159 [46 - 419]
6-MMPR pmol/8x108 RBC (n=49) 11020 [3610 - 43670]
Ratio 6-MMPR/6-TGN (n=49) 72 [29 - 367]
CRP mg/l (n=48) 7.8 [<2.5 – 63.7]
Hb g/dl (n=49) 7.8 [5.8 – 9.8]
Erythrocyte count 103/μl (n=47) 4.1 [3.1 – 5.3]
Platelet count 103/μl (n=47) 332 [102 – 603]
Leukocyte count 103/μl (n=48) 6.4 [1.9 - 22.2]
MCV (n=46) 91 [79 - 105]
Creatinine (n=48) 67 [37-100]
AP U/l (n=46) 70 [41 - 134]
γ-GT U/l (n=45) 26 [7 - 128]
AST U/l (n=35) 26 [14 - 98]
ALT U/l (n=48) 37 [11 – 339]
Laboratory results at the moment of thiopurine metabolite determination. 6-thioguaninenucleotide (6-TGN), 
6-methylmercaptopurine ribonucleotides (6-MMPR), C-reactive protein (CRP), Haemoglobin (Hb), Mean corpuscular 
volume (MCV), Alkaline phosphatase (AP), gamma-glutamyltransferase (γ-GT), aspartate aminotransferase (AST), 
Alanine aminotransferase (ALT). Results are reported as median with ranges.
Therapeutic effectiveness and tolerability of thiopurines
From the total cohort of skewed thiopurine metabolizers, 84% of patients (41/49) discontinued 
thiopurine monotherapy. The median duration of thiopurine use in the patients who failed 
thiopurine therapy was 14 weeks (range 7-155). Nineteen patients (39%) discontinued 
treatment within 12 weeks after thiopurine initiation (Figure 1a).
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Figure 1a-b. Kaplan-Meier curves regarding ongoing thiopurine use in all IBD patients in months. The 
Y-axis represents the percentage of patients continuing thiopurine therapy over time until the end of 
follow up. Figure 1b is corrected for the 6-MMPR/6-TGN ratio.
All reasons for therapy discontinuation are depicted in Table 3. The main reason for thiopurine 
therapy failure was intolerance (n=27, 55%).
Table 3. Therapeutic effectiveness and tolerability of thiopurines
N = 49 , n (%)
Patients discontinuing thiopurine therapy 41 (84)
Reason thiopurine therapy failure
 Intolerance
 Refractoriness
  primary non-response
  loss of response











 Allopurinol combination therapy
 TG
 MTX











TG (thioguanine), MTX (methotrexate)
Common AEs were hepatotoxicity (n=18), gastrointestinal complaints (n=11) and general 
malaise (n=11) including fatigue, headache and dizziness. Eight patients discontinued therapy 
due to laboratory signs of myelosuppression, of which five patients displayed an isolated 
leukopenia and three patients showed a pancytopenia. Other AE comprised dermatological 
abnormalities (n=2). (Figure 2a-2c). No pancreatitis, lymphomas, infectious complications or 
mortality were reported. In several patients more than one AE occurred.
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Figure 2a-c. Box-whisker plots of discontinuation due to adverse events in IBD patients with a skewed 
metabolism on conventional thiopurines with corresponding 6-MMPR/6-TGN ratios (2a), 6-TGN (2b) and 
6-MMPR (2c) metabolite levels. Statistical analysis in these small groups did not show statistical signifi-
cant differences between adverse events and metabolite levels.
Altogether we observed 50 AE in 36/49 patients (74%), leading to therapy discontinuation 
in 27 patients. Overall adverse events occurred more frequently in patients discontinuing 
thiopurine therapy (p <0.02). In this study, all patients (n=9) with prolonged or maintenance 
use of (low-dose) steroids discontinued thiopurine treatment over time. Patients with 
successful thiopurine therapy (n=9) achieved remission without prolonged use of steroids. 
Patients discontinuing treatment due to thiopurine refractoriness, failed therapy with 
a median duration of thiopurine use of 22 weeks (range 12-155) compared to a median 
duration of 11 weeks (range 7-108) in the AE group (p<0.05). The consequences of failure to 
thiopurine treatment are depicted in Table 3. In sixteen patients failure led to withdrawal of 
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thiopurines. Of these sixteen patients, 12 patients received escape treatment being tioguanine 
(6-TG) and methotrexate and four patients with UC achieved or maintained remission on 
monotherapy 5-ASA without alternative therapy adjustments. One patient underwent a total 
proctocolectomy with permanent ileostomy. No mortality was reported.
The addition of allopurinol in eighteen patients, generally 100mg once daily, alongside a 
3 to 4 times reduced thiopurine dose led to restoration of the aimed ‘optimal’ ratio <11 of 
metabolites in all patients.28 Initial median 6-MMPR/6-TGN ratio was 90 (range 41-367) and 
median 6-MMPR/6-TGN ratio was 1.8 (range 0.1-7.3, 1 missing) after the initiation of allopurinol. 
Although myelosuppression remained in one patient, no other AE were reported, especially no 
hepatotoxicity. Concomitant therapy of thiopurines with allopurinol induced clinical remission 
in 13 out of 18 (72%) patients. Five patients were unable to achieve clinical remission with 
thiopurine and allopurinol combination therapy, leading to the initiation of 6-TG in one patient 
and anti-TNF therapy in four patients.
Metabolite monitoring and therapy failure
The absolute (height of) concentration of either 6-TGN or 6-MMPR metabolites did not show 
statistically significant differences between patients continuing and stopping treatment. 
Median 6-MMPR/6-TGN ratio was 35 (range 33-235) in the patients continuing thiopurines 
despite a skewed metabolism, versus 82 (range 29-367) in patients discontinuing treatment 
(p<0.09). Fifteen patients (31%) displayed a relatively mild skewed thiopurine metabolism 
(ratio 20-50) of which ten (67%) patients discontinued treatment. Fifteen patients (31%) 
demonstrated a relative moderate ultramethylation (ratio 50-100) and fourteen (93%) of 
these patients discontinued treatment. Nineteen patients (38%) had a strongly skewed 
metabolism (ratio >100), 17 (89%) of these patients failed treatment (Table 4). Patients with 
a ratio >50 discontinued thiopurine treatment more often than patients displaying relatively 
mild ultramethylation (p<0.03) (Figure 1b).
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Median level 6-TGN (pmol/10e8RBC)
[range]
167 [96-294] 158 [46-210] 0.55
Median level 6-MMPR (pmol/10e8RBC)
[range]
11270 [4010-23460] 11020 [3610-43670] 0.48
Median 6-MMPR/6-TGN Ratio
[range]
35 [33-354] 82 [29-419] 0.09
Median duration thiopurine therapy
(weeks) [range]
169 [83-225] 14 [7-155] <0.0001
Level of ultramethylation
  Mild: 20-50 (n) (%)
  Moderate: 50-100 (n) (%)













Routine measurements of thiopurine metabolites. 6-thioguaninenucleotide (6-TGN), 6-methylmercaptopurine 
ribonucleotides (6-MMPR), Level of ultramethylation (6-MMPR/6-TGN, according to Lennard’s method). Results are 
reported as median with ranges. *Level of ultramethylation compared to the remaining groups.
Patients developing hepatotoxicity were more often extreme skewers (p<0.01) than patients 
in whom no hepatotoxicity was present. No variables were identified that could predict 
failure of monotherapy with thiopurine or specific adverse events such as hepatotoxicity or 
myelosuppression, including Montreal classification, specific thiopurine derivate, dosage, 
previous treatment characteristics or the absolute level of 6-TGN and 6-MMPR metabolites.
Sustained clinical benefit
Thiopurine therapy was continued in 8/49 patients (16%). Four patients achieved clinical 
remission, three patients improved clinically and one patient intentionally discontinued 
treatment at own discretion. The median duration of thiopurine therapy in patients with 
ongoing treatment at the end of follow up was 169 weeks (range 83-225) (Figure 1a).
DISCUSSION
In this retrospective, single-centre cohort study of almost fifty thiopurine ultramethylating 
IBD patients, it was demonstrated that a skewed metabolism, routinely established per local 
treatment protocol, is critical to predict intolerability and ineffectiveness of conventional 
thiopurine treatment. Eighty-four percent of these patients discontinued thiopurine therapy 
most often due to the development of intractable AEs, especially hepatotoxicity. These 
findings underline that a skewed metabolism (6-MMPR/6-TGN ratio above 20) is a prognostic 
risk factor for thiopurine therapy failure.
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In several trials and a meta-analysis it has been demonstrated that conventional thiopurine 
therapy is effective in the treatment of IBD patients for induction treatment, but primarily 
for maintenance of remission.1-3 In recent studies, it has been shown that differences in 
response to and tolerance of thiopurines are most likely to result from individual variations 
in drug metabolism in which high 6-MMPR and 6-TGN concentrations are correlated with 
the occurrence of (hepato)toxicity and myelosuppression, respectively.5,7-9,25 Furthermore a 
6-MMPR/6-TGN ratio above 20 is associated with therapeutic inefficacy.5,6,10 Several studies 
demonstrated that up to 46% to 83% of IBD patients discontinued conventional thiopurine 
treatment, usually in the first 2-3 years.4,8,28,29 The results of our study, consisting exclusively 
of ultramethylating IBD patients demonstrate that a substantially higher percentage of these 
patients (84%) discontinued thiopurine treatment at an earlier stage. Conventional thiopurine 
therapy was effective in only 16% of patients with a skewed metabolism, revealed by routine 
measurements. Although this small group of patients benefitted from conventional thiopurine 
monotherapy up to several years, this appeared the exception more than the rule. In previous 
studies in average IBD populations, over 28% of patients discontinued thiopurine therapy due 
to AE, allegedly related to a skewed thiopurine metabolism profile.1,4,8,30 In this study the rate at 
which patients discontinued therapy due to AE was nearly twice as high (55%). The majority of 
patients discontinued therapy due to AE, mainly thiopurine induced hepatotoxicity (37% of all 
patients), and this was associated with a strongly skewed metabolism. These results are in line 
with the hypothesis that induction of hepatotoxicity and other AEs are specifically associated 
with high 6-MMPR levels.7-9 Moreover, eight patients discontinued treatment due to thiopurine-
induced myelotoxicity. This finding suggests that the risk of developing thiopurine induced 
haematological events is not exclusively related to 6-TGN metabolites, but that also 6-MMPR 
metabolites play an important role in this phenomenon: 6-MMPR metabolites can inhibit the 
de novo purine synthesis leading to a depletion of purines which are essential elements for 
DNA and RNA formation and may interfere with cellular replication.5,25,31
In the past, it has been suggested that high TPMT activity leads to high 6-MMPR concentrations 
and was therefore associated with therapy failure. However, van Egmond et al14 found that 
differences in TPMT enzyme activity did not predict preferential 6-MMPR metabolite production 
and other factors had to contribute to this aberrant and unfavourable metabolism. The 
phenomenon of ultramethylation is generally discovered by the occurrence of insurmountable 
AEs or lack of clinical response, sometimes after several months of treatment, leading to 
metabolite measurements helping to unravel its cause. Therefore it is not surprising that 
ultramethylators discontinue thiopurine treatment more frequently than patients without 
preferential 6-MMPR metabolite generation. In all our 49 patients, metabolites were measured 
as a routine after initiation of thiopurine therapy, thus making an overestimation of patients 
less plausible. This study confirmed that a skewed metabolism is a strong risk factor for 
future thiopurine treatment failure. Determination of thiopurine metabolite concentrations 
as a routine to identify patients with a skewed metabolism may result in the reduction of 
potentially redundant and unnecessary AEs by early therapy adjustments. This combination of 
findings provides some support for the conceptual premise that adjustment of treatment in the 
2
binnenwerk_joany.indd   43 7-12-2020   13:27:25
44 |
Chapter 2
form of thiopurine dose-reduction in combination with allopurinol is an effective alternative 
immunosuppressive strategy.8,13
There are some limitations to our study. Firstly, numerous patients received previous 
(thiopurine) treatment before being referred to our hospital, resulting in different therapy 
strategies in the past. Furthermore, several patients received thiopurine treatment with a 
concomitant biological drug, conceivably representing a more complex type of IBD in this 
group, possibly conflicting with clinical outcomes in the present study. Secondly, we used 
the first assessment of thiopurine metabolites for each patient. Although all metabolites 
were routinely determined, the time of measurement after thiopurine initiation was to some 
extent variable. Nine patients with a skewed metabolism of MP showed normal metabolite 
levels during previous AZA usage. Whether the explanation for this finding can be assigned 
to dosage, a different thiopurine metabolism, for example being caused by a different first-
pass effect, or increasing metabolite levels over time due to co-medication or disease activity 
remains to be elucidated.20
In conclusion, we observed that IBD patients with a skewed metabolism of conventional 
thiopurines, established during a routine measurement, with corresponding high 6-MMPR/6-
TGN ratios discontinued therapy early and at an excessively high rate of 84%, mostly due to 
AEs, with 6-MMPR-associated hepatotoxicity being the commonest culprit. For a more accurate 
risk stratification, thiopurine metabolite levels may be routinely measured in patients starting 
conventional thiopurines, identifying those benefitting from therapy adjustments early.
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THIOPURINE INDUCED 
LEUKOPENIA CAUSED BY ELEVATED 
6-MMPR LEVELS: CLINICAL 
CHARACTERISTICS AND OUTCOME 
OF THERAPY OPTIMIZATION
Meijer B, Kreijne JE, van Moorsel SAW, Derijks LJJ, Bouma G, Mulder CJJ, Wong 
DR, van der Woude CJ, van Bodegraven AA, de Boer NK.
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ABSTRACT
Background: Thiopurines have a favorable benefit–risk ratio in the treatment of 
inflammatory bowel disease. A feared adverse event of thiopurine therapy is myelotoxicity, 
mostly occurring due to toxic concentrations of the pharmacologically active metabolites 
6-thioguaninenucleotides. In oncology, myelosuppression has also been associated with 
elevated 6-methylmercaptopurine ribonucleotides (6-MMPR). In this case series, we provide 
a detailed overview of 6-MMPR-induced myelotoxicity in inflammatory bowel disease 
patients.
Methods: We retrospectively scrutinized pharmacological laboratory databases of five 
participating centers over a 5-year period. Patients with leukopenia at time of elevated 6-MMPR 
levels (>5,700 pmol/8 x 108 red blood cells (RBCs)) were included for detailed chart review.
Results: In this case series, we describe demographic, clinical and pharmacological 
aspects of 24 cases of 6-MMPR induced myelotoxicity on weight-based thiopurine therapy 
with a median 6-MMPR level of 14,500 pmol/8 x 108 RBCs (range 6,600-48,000). All patients 
developed leukopenia (white blood cell count 2.7±0.9 x 109/L) after a median period of 11 
weeks after initiation of thiopurine therapy (interquartile range 6-46 weeks). Eighteen patients 
(75%) developed concurrent anemia (median haemoglobin concentration 6.9 x 109/L) and 
four patients developed concurrent thrombocytopenia (median platelet count 104 x 109/L). 
Leukopenia resolved in 20 patients (83%) within four weeks upon altered thiopurine treatment 
regimen, and white blood cell count was increasing, but not yet normalized, in the remaining 
four patients.
Conclusion: We observed that thiopurine-induced myelotoxicity also occurs because of 
(extremely) high 6-MMPR concentrations in patients with a skewed thiopurine metabolism. 
Continued treatment with adapted thiopurine therapy was successful in almost all patients.
Chapter 3
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INTRODUCTION
Thiopurines (i.e. azathioprine and mercaptopurine) are immunosuppressive drugs that 
play an indispensable therapeutic role in maintaining remission in the majority of patients 
with inflammatory bowel disease (IBD) (primarily Crohn’s disease and ulcerative colitis).1-3 
The complex metabolism of thiopurines has been largely unravelled over the years, 
leading to the observation that thiopurine S-methyl transferase (TPMT) plays a pivotal 
role in the bioavailability of the pharmacologically active end-metabolites: 6-thioguanine 
nucleotides (6-TGN, therapeutic window 230–450 pmol/8 × 108 red blood cells [RBC]) and 
6-methylmercaptopurine ribonucleotides (6-MMPR, normal value <5700 pmol/8 × 108 RBC).4,5 
Hepatotoxicity induced by thiopurines is largely associated with the 6-MMPR metabolites, 
whereas myelotoxicity is mostly ascribed to high concentrations of 6-TGN, leading to apoptosis 
and direct cytotoxicity due to DNA strand breakage.6-8 However, when 6-MMPR concentrations 
are (extremely) high, as seen in high-dose thiopurine therapy in oncological patients, or 
in IBD patients with a skewed thiopurine metabolism (e.g. but not solely, caused by high 
TPMT activity), 6-MMPR can inhibit the de novo purine synthesis, thus causing subsequent 
myelotoxicity.4,9,10 Monitoring of thiopurine metabolites (6-TGN and 6-MMPR) in RBC and/or 
TPMT mutation analysis is becoming integrated in general IBD practice to optimize efficacy 
and to minimize thiopurine toxicity. Furthermore, when starting thiopurine therapy, it is 
advised to monitor laboratory parameters on a regular basis for early detection of toxicity.2,3 
Myelotoxicity caused by high 6-MMPR levels is believed to be an uncommon adverse event 
in IBD patients.11-13 Here, we present 24 cases with 6-MMPR induced leukopenia and describe 




The pharmacological laboratory databases of three tertiary referral centers in the Netherlands 
(VU University Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; and Maastricht 
University Medical Center,Maastricht) and two large teaching hospitals (Zuyderland Medical 
Center, Heerlen-Sittard-Geleen and Máxima Medical Center, Veldhoven) were scrutinized by an 
automated search over a time period of 5 years (January 1,2011–December 31, 2015) for this 
retrospective study. Furthermore, these databases were crosschecked with IBD databases 
on site.
Patient selection
The pharmacological reports of all patients using thiopurines and having at least one 
metabolite measurement in the selected time period were analyzed. We included all IBD 
patients with 6-MMPR concentrations above 5700 pmol/8 x 108 RBC for detailed chart review. 
Leukopenia was defined as white blood cell count below 4.0 x 109/L. Exclusion criteria were 
3
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the absence of leukopenia (i.e. white blood cell count ≥ 4.0 x 109/L), 6-TGN concentrations 
above normal limits (i.e. > 450 pmol/8 x 108RBC), the absence of a skewed metabolism (i.e. 
6-MMPR/6-TGN ratio < 20) or the lack of laboratory measurements within 3 days prior to or 
after metabolite measurement.
Demographic characteristics
At time of leukopenia, we collected the following data on patient characteristics: sex, age, 
weight, IBD type, Montreal classification14, specific thiopurine derivative, dosage and duration 
of thiopurine therapy, and concomitant medication, in particular drugs known to induce 
myelosuppression by itself (e.g. allopurinol15, ACE inhibitors8, ribavirin16 and mesalazine17,18, 
or interfere with thiopurine metabolism. Treatment strategies following (allegedly) 6-MMPR-
induced leukopenia (i.e. discontinuation, dose reduction, low dose thiopurine combined with 
allopurinol (LDTA), or switch to thioguanine) were evaluated. When patients were admitted to 
the hospital with fever at time of diagnosed leukopenia, routine blood cultures and virologic 
tests were assessed to rule out other causes (e.g. viral infection or sepsis).
Laboratory tests
We collected the following hematologic parameters from all included patients at time of 
diagnosed leukopenia and 2–6 weeks after application of thiopurine optimization strategy: 
white blood cell count (WBC; normal range 4.0–10.0 x 109/L), hemoglobin concentration (Hb; 
normal range male 8.5–11.0 x 109/L, female 7.5–10.0 x 109/L), mean corpuscular volume (normal 
range 80–100 fL), platelet count (normal range 150–400 x 109/L), aspartate aminotransferase 
(reference value male ≤ 35 U/L, female ≤ 40 U/L), and alanine aminotransferase (reference 
value ≤ 55 U/L). Differentials of WBC were collected when determined within 3 days after 
diagnosed leukopenia. Furthermore, we collected thiopurine metabolites ([6-MMPR] and 
[6-TGN]) at time of myelotoxicity (within 3 days prior to or after diagnosed leukopenia) and 
during follow-up (i.e. 2–6 weeks after optimizing therapy), when available. Concentrations 
of metabolites were measured using a previously described method by Dervieux et al.19 or 
Lennard et al.20 The Lennard method has found the greatest application in clinical studies yet 
and has served as the basis for the establishment of treatment-related therapeutic ranges for 
thiopurine therapy.21 Laboratory measurements of the Maastricht University Medical Center 
and the Máxima Medical Center were performed in the Zuyderland Medical Center. In the 
Zuyderland Medical Center, concentrations of metabolites were measured using the method 
described by Lennard until April 2013. From April 2013, the method by Dervieux was applied. 
Concentrations of metabolites in the other two centers were measured using the method 
described by Dervieux. In these centers, concentrations of 6-TGN were divided by a factor 2.6 
to make them comparable to those determined by the Lennard method.22,23 Concentrations 
of 6-MMPR are similar in both assays.21
Data analysis
All data are given descriptively or tabulated. Data are expressed as median with interquartile 
range (IQR), range, or as mean with standard deviation according to distribution. Metabolite 
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concentrations at baseline and after applying treatment optimization strategies were 
compared using the Wilcoxon signed-rank test. Correlations between nonparametric values 
were measured using the Spearman’s rank order correlation test.
Ethical approval
This study was approved by the Medical Ethics Review Committee of the VU University Medical 
Center with file-number 2016-824.
RESULTS
Patient characteristics
A total of 24 patients (50% male, 50% female) were included with a mean age at initiation of 
thiopurine therapy of 44 ± 18 years. Crohn’s disease and ulcerative colitis were diagnosed 
in nine (38%) and 15 (62%) patients, respectively. Median duration of thiopurine therapy 
until development of myelotoxicity was 11 weeks (IQR 6–46). All patient characteristics are 
summarized in Table 1.
Development of leukopenia
After a median period of 11 weeks after initiation of thiopurine therapy, leukopenia developed 
with a mean WBC of 2.7±0.9 x 109/L. In 18 patients (75%), hemoglobin decreased under the 
lower reference limit to a median of 6.9 x 109/L (range 3.2 – 8.4) simultaneously. Concurrent 
thrombocytopenia occurred in four patients (17%) with a median of 104 x 109/L (range 79 - 
132). Three patients developed pancytopenia. Median 6-MMPR was 14,500 pmol/8 x 108 RBC 
(range 6,600-48,000) with with therapeutic 6-TGN in nine patients (38%; mean concentration 
196±98 pmol/8 x 108 RBC) In the other 15 patients, 6-TGN concentrations were lower than the 
therapeutic cut-off level (i.e. <235 pmol/8 x 108 RBC). The median 6-MMPR/6- TGN ratio was 
102 (range 24–327). The 6-MMPR/6-TGN ratio was not correlated to WBC (p=0.23), but there 
seemed to be a trend towards lower WBC in patients with higher 6-MMPR concentrations 
(r=-0.30, p=0.08). An overview of these results is depicted in Tables 2 and 3. Four patients 
(nos 6, 15, 20, and 21) were admitted to the hospital because of complicated myelotoxicity 
combined with fever, deep anemia, and/or worsening of IBD. Of these patients, three patients 
(nos 6, 15, and 21) were febrile and treated with intravenous antibiotics per local protocol. 
One patient (no. 20) was admitted for blood transfusion (Hb 3.2x109/L) and received three 
units of erythrocytes concentrate, after which the anemia resolved. Patient nos 15 and 20 
were also admitted because of worsening of IBD course and received an induction course of 
prednisolone. In these patients, thiopurine treatment was immediately ceased.
3
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Table 1. Demographics of included patients
No. Sex Age
(years)










1 F 55 CD A2L2B1 MP 50 64 0.8 none 1000
2 F 80 CD A3L1B2 MP 75 67 1.1 none 220d
3 M 33 CD A2L3B1p MP 75 60 1.3 none 9
4 F 24 CD A2L1B2 MP 75 56 1.3 none 6
5 F 34 CD A2L3B1 MP 100 87 1.1 none 110
6 M 18 CD A2L1B1 MP 100 68 1.5 none 6
7 F 43 CD A2L3B1 MP 100 65 1.5 mesalazine 20
8 M 21 CD A1L3B1 MP 100 56 1.8 none 6
9 F 62 CD A3L2B1 AZA 150 72 2.1 lisinopril 4
10 F 26 CD A2L1B1 AZA 175 76 2.3 none 46
11 M 74 UC E3 MP 75 71 1.1 mesalazine 12
12 M 23 UC E3 MP 75 65 1.2 mesalazine 12
13 F 49 UC E3 MP 75 65 1.2 mesalazine 6
14 M 50 UC E3 MP 100 78 1.3 none 104
15 F 67 UC E2 MP 100 75 1.3 mesalazine 6
16 F 75 UC E2 MP 100 75 1.3 none 45
17 F 34 UC E3 MP 100 57 1.8 none 5
18 M 31 UC E2 MP 125 89 1.4 mesalazine 6
19 F 32 UC E3 MP 150 92 1.6 none 12
20 M 51 UC E3 MP 150 86 1.7 mesalazine 4
21 M 35 UC E3 MP 150 84 1.8 none 5
22 M 63 UC E1 AZA 125 67 1.9 none 156
23 M 51 UC E2 AZA 150 60 2.5 mesalazine 45
24 M 34 UC E3 AZA 200 87 2.3 mesalazine 9
M: male, F: female, D: diagnosis, CD: Crohn’s disease, UC: ulcerative colitis, MP: mercaptopurine, AZA: azathioprine. a 
Montreal classification: A: age at diagnosis – 1: below 16 years, 2: 17-40 years, 3: above 40 years. L: location – 1: ileal, 
2: colonic, 3: ileocolonic. B: behaviour – 1: non-stricturing non-penetrating, 2: stricturing, 3: penetrating, p: perianal 
involvement. E: extent – 1: proctitis, 2: left-sided colitis, 3: extensive colitis. b Relevant co-medications were defined as 
mesalazine, sulfasalazine, ace-inhibitors, trimethoprim, indometacine and ribavirine. c week of diagnosed leukopenia. 
d Leukopenia developed 4 weeks after dose increase.
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Table 2. Laboratory parameters of patients developing myelotoxicity on thiopurine therapy due to high 
6-methylmercaptopurine concentrations
CASE















1 2.2 7.5 122 194 130 88 19 000 139 137
2 3.7 7.1 97 294 27 38 12 500 58 216
3 3.2 8.4 101 152 - 30 13 000 296 44
4 2.7 7.7 - 225 - 100 12 000 212 57
5 3.6 4.9 - 167 - 30 36 500 139 263
6 1.7 6.8 89 234 20 36 33 000 173 173
7 2.3 6.3 112 203 - - 48 000 279 172
8 2.0 7.8 - 269 - 14 11 000 423 26
9 2.5 7.6 122 132 69 55 22 000 215 102
10 3.7 8.5 94 311 18 15 6 600 85 78
11 3.5 6.6 110 79 51 50 7 500 308 24
12 2.6 6.6 90 329 28 52 13 000 262 50
13 3.5 7.5 - 253 - 35 13 000 169 77
14 3.9 9.6 89 249 - 181 16 000 80 200
15 1.8 7.2 98 125 29 39 46 000 273 168
16 3.8 7.3 108 267 60 68 22 000 273 81
17 3.4 7.0 106 209 - 10 36 000 110 327
18 1.8 6.6 91 409 - 69 30 000 319 94
19 2.3 6.5 99 199 - 61 37 000 262 141
20 1.6 3.2 100 417 11 9 19 000 73 260
21 0.8 5.8 - 155 111 274 13 000 65 200
22 2.2 7.4 104 82 27 38 13 000 127 102
23 3.5 8.4 90 315 47 41 10 000 223 45
24 2.5 8.1 90 204 17 20 12 000 133 90
The symbol (-) means not available. ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, 
hemoglobin concentration; MCV, mean corpuscular volume; PC, platelet count; WBC, white blood cell count. 6-MMP, 
6-methylmercaptopurine; 6-TGN, 6-thioguaninenucleotides (Lennard). Metabolite concentrations are displayed as 
pmol/8 × 108 red blood cells. All hematologic parameters were determined at the time of metabolite measurement. 
These values do not have to be the lowest by definition.
3
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White blood cell count differentials
As depicted in Table 3, WBC differentials were available in 9/24 patients (38%). In four patients, 
there was an isolated absolute neutropenia, and in one patient, there was an isolated absolute 
lymphopenia. In the other four patients, both neutrophil count and lymphocyte count were 
decreased.
Alternative optimizing treatment strategies after 6-MMPR induced leukopenia
Of all patients developing leukopenia on thiopurine therapy, 11 patients (45%) received 
subsequent allopurinol 100 mg/day combined with the original thiopurine in a reduced dose 
(25–33% of original dose), leading to a normalization of 6-MMPR to a median of 220 pmol/8 x 
108 RBC [IQR 100-288] (p<0.01) in all patients. Concentrations of 6-TGN did neither differ from 
pre-treatment (6-TGN; median 206 vs 192 pmol/8 x 108 RBC, p=0.54) in this subgroup nor in the 
total group (median 188 vs 193 pmol/8 x 108 RBC, p=0.95), but 6-MMPR/6-TGN ratios decreased 
from a median of 102 to 1.3 (P < 0.001) in the total group. In five patients (21%), thiopurine 
therapy was switched into the alternative thiopurine derivative thioguanine, which undergoes 
a less complex metabolism without the formation of 6-MMPR. Four patients (17%) with mild 
myelotoxicity (nos 3, 4, 5, and 16) received a 50% dose reduction of the original thiopurine 
with subsequent normalization of hematologic parameters. In three patients, 6-MMPR and 
6-TGN concentrations decreased (6-TGN to suboptimal levels) after dose reduction, and in 
the other patients, thiopurine metabolites were not measured. In four patients (17%; nos 
5, 6, 11, and 22), thiopurine therapy was discontinued with normalization of hematologic 
parameters shortly (respectively 21 and 30 days) after discontinuation. Thiopurine therapy 
was not rechallenged in these patients, based on patient’s request. In 20 of 24 (83%) patients, 
leukocyte count normalized 4 weeks after changing treatment regimen. In the remaining four 
patients, WBC was not normalized yet but improved compared with the initial leukopenia 
(Figure 1).
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1 2.2 - - - - -
2 3.7 - - - - -
3 3.2 1.92 (60%) 0.96 (30%) 0.06 (2%) 0.20 (6%) -
4 2.7 - - - - -
5 3.6 - - - - *1/*1
6 1.7 0.54 (32%) 1.14 (68%) 0.00 0.02 (1%) -
7 2.3 - - - - *1/*1
8 2.0 - - - - -
9 2.5 1.21 (48%) 1.04 (42%) 0.07 (3%) 0.19 (7%) -
10 3.7 - - - - *1/*1
11 3.5 1.43 (41%) 1.47 (42%) 0.19 (5%) 0.34 (10%) -
12 2.6 1.12 (43%) 1.20 (46%) 0.13 (5%) 0.14 (5%) -
13 3.5 - - - - -
14 3.9 - - - - *1/*1
15 1.8 0.64 (36%) 0.97 (54%) 0.07 (5%) 0.09 (5%)
16 3.8 - - - - *1/*1
17 3.4 - - - - -
18 1.8 1.13 (63%) 0.53 (29%) 0.02 (1%) 0.07 (4%) -
19 2.3 - - - - -
20   0.9† 0.46 (51%) 0.13 (14%) 0.22 (24%) 0.02 (2%) -
21 0.8 0.40 (50%) 0.34 (43%) 0.00 0.06 (7%) -
22 2.2 - - - - -
23 3.5 - - - - *1/*1
24 2.5 - - - - *1/*1
TPMT, thiopurine methyl-S-transferase, WBC, white blood cell count, *1/*1, wildtype genotype. 
† 3 days after initial diagnosed leukocytopenia. The symbol (-) means result unavailable. Values expressed in bold are 
lower than reference values.
3
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Figure 1. Change in white blood cell count four weeks after optimizing treatment strategy
Anemia at initial presentation resolved in 12/18 (67%) of patients and improved in the 
remaining six patients. At follow-up, four patients (17%) had thrombocytopenia. No mortality 
was observed in our cohort. These results are summarized in Table 4. Overall, restart with 
adapted thiopurine therapy was successful in 20 of 24 (83%) patients. 6-MMPR concentrations 
were neither correlated with the use of co-medication (i.e. mesalazine), nor with the dose 
of thiopurine therapy in the different patients. The development of leukopenia was not 
correlated with the use of co-medication. Genotyping of the TPMT enzyme (i.e. wild-type 
*1/*1 vs. heterozygous/homozygous polymorphisms) was performed using a polymerase chain 
reaction in seven patients at baseline (29%; nos 2, 5, 7, 10, 16, 23, and 24). All these patients 
were carriers of the wild-type TPMT genotype (*1/*1).
Table 4. Laboratory parameters of patients developing myelotoxicity on thiopurine therapy due to high 
6-methylmercaptopurine concentrations after changing treatment strategy
CASE






(x109/L) 6-MMPR 6-TGN Strategy
1 4.4 8.7 264 0 695 Thioguanine
2 4.9 7.2 254 0 140 Thioguanine
3 5.1 9.4 207 2 800 215 Dose reduction
4 5.0 8.4 177 6 800 173 Dose reduction
5 6.0 5.8 226 - - Discontinuation
6 9.5 9.1 146 760 0 Discontinuation
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Table 4. Continued.
CASE






(x109/L) 6-MMPR 6-TGN Strategy
7 4.1 7.1 164 4 500a 68 Thioguanine
8 5.6 9.0 318 310 273 LDTAb
9 4.5 7.6 153 200 207 LDTAb
10 4.0 8.7 264 - - Dose reduction
11 4.0 7.3 65 - - Discontinuation
12 5.1 7.6 247 280 188 LDTAb
13 3.8 7.9 221 190 219 LDTAb
14 4.0 8.5 228 254 204 LDTAb
15 6.4 7.3 120 - - LDTAb
16 4.7 8.0 240 <100 538 LDTAb
17 5.6 7.9 235 0 235 Thioguanine
18 11.9 8.2 395 240 327 LDTAb
19 5.6 - - 1 300a 27 Thioguanine
20 3.3 8.2 316 <100 162 LDTAb
21 4.5 9.6 229 <100 62 LDTAb
22 3.2 7.4 81 - - Discontinuation
23 5.7 8.5 345 880 46 Dose reduction
24 3.8 8.9 183 724 127 LDTAb
Hb, Hemoglobin concentration; PC, platelet count; WBC, white blood cell count; 6-MMP: 6-methylmercaptopurine; 
6-TGN: 6-thioguaninenucleotides (Lennard); LDTA, low dose thiopurine and allopurinol. Metabolite concentrations 
are displayed as pmol/8 × 108 red blood cells. The symbol (-) means not available. 
aDetectable because mercaptopurine was only terminated recently. baddition of allopurinol 100mg/day to a reduced 
(25–33%) dose of the original thiopurine.
DISCUSSION
In this case series, a detailed description of 24 patients developing myelotoxicity on thiopurine 
therapy due to a skewed, ultramethylating thiopurine metabolism, and their follow-up is 
provided. In these patients, 6-MMPR-induced leukopenia developed after a median of 11 weeks 
after initiation of thiopurine therapy and resolved within 4 weeks upon altered treatment 
regimen in 83% of the patients. One case has been published before.13
Over recent years, metabolism of thiopurines in IBD patients has been extensively investigated. 
Most dose-dependent adverse events of thiopurines in IBD patients have been ascribed to 
two metabolite groups, 6-MMPR and 6-TGN. Thiopurine-induced myelotoxicity is almost 
exclusively being described in relation to grossly elevated 6-TGN levels, causing DNA strand 
breakage leading to direct cytotoxicity and apoptosis of activated T-lymphocytes. 4,9 High 
3
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6-TGN concentrations are associated with low TPMT activity caused by a mutant genotype, 
thus shifting the balance between 6-MMPR and 6-TGN formation. Besides toxic 6-TGN 
concentrations, 6-MMPR in (extremely) high concentrations can cause myelotoxicity as well, 
because of inhibition of de novo purine synthesis.4,18,24 Purines are essential compounds in 
nucleic acids, needed for the generation of DNA.25 When thiopurines are administered in high 
(oncological) dosages, the median time to develop leukopenia is approximately ten days.26 In 
IBD, dosage of thiopurine therapy is substantially lower because of another mode-of-action, 
because the required effect is mainly antiapoptotic, instead of anti-metabolic.4 In the current 
analysis with lower IBD dosages, in which high 6-MMPR concentrations were studied as a 
result of a skewed thiopurine metabolism, the median time to leukopenia was 11 weeks.8
We observed that 11 (45%) patients who developed myelotoxicity because of ultramethylation 
benefitted from the addition of allopurinol to a reduced (25–33%) dose of the original 
thiopurine (LDTA). Allopurinol is an inhibitor of the enzyme xanthine oxidase and also has 
an indirect inhibiting function on TPMT enzyme activity, thus leading to lower 6-MMPR and 
higher 6-TGN production.27-29 In addition, allopurinol seems to have an enhancing effect on 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT), contributing to higher 6-TGN 
formation as well.24,30 Additionally, five patients with leukopenia on conventional thiopurine 
therapy benefitted from a switch to thioguanine therapy, hereby avoiding the formation of 
6-MMPR.31
As shown in a large prospective cohort study by Chaparro and colleagues, leukopenia was 
witnessed in about 4% of the patients treated with thiopurines after a median period of 7 
months.32 This finding was underlined in a systematic review by Gisbert et al.33 This effect is 
predominantly seen in patients with high 6-TGN concentrations (e.g. caused by heterozygote/
homozygote TPMT mutations or patients with a NUDT15 mutation), and incidence is probably 
lower in patients with high 6-MMPR levels.34-36
Recently, results of a prospective study showed that elevated 6-MMPR and 6-TGN metabolites 
assessed one week after initiation were independently associated with thiopurine-induced 
leukopenia.37 Furthermore, it was demonstrated that patients who show excessive 6-MMPR 
formation are also at risk for early thiopurine failure because of intolerable adverse events 
or refractoriness.38
One of the limitations of our case series is the retrospective nature. Another possible limitation 
is that patients in this cohort were identified based on a skewed thiopurine metabolism, and 
these results were linked to leukopenia afterwards. Because therapeutic drug monitoring 
is not performed routinely in all patients of the participating centers, the total number of 
6-MMPR-induced leukopenia might be higher than suggested in our analysis. Unfortunately, 
differentials of WBC were available in only 9/24 patients, because this measurement is not 
performed per protocol in the participating centers. Only WBC differentials within 3 days after 
diagnosed leukopenia were added to our analysis. Interestingly, it is not clear why patients 
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develop neutropenia and/or lymphopenia, as shown in our results. To our knowledge, there 
are no data available describing the relative incidence of neutropenia or lymphopenia in 
thiopurine users.
In this cohort, we did not determine TPMT genotyping systematically. However, we expect all 
patients to have normal/high TPMT activity (wild-type genotype), because 6-MMPR formation 
is mainly driven by TPMT activity. Whereas it has been described that preferential 6-MMPR 
production could occur in patients with TPMT mutations, we believe this will not be of added 
value to this paper, because other risk factors, besides 6-MMPR, for developing leukopenia are 
not assessed in this retrospective study.13 Furthermore, even though we ruled out common 
causes of leukopenia (e.g. viral infection or sepsis), it is not ruled out that other factors (e.g. 
hematologic or autoimmune disorders and deficiencies of dietary vitamins) might have 
contributed to the development of leukopenia in these patients, especially in those patients 
with only marginal elevated 6-MMPR concentrations.39
With this detailed case series, we underline that myelotoxicity may also be caused by grossly 
elevated levels of 6-MMPR. This is added to what has previously been demonstrated, namely 
that myelotoxicity is mainly caused by elevated cytotoxic levels of 6-TGN, the use of certain 
co-medications or intercurrent (viral) infections. Our findings might also be an explanation 
for unexplained leukopenia during thiopurine therapy without genetic variations (e.g. TPMT 
or NUDT15 mutation).25,40,41
CONCLUSION
We demonstrated that leukopenia develops in patients with (extremely) elevated 
concentrations of 6-MMPR. Almost all patients were successfully treated with LDTA or from a 
switch to thioguanine. Adapted thiopurine therapy was successful in the majority of patients 
who developed leukopenia resulting from a skewed metabolism. As myelotoxicity mainly 
seems to occur shortly after introduction of thiopurine therapy, we stress the importance 
of therapeutic drug monitoring in case of myelotoxicity, especially in the first weeks after 
initiation.
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CHAPTER 4
REAL-LIFE STUDY OF SAFETY 
WITH THIOPURINE-ALLOPURINOL 
COMBINATION THERAPY 
IN INFLAMMATORY BOWEL 
DISEASE: MYELOTOXICITY AND 
HEPATOTOXICITY RARELY AFFECT 
MAINTENANCE TREATMENT
Kreijne JE, de Veer RC, de Boer NK, Dijkstra G, West RL, van Moorsel SAW, de 
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ABSTRACT
Background: Low-dose thiopurine-allopurinol (LDTA) combination therapy is a commonly 
applied optimization strategy in IBD patients with a skewed thiopurine metabolism.
Aim: To assess continued LDTA maintenance treatment at annual intervals, and explore risk 
factors for treatment cessation.
Methods: Adult IBD patients treated with LDTA between 2009-2016 were retrospectively 
included. Data on the incidence of clinical and laboratory adverse events (AEs), including 
hepatotoxicity and myelotoxicity, imposing LDTA therapy cessation and associated risk factors 
were collected.
Results: In total, 221 IBD patients (46% males, median age 42 years) were included. 
Maintenance LDTA treatment was continued in 78% at 1 year (n=145), 66% at 2 years (n=83), 
57% at 3 years (n=52), and 52% at 4 years (n=33). Treatment in patients receiving LDTA therapy 
for AEs during thiopurine monotherapy was more often continued than in patients initiating 
LDTA for other indications (i.e. ineffectiveness of thiopurine monotherapy, routinely discovered 
skewed metabolism) (P=0.016). Myelotoxicity during thiopurine monotherapy resolved in 87% 
and hepatotoxicity in 86% after median of 1.2 and 1.4 months after LDTA initiation. Cumulative 
incidence of AEs during LDTA imposing therapy cessation within total follow-up of 449 
treatment-years was 7% for clinical AEs, 4% for myelotoxicity and 1% for hepatotoxicity.
Conclusion: LDTA therapy is a safe and beneficial optimization strategy in IBD patients. 
Continued maintenance LDTA treatment is 52% after 4 years of treatment, and most commonly 
affected by ineffectiveness of LDTA rather than LDTA-attributed laboratory toxicity. LDTA 
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INTRODUCTION
Adverse events are an important reason for discontinuation of thiopurine monotherapy in 
IBD patients. Both clinical adverse events, such as nausea or general malaise, and laboratory 
adverse events such as hepatotoxicity and leukopenia are common during thiopurine 
therapy.1-5 Safety concerns associated with thiopurines can be attenuated by the early 
identification of toxicity through routine laboratory monitoring and subsequent modification 
of therapy.6-8
Azathioprine (AZA) and mercaptopurine (MP) are converted by three major enzymatic 
pathways, involving thiopurine methyltransferase (TPMT), into active 6-thioguanine 
nucleotides (6-TGN) and the byproducts 6-methyl mercaptopurine ribonucleotides (6-
MMPR).1 The active 6-TGN metabolites are responsible for the immunosuppressive effect 
and related clinical response, but high 6-TGN levels are associated with myelotoxicity. The 
6-MMPR metabolites are associated with adverse events such as hepatotoxicity and also 
myelotoxicity.9, 10 Therapeutic response and toxicity are highly variable between patients, 
partly explained by differences in formation of these metabolites, due to genetic variants in 
the genes encoding for crucial enzymes in the thiopurine metabolism.11
Therapeutic drug monitoring through assessment of pharmacogenetics and thiopurine 
metabolite levels, allows for identification of drug metabolism variations, thiopurine under-
dosing/ over-dosing, and noncompliance. A considerable proportion of patients harbor drug 
metabolism variations that lead to a ‘skewed thiopurine metabolism’, where methylation 
results in excessive amounts of 6-MMPR at the expense of 6-TGN levels that usually remain 
below the therapeutic range. These patients are particularly at risk for poor treatment 
response and development of adverse events.12 Allopurinol is a xanthine oxidase inhibitor 
and redirects the thiopurine metabolism towards 6-TGN formation resulting in increased levels 
of 6-TGN and reduced 6-MMPR levels.13-15 The optimization strategy of low-dose thiopurine 
combined with allopurinol (LDTA) improved thiopurine efficacy in patients who previously 
failed thiopurine monotherapy due to a skewed metabolism. Moreover, liver test abnormalities 
associated with high 6-MMPR improved upon LDTA therapy.16-19
Although LDTA therapy is a commonly applied optimization strategy, data on continued 
maintenance LDTA treatment and incidence of laboratory toxicity are scarce.20-22 In this study, 
we aimed to i) assess continued maintenance LDTA treatment in adult IBD patients and ii) 
explore the reasons for discontinuation as well as iii) the incidence of laboratory toxicity i.e. 
hepatotoxicity and myelotoxicity.
4





A retrospective cohort study was conducted in four tertiary referral centers and two teaching 
hospitals in the Netherlands. This protocol was approved by the institutional ethical 
review committee of the corresponding center, and in all participating centers as per local 
regulations.
Adult IBD patients treated with combination therapy of allopurinol and LDTA, between 
January 1st 2009 and December 31st 2016 were eligible for this study. Patients were 
retrieved from the outpatient clinics and local databases, and crosschecked with pharmacy 
records holding prescriptions for both allopurinol and AZA or MP. Exclusion criteria were 
unavailability of laboratory assessments, a known history of chronic liver disease (i.e. viral 
hepatitis, auto-immune hepatitis, steatosis hepatitis, primary sclerosing cholangitis, primary 
biliary cholangitis or liver cirrhosis), and treatment with concomitant immunosuppressive 
or immunomodulatory medication, long-term use systemic corticosteroids (i.e. >3 months 
after start of LDTA therapy), methotrexate, cyclosporin, tacrolimus, mycofenolaatmofetil and/
or biological agents), and thiopurine therapy for a non-IBD indication. In addition, patients 
with short bowel syndrome (<200 cm small bowel) were excluded from analysis, because of 
possible interference with thiopurine bioavailability as allopurinol is a XO-inhibitor, and XO 
activity is particularly high in the intestinal mucosa.23
Data collection
Individual patient records and laboratory reports were reviewed. Baseline was set at the 
moment of starting LDTA therapy. Data collection was completed until December 31st 2016. 
Demographic data were collected including gender, age, weight, diagnosis, smoking behavior 
and history of IBD related surgery. IBD was classified according to the Montreal Classification 
for Crohn’s disease (CD) or ulcerative colitis/IBD-unclassified (UC/IBDU). Reasons for initiating 
LDTA therapy were recorded, and categorized into thiopurine monotherapy-attributed AEs 
(i.e. laboratory toxicity or clinical AEs, ineffectiveness of thiopurine monotherapy, skewed 
thiopurine metabolism at routinely performed TDM, and allopurinol prescribed for other 
diseases (e.g. gout). Therapy characteristics were collected including duration of preceding 
thiopurine monotherapy, type of thiopurine (AZA or MP), dosage of thiopurine and allopurinol, 
and duration of LDTA therapy.
Continued maintenance LDTA treatment
The primary outcome measure was continued maintenance ongoing LDTA treatment at annual 
intervals. Secondary outcomes were incidence rates of LDTA-attributed adverse events 
imposing therapy cessation, and incidence rates of LDTA-attributed laboratory toxicity, i.e. 
hepatotoxicity and myelotoxicity. Reasons for discontinuation of therapy were explored and 
subdivided into IBD flare, AEs, long-term remission, and other reasons (e.g. patient initiative 
and loss to follow-up). Flare of IBD was defined as clinical, biochemical and/or endoscopic 
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disease activity according to the clinical charts, which led to modification of therapy i.e step-
up treatment with systemic corticosteroids and/or immunomodulators or biological agents 
or surgery. Adverse events during LDTA treatment were divided into clinical adverse events 
such as fatigue, gastro-intestinal complaints and skin abnormalities, and laboratory toxicity 
(hepatotoxicity, myelotoxicity).
Evaluation of laboratory toxicity
All laboratory assessments performed during LDTA therapy were recorded, and screened for 
signs of toxicity. Myelotoxicity was defined as a leukocyte count <4.0 × 10⁻⁹/L and/or platelet 
count <150 × 10⁻⁹/L. Leukopenia was classified into mild (3.0-4.0 × 10⁻⁹/L ), moderate (2.0-
3.0 × 10⁻⁹/L) and severe (<2.0 × 10⁻⁹/L). Thrombocytopenia was also classified into mild (100-
150 10e9/l), moderate (50-100 × 10⁻⁹/L) and severe (<50 × 10⁻⁹/L). When both leukopenia and 
thrombocytopenia were detected within a laboratory assessment, myelotoxicity was graded 
based on the most severe value detected. Hepatotoxicity was defined as liver enzymes values 
above the upper limit of normal (ULN), i.e. alkaline phosphatase, gamma-glutamyltransferase, 
alanine aminotransferase and/or alanine aminotransferase. Hepatotoxicity was classified 
into 3 grades according to the Common Terminology Criteria for Adverse Events (CTCAE) v. 
3.0.24 Grade 1 is defined as liver tests between ULN and 2.5 x ULN, grade 2 is between 2.5–5.0 
x ULN and grade 3 is between 5.0–20.0 x ULN. In line with previous literature, an isolated 
increase in AP or AST < 2.5 x ULN was not considered as hepatotoxicity as it is not necessarily 
a sign of liver injury.6, 25, 26 When more than 1 aberrant liver test was detected within a 
laboratory assessment, hepatotoxicity was graded based on the most severe value detected. 
In addition, aberrant laboratory values at baseline leading to initiation of LDTA therapy were 
also collected to evaluate toxicity over time. Dose adjustments due to laboratory adverse 
events were documented.
Statistical analysis
The primary outcome of this study was continued maintenance LDTA treatment, defined as the 
percentage of patients on LDTA therapy at 12, 24, 36, 48 and 60 months after initiation of LDTA 
treatment using Kaplan Meier survival analysis. Treatment cessation was used as the endpoint 
for analyses regarding continued LDTA treatment, defined as IBD flare, drug withdrawal 
due to LDTA-attributed AEs (i.e. clinical or laboratory toxicity) or ineffectiveness, cessation 
of LDTA on patients initiative. All other patients were censored at time of LDTA withdrawal 
due to long-term remission or last follow-up. Kaplan–Meier curves with separate lines for 
reasons of initiation of LDTA (i.e. thiopurine monotherapy-attributed AEs, ineffectiveness of 
monotherapy and optimization of therapy due to TDM) were plotted to explore differences 
in rates of continued maintenance LDTA treatment. Log-rank tests were used to compare 
the Kaplan–Meier curves. Univariate Cox proportional hazard models were employed to 
assess associations between continued maintenance LDTA treatment and patient factors. 
The assumption of proportional hazards was assessed visually, using a log(-log(survival)) 
versus log of survival graph. Additionally, a multivariable Cox proportional hazard model 
was constructed, using the predictors with a P-value of <0.20 in the univariate models, using 
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stepwise backward elimination (probability of F to remove >0.10). In calculations including 
drug doses, we calculated the AZA dose into an equivalent MP dose with a conversion factor of 
2.08.27 Incidence rates of myelotoxicity and hepatotoxicity were expressed as the percentage 
of patients with detected laboratory toxicity per patient per treatment year (abbreviated 
as treatment year) and stratified according to the severity of toxicity (mild, moderate and 
severe toxicity). Patients were categorized based on the most severe value of myelotoxicity 
detected during follow-up. Detection rates of myelotoxicity and hepatotoxicity were expressed 
as the percentage of laboratory assessments showing signs of toxicity. Recovery of baseline 
laboratory toxicity was defined as the interval between date of commencement of LDTA and 
date of normalization of laboratory toxicity (date of laboratory assessment). Descriptive 
data were expressed as numbers with percentages. Continuous variables were expressed 
as mean with standard deviation (SD) data, or in case of non-normal distributions as median 
with interquartile range (IQR), defined as the 25th percentile and the 75th percentile. A value 
of P<0.05 was considered to be statistically significant. All analyses were conducted using IBM 
SPSS Statistics V.21.0 (Armonk, NY, USA: IBM).
RESULTS
Study population characteristics
A total of 221 adult IBD patients (46% males, median age 42 years [IQR 31-54]) treated with 
LDTA were included, with a total of 449 treatment-years of follow-up (Table 1). Hundred forty-
three patients (65%) were diagnosed with Crohn’s disease (CD) and 78 patients (35%) with 
UC/IBDU. Reasons for starting LDTA therapy were ineffectiveness of thiopurine monotherapy 
(45%), skewed thiopurine metabolism at routine TDM (23%), thiopurine monotherapy-
attributed laboratory toxicity i.e. hepatotoxicity and/or myelotoxicity (12%), clinical adverse 
events (3%) and combined ineffectiveness and laboratory toxicity (10%) (Table 1). In total, 
133 patients (60%) were treated with LDTA and AZA (adjusted median dose 0.3 mg/kg [IQR 
0.3-0.4]) and 88 patients (40%) were treated with LDTA and MP (median dose 0.4 mg/kg [IQR 
0.3-0.5]). No statistically significant differences were observed in dosages between AZA and 
MP (P=0.370). Co-prescription of 5-ASA was used as maintenance strategy in 48 patients (22%). 
Corticosteroids for induction treatment at the initiation of LDTA therapy was recorded in 34 
patients (15%).
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Table 1. Baseline cohort characteristics
N = 221
Male sex, n (%) 101 (46)
Age (yr) 42 .8 [31.4-55.0]
Age at diagnosis (yr) 30.8 [21.9-44.0]






































Bowel surgery, n (%) 42 (19)
Current smokers, n (%)a 50 (23)


















Reason initiation LDTA, n (%)
Ineffectiveness monotherapy
Adverse events thiopurine monotherapy
Laboratory toxicity
Clinical adverse events
Ineffectiveness + laboratory toxicity








IBD, inflammatory bowel disease; Yr, years; IQR, interquartile range; kg, kilogram; UC, ulcerative colitis; CD, Crohn’s 
Disease; IBDU, IBD-unclassified; AZA, azathioprine; MP, mercaptopurine; mg, milligram; 5-ASA, 5-Aminosalicylic acid; 
TPMT, thiopurine S-methyltransferase. Data are reported as median with interquartile range.
a Missing data for weight, n=1; for smoking status n=36; for thiopurine dose, n= 1; b Combined for UC and IBDU.
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Continued maintenance LDTA treatment
Maintenance LDTA treatment in IBD patients was continued in 78% at 1 year (n=145), 66% 
at 2 years (n=83), 57% at 3 years (n=52), and 52% at 4 years (n=33) (Figure 1). After a median 
follow-up of 19.4 months [IQR 8.5-34.9], treatment was discontinued in 94/221 patients (43%) 
(Table 2).
Figure 1. Continued LDTA maintenance treatment. Kaplan-Meier estimates of time to drug cessation 
after LDTA onset (T0) are shown. Patients were censored at time of LDTA withdrawal due to long-term 
remission or last follow-up.
Reasons for withdrawal of LDTA were ineffectiveness (15%), LDTA-attributed AEs 12%), on 
patient’s initiative (9%), long-term remission (3%) and other reasons (4%). With regard to the 
AEs imposing LDTA cessation, 15 patients (7%) stopped treatment due to clinical AEs (details in 
Table 2), 9 patients (4%) for myelotoxicity and 4 patients (2%) for hepatotoxicity. A significantly 
greater proportion of patients treated with MP stopped LDTA treatment during follow-up 
than AZA users (47.7% vs. 29.3%, P=0.005). In subgroup analysis of patients that withdrew 
LDTA, thiopurine dose was higher in MP patients than in AZA patients (0.42 mg/kg (SD 0.17) 
vs. 0.35mg/kg (SD 0.12), P=0.030)). No difference was observed in the rate of continued LDTA 
maintenance therapy in patients with concomitant 5-ASA therapy (P=0.985).
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Table 2. Clinical outcome of LDTA therapy
N = 221
Cessation of LDTA therapy, n (%) 94 (43)






























Reasons for cessation of LDTA therapy. AEs, adverse events; IQR, interquartile range. a The reported LDTA-attributed 
adverse events imposed therapy cessation. b Patient discontinued due to recurrent viral (airway) infections, no 
laboratory toxicity was observed. c Myelotoxicity was defined as a leukocyte count <4.0 × 10⁻⁹/L and/or platelet count 
<150 × 10⁻⁹/L. Hepatotoxicity was defined as liver enzymes values above the upper limit of normal (ULN), i.e. alkaline 
phosphatase (AP), gamma-glutamyltransferase (ɣ-GT), alanine aminotransferase (ALT) and/or alanine aminotransferase 
(AST). Both myelotoxicity and hepatotoxicity were classified into 3 grades according to the Common Terminology 
Criteria for Adverse Events (CTCAE) v. 4.0. d During follow-up, 8 dose reductions were performed due to leukopenia.
Overall, continued LDTA maintenance treatment in patients receiving therapy for monotherapy-
attributed AEs was 77% after median follow-up of 22 months [IQR 10-40] and significantly 
higher than 56% in the total group of patients initiating LDTA for other reasons after median 
follow-up of 19 months [IQR 8-34] (P=0.016) (Figure 2, log-rank P=0.03).
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Figure 2. Continued LDTA maintenance treatment related to reason for initiation. The dotted line rep-
resents continued treatment in patients that initiated LDTA therapy for AEs during thiopurine mono-
therapy (n=56). The black line represents continued treatment in patients that initiated LDTA therapy 
for other reasons than AEs i.e. Ineffectiveness monotherapy, routinely discovered skewed metabolism 
or other reasons (n=165).
In univariate cox regression analysis, LDTA initiated for AEs was associated with longer 
LDTA maintenance treatment (Hazard Ratio (HR) 1.38 (95% CI 1.03-1.86, P=0.034)). Also, a 
higher thiopurine dose was associated with longer LDTA maintenance treatment (HR 1.73 
(95% CI 0.41-7.27, P=0.055)). However, in multivariable Cox regression analysis no statistically 
significant association was observed. The presence of myelotoxicity (HR 1.52, P=0.082) and 
LDTA initiated for monotherapy-attributed AEs during monotherapy (HR 1.77, P=0.063) showed 
no statistically significant difference in longer LDTA maintenance treatment (Table 3). No 
other factors, including diagnosis, gender, age or disease characteristics, were associated 
with continued LDTA maintenance treatment.
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Table 3. Covariates associated with continued maintenance LDTA treatment
Univariate analysis Multivariable analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Male gender 0.80 (0.52-1.23) 0.308
UC/IBDUa 1.00 (0.64-1.57) 0.997
Age at baseline (years) 0.99 (0.97-1.00) 0.153* 0.99 (0.98-1.01) 0.475
Active smoker 0.909 (0.48-1.69) 0.740
Azathioprineb 1.33 (0.86-2.07) 0.198* 0.67 (0.42-1.07) 0.093
Thiopurine dosec 1.73 (0.41-7.27) 0.055* 1.83 (0.41-8.19) 0.428
LDTA initiated for AEsd,e 1.38 (1.03-1.86) 0.034* 1.77 (0.97-3.25) 0.063
UC, Ulcerative colitis; IBDU, IBD-unclassified; AEs, adverse events; CI, confidence interval; HR, hazard ratio; LDTA, low 
dose thiopurine and allopurinol. * Covariates with a p-value <0.2 were included in the multivariable regression analysis. 
a IBD diagnosis, Ulcerative colitis/IBD-unclassified vs. Crohn’s disease. b Drug type, mercaptopurine vs. Azathioprine. 
c Azathioprine dose in mg/kg was divided by a factor 2.08 to compare with MP dosage. d LDTA initiated for thiopurine 
monotherapy-attributed AEs (n=56) compared to the total group of patients initiating LDTA for other reasons (n=165). 
e Adverse events comprise both clinical AEs and laboratory toxicity. Presence of toxicity (hepatotoxicity and/or 
myelotoxicity) was classified according to the Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0
Laboratory toxicity
During LDTA treatment, 130 patients (59%) had signs of toxicity in one or more laboratory 
assessments (Table 4). Signs of myelotoxicity and/or hepatotoxicity were detected in 481/1827 
assessments (26%). Thiopurine dose was slightly higher in patients with laboratory toxicity 
during LDTA than in patients without laboratory toxicity (0.40 mg/kg (SD 0.16) vs. 0.36 mg/kg 
(SD 0.13)), without statistical significance (P=0.053). No difference was observed in laboratory 
toxicity between patients with or without concomitant treatment with 5-ASA (P=0.297). 
Myelotoxicity was observed in 87/221 (39%) patients, and in 265/1827 assessments (15%). 
In addition to 7% of patients (n=15) that showed myelotoxicity at baseline, the incidence 
rate of myelotoxicity was 39% (n=64) during the first year of LDTA treatment. After the first 
year, myelotoxicity incidence rate was 11% per treatment year. The majority of detected 
myelotoxicity in laboratory assessments was classified as mild (86%) and comprised 
leukopenia in 94%. No cases of severe myelotoxicity were detected in this cohort. LDTA 
therapy was stopped in 9 patients (4%) due to de novo myelotoxicity (mild n=4, moderate 
n=5). In addition, myelotoxicity was managed by thiopurine dose reduction in 8 patients 
(4%). All patients were then able to continue LDTA therapy after thiopurine dose reduction. 
Median follow up after dose reduction was 13.6 months (IQR 6.7-27.7). Ongoing LDTA use was 
documented in 7 patients until the end of follow up and 1 patient stopped LDTA treatment 
due to sustained remission.
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Table 4. Detection rate of laboratory toxicity
Patients Overall assessments
n=221 n= 1827

























Incidence rate of toxicity during LDTA therapy. Myelotoxicity was defined as a leukocyte count <4.0 x 10⁻⁹/L and/or 
platelet count <150 × 10⁻⁹/L.. Hepatotoxicity was defined as liver enzymes values above the upper limit of normal (ULN), 
i.e. alkaline phosphatase (AP), gamma-glutamyltransferase (ɣ-GT), alanine aminotransferase (ALT) and/or alanine 
aminotransferase (AST). Both myelotoxicity and hepatotoxicity were classified into 3 grades according to the Common 
Terminology Criteria for Adverse Events (CTCAE) v. 4.0. Patients were classified according to the most severe grade of 
toxicity. Combined myelotoxicity and hepatotoxicity was detected in 27 patients (12%).
Hepatotoxicity was present in 259/1827 (14%) assessments in 69/221 patients (31%). In addition 
to 17% of patients (n=37) that initiated LDTA due to monotherapy-attributed hepatotoxicity 
during thiopurine monotherapy with signs of hepatotoxicity present at baseline, the incidence 
rate of hepatotoxicity in the first year of LDTA treatment was 22% (n=36). The incidence rate 
of hepatotoxicity after the first year was 11% per treatment year. The majority of detected 
hepatotoxicity was classified as mild (91%), 5% moderate and 4% severe. Two patients (1%) 
with de novo hepatotoxicity had to withdraw LDTA. Clinical treatment-related complications 
with concurrent laboratory toxicity were detected in 2 patients (10.9%). Both patients were 
admitted to the hospital and received a transfusion with packed cells for anemia (n=1) or 
pancytopenia (n=1). No cases of nodular regenerative hyperplasia were reported. No mortality 
was observed.
Laboratory toxicity prior to LDTA
Within the subgroup of 49 patients that started LDTA due to thiopurine monotherapy-
attributed laboratory toxicity, myelotoxicity resolved in 10/12 patients (83%), hepatotoxicity 
resolved in 29/34 patients (85%) and laboratory abnormalities normalized in all 3 patients with 
combined toxicity (100%). Median time to myelotoxicity resolved after a median duration of 
1.2 months [IQR 0.8-5.4] and hepatotoxicity after 1.4 months [IQR 0.7-5.0] (Figure 3). None of 
these 50 patients had to withdraw LDTA due to laboratory toxicity.
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Figure 3. Resolution of thiopurine-monotherapy associated laboratory toxicity during LDTA therapy. 
The black line represents time to normalization of myelotoxicity established with laboratory assessment 
obtained during LDTA therapy (n=15). The dotted line represents time to normalization of hepatotoxicity 
established with laboratory assessment obtained during LDTA therapy (n=37).
DISCUSSION
In this large real life cohort of 221 of IBD patients maintenance LDTA treatment was continued 
in 78% after 1 year, 66% after 2 years, 57% after 3 years, and 52% at 4 years of treatment. 
Although mild myelotoxicity and hepatotoxicity are commonly detected during LDTA, 
these laboratory results rarely induce LDTA withdrawal. Our data demonstrate that LDTA 
optimization strategy is beneficial in IBD, especially in patients failing thiopurine monotherapy 
due to AEs.
In this study, we confirm that long-term continued maintenance LDTA treatment is considerable 
and tolerance of LDTA in patients after failure of thiopurine monotherapy. As definitions for 
effectiveness of LDTA vary among available studies, direct comparison of the results is difficult. 
However, considerably high effectiveness was reported uniformly, regardless of the outcome 
measure after failure of thiopurine monotherapy. Studies evaluating effectiveness of LDTA 
using clinical disease activity scores have reported steroid-free clinical response, i.e. decline 
in Harvey Bradshaw Index or Simple Clinical Colitis Activity Index ≥3, ranging from 65% after 
median follow-up of 19 months to 86% after median follow-up of 31 months.19, 28A retrospective 
trial reported clinical remission (Harvey Bradshaw Inde ≤3 or Lichtiger Index ≤3) in 64% of 
LDTA treated patients an average of 34 months.28 Data on endoscopic effectiveness of LDTA 
are scarce, and remarkably only data in patients with clinical response to LDTA for the total 
group of both thiopurine naïve patients and after monotherapy failure have been reported: 
endoscopic improvement was observed in 92% of the patients and endoscopic remission in 
54% of patients after median follow-up of 19 months.19 Similar to the indicator of effectiveness 
of LDTA in our study, Hoentjen et al. evaluated long-term drug survival of LDTA at yearly time 
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points in 77 IBD patients failing thiopurine monotherapy.21 Reported drug survival rates in this 
smaller cohort of patients were slightly higher compared to our cohort: 87% at 1 year, and 65% 
at 5 years of follow-up. A possible explanation for these differences is that 9% of patients in this 
cohort received co-treatment with anti-TNF during LDTA therapy, possibly enhancing a more 
favorable outcome.29 In addition, a disease flare during LDTA therapy demanding (temporary) 
addition of systemic corticosteroid treatment was considered as cessation of LDTA therapy, 
whereas in the cohort of Hoentjen et al. rescue treatment was not censored in the survival 
analysis.21, 30 14
In this study, we have shown that LDTA is particularly beneficial in patients failing monotherapy 
due to AEs, including laboratory toxicity. The following three observations substantiate this 
conclusion. Firstly, we have shown that overall continued LDTA maintenance treatment is 
higher in patients starting LDTA for thiopurine monotherapy-attributed AEs, than in patients 
starting LDTA for other indications, including ineffectiveness of monotherapy or patients 
with a skewed thiopurine metabolism at routinely performed TDM. Secondly, we have shown 
that mild hepatotoxicity and myelotoxicity are detected often during LDTA, however severe 
laboratory toxicity is uncommon. Thirdly, our study showed that thiopurine monotherapy-
associated myelotoxicity and hepatotoxicity frequently improved after LDTA initiation 
and none of the patients with laboratory AEs as indication for LDTA stopped treatment for 
laboratory toxicity.
We observed high rates of continued maintenance treatment in patients starting LDTA after 
failing monotherapy thiopurines due to AEs. However, these observations are not in line with 
the results of a recent cohort study by Pavlidis et al.19 The latter study showed that overall 
clinical response rates of LDTA (Harvey Bradshaw Index and Simple Clinical Colitis Activity 
Index scores) were comparable in a subgroup of patients failing monotherapy due to AEs (n=74) 
and the subgroup of patients that received LDTA for ineffectiveness of monotherapy (n=116) 
(61% vs. 65%). In addition to a different outcome measure for therapy effectiveness used in 
both studies, 92% of patients used concomitant steroids at start of LDTA in the study of Pavlidis 
et al., as compared to only 15% in our study. The high percentage of symptomatic patients 
in the subpopulation of patients with monotherapy-attributed AEs as the primary indication 
for LDTA in the study from Pavlidis et al. probably explains the difference between the study 
findings, as therapy effectiveness will be different between symptomatic and asymptomatic 
patients with laboratory toxicity.
Although patients remain susceptible to mild laboratory toxicity during LDTA therapy, no 
cases of severe myelotoxicity were observed and severe hepatotoxicity was detected rarely in 
our cohort. We observed that the incidence rate of myelotoxicity is highest in the first year of 
treatment (39%), and decreased to 11% per year afterwards. These data can only be compared 
to other reports with cumulative incidences, as yearly incidence rates of myelotoxicity LDTA 
are unavailable. Myelotoxicity was present in 39% of patients during median follow-up of 19.4 
months. This incidence is within the wide range of reported incidences of myelotoxicity in 
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LDTA, varying from 1.3% within median follow-up of 19 months to 48% within median follow-
up of 15 months.16, 19-21, 28, 30 The wide range of incidences of myelotoxicity results from varying 
definitions, and the high percentage of mild myelotoxicity, illustrated by the observation in 
our study that 71% of patients with myelotoxicity had WBC between 3.0 and 4.0 × 10⁻⁹/L. In 
our study, a conservative definition of myelotoxicity was used, to avoid underestimation of 
clinical consequences of laboratory toxicity. As a result, the incidence of myelotoxicity may 
be somewhat overestimated. Another possible explanation for the wide range of reported 
rates of myelotoxicity in literature is the use of either AZA or MP.19, 28 Mercaptopurine has been 
associated with dose-dependent side effects, in particular myelotoxicity. 28, 31 This finding has 
been attributed to higher dosing of MP, due to limited availability of pharmaceutical dosage 
forms of MP. Our data do not confirm higher dosing of MP than AZA in LDTA therapy. Similar 
to myelotoxicity, we found that the incidence rate of hepatotoxicity was as high as 22% in the 
first year of treatment, and decreased to 11% per patient year during maintenance treatment. 
These data add significantly to available literature as data are currently lacking in available 
reports.
Another benefit of LDTA treatment is the rapid recovery of baseline thiopurine monotherapy-
attributed laboratory toxicity after LDTA initiation.19, 21, 28, 32, 33 We observed high success rates in 
the resolution of hepatotoxicity in 86% of LDTA treated patients. Remarkably, we also observed 
benefit of LDTA prescribed for thiopurine therapy associated myelotoxicity in 87% of these 
patients. Indeed, it has been described that myelotoxicity can be induced by the presence 
of substantially elevated 6-MMPR levels.9 Allopurinol is an inhibitor of xantine oxidase and 
has an indirect inhibiting function on TPMT enzyme activity, and therefore induces a shift in 
metabolites favouring 6-TGN and lowering 6-MMPR production.32, 34 In addition, allopurinol 
seems to have an enhancing effect on hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT), contributing to higher 6-TGN formation as well.13, 15, 35 This therapeutic profile is 
associated with low AE rates and high efficacy. The prompt normalization of monotherapy-
attributed myelotoxicity after initiation of LDTA observed in this cohort supports this 
hypothesis. An incidental finding, that underlines the insignificant role of laboratory toxicity 
during LDTA, was that the presence of hepatotoxicity was a predictor of longer LDTA treatment 
(HR 1.74, data not shown), even when excluding patients that initiated LDTA due to thiopurine 
monotherapy-attributed hepatotoxicity in post-hoc analysis (HR 2.53). Both higher rates of 
continued LDTA maintenance treatment as well as the presence of this dose-dependent AE 
could be explained by a higher thiopurine dose established in patients with laboratory toxicity, 
probably by increased efficacy.
Our study describes a large real-world IBD population on LDTA after thiopurine monotherapy, 
with detailed information on an individual patient level, especially regarding laboratory 
toxicity. A major strength of this study is that it reflects current clinical practice in a real-life, 
non-standardized cohort, which enables the generalizability of these results. Nevertheless, 
some limitations associated with this retrospective study design need to be addressed. First, 
due to the retrospective study design, we are not able to draw conclusions on long-term 
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remission rates during LDTA as data on endoscopic parameters and faecal biomarkers were 
not collected. Second, it has to be noted that the decision for LDTA commencement was not 
always guided by 6-TGN and 6-MMPR measurements. Therefore, it is not possible to distinguish 
between ineffectiveness of thiopurine monotherapy due to a skewed metabolism or non-
response to thiopurine therapy in general, possibly affecting susceptibility to LDTA therapy. 
In addition, considerations regarding favourable thiopurine dose in LDTA therapy is hampered 
by the lack of available thiopurine metabolites during LDTA treatment. Nevertheless, our 
data show that LDTA combination therapy can be safely used in clinical practice, even when 
thiopurine metabolite measurements are unavailable. Third, a majority of patients (78%) 
was selected from tertiary referral hospitals. Rates of LDTA ineffectiveness might have been 
increased in these patients due to the complexity of IBD disease course. Also, this might have 
led to more frequent outpatient visits and laboratory assessments during LDTA therapy and 
thus a higher detection rate of toxicity and clinical AEs interfering with therapy outcome
In conclusion, LDTA therapy is a safe and beneficial optimization strategy in IBD patients and 
should not be disregarded after failure of thiopurine monotherapy. A considerably high rate 
of continued LDTA maintenance treatment during was established during long-term follow-
up and seems most advantageous in patients failing thiopurine monotherapy due to adverse 
events. Although mild myelotoxicity and hepatotoxicity are commonly observed, they rarely 
affect LDTA treatment cessation.
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Background: To timely detect myelotoxicity and hepatotoxicity, laboratory-monitoring at 
3-month intervals is advised throughout thiopurine maintenance treatment for inflammatory 
bowel disease (IBD). However, reported incidence rates of myelotoxicity and hepatotoxicity 
in maintenance treatment are low.
Aim: To assess incidence rates and clinical consequences of myelotoxicity and hepatotoxicity 
in thiopurine maintenance therapy after at least 1 year of thiopurine treatment.
Methods: Retrospective analysis of therapy adjustment for laboratory toxicity in adult IBD 
patients after 12 consecutive months of azathioprine (AZA) or mercaptopurine monotherapy 
(i.e. baseline) between 2000-2016. Incidence rates of laboratory toxicity (i.e. myelotoxicity 
(leukocyte count<4.0x10e9/L, and/or platelet count<150x10e9/L) and/or hepatotoxicity 
(AP, GGT, ALT, and/or AST above ULN, excluding isolated increased AST/AF)) and associated 
diagnostic procedures and complications were assessed.
Results: In total, 12.391 laboratory assessments were performed in 1132 patients (56% 
female, AZA 74%) during 3.3 years median follow-up. Median monitoring frequency was 
3.1 assessments/treatment-year. Only 83/12.391 (0.7%) assessments resulted in therapy 
adjustment, dose-reduction in 46 patients, cessation in 28 and allopurinol initiation in 9; 
risk of therapy adjustment was 1.9%/treatment-year. Incidence rates of myelotoxicity were 
7.1% (5.1% mild/1.8% moderate/0.1% severe) and hepatotoxicity 5.1% (3.8% mild/1.1% 
moderate/0.2% severe) per treatment-year. Treatment-related complications with concurrent 
laboratory toxicity occurred in 12 patients (1.1%) and would not have been prevented by 
monitoring.
Conclusion: Severe laboratory toxicity is uncommon after 1 year of thiopurine monotherapy 
at 4-month monitoring intervals. Therapy adjustments are rare after detection of laboratory 
toxicity. After 1 year of thiopurine monotherapy, laboratory-monitoring may be lowered to 
less than a 4-month interval.
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INTRODUCTION
Thiopurines, azathioprine (AZA) and mercaptopurine (MP), are an effective maintenance 
therapy for patients with inflammatory bowel disease (IBD). Advantages of thiopurine 
therapy include a steroid-sparing effect, and its association with a reduced risk of colorectal 
carcinoma.1-3 A recent study on the effect of thiopurines on the natural history of ulcerative 
colitis showed that thiopurine continuation was associated with a lower rate of hospital 
admission and a reduced risk of progression of disease extent and a colectomy.1 Adverse 
events (AEs) are the most important downside of thiopurine therapy and result in therapy 
withdrawal in up to 40% of patients, primarily within the first months of treatment.4-6 These AEs 
can be divided into dose-independent events, such as pancreatitis and arthralgia, and dose-
dependent events. The most alarming dose-dependent AEs, hepatotoxicity and myelotoxicity, 
warrant laboratory monitoring, including a full blood count (FBC) and serum liver enzyme tests 
(LTs).7 The risk of laboratory toxicity is high in the first year of treatment, which is reflected by 
high incidence rates of 11% for myelotoxicity and 13% for hepatotoxicity.8-10 Myelotoxicity and 
hepatotoxicity rates may be reduced after the introduction of thiopurine S-methyltransferase 
(TPMT) genotype testing before- and/or assessment of drug metabolites in thiopurine 
therapy.7,11
Safety concerns associated with thiopurines can be attenuated by the early identification of 
toxicity through routine laboratory monitoring and subsequent modification of therapy.8,10-13 
This potential benefit of laboratory monitoring should be balanced against the burden 
for patients and associated direct and indirect healthcare costs. Currently, international 
guidelines advise an intensive laboratory monitoring schedule in the first 3 months of 
treatment.14 During subsequent maintenance therapy, routine laboratory monitoring at 2 to 
3 month intervals is recommended. Laboratory toxicity is not always clinically relevant as it 
often reverses spontaneously.9,10,15,16 Also, laboratory toxicity usually develops within the first 
few months of treatment and the reported incidence rate in maintenance treatment is low.9,10 
In addition, leukopenia can develop at any time during treatment without preceding signs of 
myelotoxicity.9,15 Therefore, frequent routine assessment of laboratory parameters in long-
term maintenance thiopurine therapy may have a limited clinical impact. Data on therapy 
adjustments or diagnostic procedures based on toxicity found with laboratory monitoring are 
lacking. This study aims to assess the incidence rate and clinical consequences of myelotoxicity 
and hepatotoxicity detected with the current laboratory monitoring regimen in IBD patients 
who have been on thiopurine maintenance therapy for more than 1 year.
METHODS
Study design and patient selection
A retrospective cohort study was conducted in four tertiary referral centers and two teaching 
hospitals in the Netherlands. Adult IBD patients with confirmed diagnosis of Crohn’s disease 
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(CD), ulcerative colitis (UC), or IBD-unclassified (IBDU), treated with AZA or MP between 
January 1st 2000 and December 31st 2016 were included after 1 year of thiopurine treatment. 
Inclusion criteria were maintenance thiopurine monotherapy, defined as 12 consecutive 
months of treatment, and quiescent disease, defined as clinical, systemic steroid-free 
remission without the need for step-up treatment. Exclusion criteria were unavailability of 
laboratory assessments, a known history of chronic liver disease (i.e. viral hepatitis, auto-
immune hepatitis, steatosis, primary sclerosing cholangitis, primary biliary cholangitis or 
liver cirrhosis), treatment with concomitant immunosuppressive medication (systemic 
corticosteroids, methotrexate, cyclosporin, tacrolimus, mycophenolate mofetil and/or 
biological agents), and thiopurine therapy for a non-IBD indication. In addition, patients 
with short bowel syndrome (<200 cm small bowel) were excluded from analysis, because of 
possible interference with thiopurine absorption. This study conformed to the principles of 
the Declaration of Helsinki and was approved by the institutional ethical review committee of 
the corresponding center and all participating centers as per local regulations.
Data collection
Baseline was set at the first laboratory assessment after 1 year of thiopurine treatment. 
Data collection was completed December 31st 2016. The following patient characteristics 
were collected from the patient’s electronic medical records: gender, weight, smoking 
status, and IBD-type and Montreal classification. Treatment characteristics included type 
of thiopurine, date of initiation, dosage, concomitant IBD medication, and TPMT genotype. 
Laboratory results performed throughout maintenance thiopurine treatment (i.e. after 1 year 
of treatment) were recorded and screened for toxicity. Myelotoxicity was defined as leukopenia 
and/or thrombocytopenia. Leukopenia was classified into mild (3.0-4.0x10e9/L), moderate 
(2.0-3.0x10e9/L) and severe (<2.0x10e9/L). Thrombocytopenia was also classified into mild 
(100-150x10e9/L), moderate (50-100x10e9/L) and severe (<50x10e9/L). When both leukopenia 
and thrombocytopenia were detected within a laboratory assessment, myelotoxicity was 
graded based on the most severe detected value. Hepatotoxicity was defined as abnormal 
liver tests (LTs), i.e. alkaline phosphatase (AP), gamma-glutamyltransferase (ɣ-GT), alanine 
aminotransferase (ALT) and/or alanine aminotransferase (AST), defined as an increase above 
the upper limit of normal (ULN). Hepatotoxicity was classified into 3 grades according to the 
Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0. 17 Grade 1 is defined as LTs 
between ULN-2.5xULN, grade 2 is between 2.5–5.0xULN and grade 3 is between 5.0–20.0xULN. 
In line with previous literature, an isolated increase in AP or AST < 2.5xULN was not considered 
as hepatotoxicity as it is not necessarily a sign of liver injury.10,18 When more than 1 aberrant 
LT was detected within a laboratory assessment, the grade of hepatotoxicity was based on 
the most severe detected value. When myelotoxicity and hepatotoxicity were detected in 1 
assessment, the severity of ‘combined’ toxicity was based on the most severe detected grade. 
Treatment changes and/or additional diagnostic procedures were recorded for patients with 
laboratory toxicity. Patients were followed until treatment cessation or end of follow up at 
December 31st 2016. Reasons for cessation of treatment included disease flare warranting 
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step-up treatment or initiation of therapy with systemic (gluco-cortico)steroids, long-term 
remission, AEs, on patient initiative, family planning or loss to follow up.
Outcomes
The primary outcome was therapy adjustment based on laboratory toxicity, defined as 
therapy cessation, dose reduction or additional therapy with allopurinol alongside a reduced 
thiopurine dose (LDTA). Secondary outcomes were additional diagnostic procedures triggered 
by laboratory toxicity, incidence rates of myelotoxicity and hepatotoxicity and laboratory 
toxicity related complications. Additional diagnostic procedures comprised extra laboratory 
assessments, abdominal ultrasonography, magnetic resonance imaging, bone marrow 
examination and liver biopsy. Complications associated with concurrent laboratory toxicity 
(including hospitalization, surgery or infections) were classified according to the CTCAE 
(version 4.0) and categorized according to system organ class and severity. Severity was 
subdivided in grade 1 (asymptomatic or mild symptoms without indication for treatment or 
intervention), grade 2 (moderate symptoms; local or non-invasive intervention indicated), 
grade 3 (severe medically significant symptoms, invasive treatment and/or hospitalization 
indicated), grade 4 (life-threatening consequences) or grade 5 (death related to AE). Only 
therapy-related clinical complications were included in the analysis.
Statistics
The primary outcome of this study was defined as therapy adjustments based on laboratory 
toxicity. For Kaplan-Meier survival analyses, patients without therapy adjustments were 
censored at time of last follow-up or treatment cessation for other reasons than laboratory 
toxicity. Characteristics between patients with and without AEs were compared by the chi-
square test for dichotomous variables, and student’s t tests or Mann–Whitney U tests were 
used for continuous variables. Univariate and multivariable Cox proportional hazards models 
and logistic regression models were performed to assess risk factors of patient characteristics 
and laboratory covariates associated with therapy adjustments, and the time of development 
of laboratory toxicity. Variables with a P<0.20 were included in a multivariate Cox-proportional 
hazard model. Incidence rates of myelotoxicity and hepatotoxicity were expressed as the 
percentage of patients with detected laboratory toxicity per patient per treatment year 
(abbreviated as treatment year). Cumulative incidence of myelotoxicity and hepatotoxicity 
was calculated using Kaplan-Meier estimates, and stratified according to the most severe value 
(mild, moderate or severe toxicity), with time to event set at the first event in the corresponding 
category of severity. Detection rates of myelotoxicity and hepatotoxicity were expressed as 
the percentage of laboratory assessments showing signs of toxicity. The AZA drug dose was 
calculated into an equivalent pharmaceutical MP dose with a conversion factor of 2.08 based 
on molecular weight and bioavailability, the so-called AZA adjusted dose.19 Data are presented 
as median and its interquartile range for continuous variables when applicable. A value of P 
<0.05 was considered to be statistically significant. All analyses were conducted using IBM 
SPSS Statistics V.22.0 (Armonk, NY, USA: IMB).
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A total of 1132 IBD patients on long-term thiopurine treatment were included (56% female, 
median age 37 years (IQR 26-49). In total, 843 patients (74%) were treated with AZA (adjusted 
median dose 0.9 mg/kg (IQR 0.8-1.0)) and 289 patients (26%) were treated with MP (median 
dose 0.8 mg/kg [IQR 0.6-1.1]). Median follow up until cessation of therapy or censoring was 3.3 
years [IQR 1.7-5.6] (Table 1). Treatment was discontinued in 641 patients (57%) after median 
follow up of 4.4 years [IQR 28-6.7]. Reasons for discontinuation were IBD flare in 265 patients 
(23%), sustained remission in 167 patients (15%), on patient initiative in 70 patients (6%) and 
AEs in 70 patients (6%). These AEs comprised clinical AEs in 29 patients (2.6%) (general malaise 
n=11, skin reactions n=11, arthralgia n=4, other n=3) and laboratory toxicity in 41 patients 
(3.5%).
Detection rate of myelotoxicity and hepatotoxicity
Overall, toxicity was detected in 2.030 (16%) of 12.391 laboratory assessments. During 
follow-up, 546 patients (48%) had signs of toxicity in one or more laboratory assessments. 
No difference was observed in monitoring rates between patients with or without laboratory 
toxicity (p=0.259). Myelotoxicity was observed in 370 patients (33%) in 1066 assessments. 
Overall detection rate of myelotoxicity was 8.6% i.e. 7.6% for mild myelotoxicity, 0.9% for 
moderate myelotoxicity and 0.04% for severe myelotoxicity (Table 2). Hepatotoxicity was 
present in 275 patients (24%) in 950 assessments with an overall detection rate of 7.7% i.e. 6.7% 
for mild hepatotoxicity, 0.8% for moderate hepatotoxicity and 0.1% for severe hepatotoxicity 
(Table 2).
Table 1. Baseline Characteristics
N=1132
Male sex, n (%) 500 (44)
Age (yr), median [IQR] 37 [26-49]
Age at IBD diagnosis (yr), median [IQR] 26 [20-36]
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Table 1. Continued.
N=1132














History of IBD related surgery, n (%) 334 (30)
















57 (5) / 42 (4)









IBD, inflammatory bowel disease; IQR, interquartile range; kg, kilogram; AZA, azathioprine; MP, mercaptopurine; mg, 
milligram; 5-ASA, 5-Aminosalicylic acid; TPMT, thiopurine S-methyltransferase. a limited data for weight, n=1124; for 
Montreal disease extent, n=369; for smoking status n=1020; for thiopurine dose, n= 1124; for TPMT genotype, n=193; 
b Combined for UC /IBDU. c Excluding patients with concomitant use of allopurinol (n=99). d Adjusted AZA drug dose 
represents the equivalent pharmaceutical MP dose with a conversion factor of 2.08.





Median monitoring frequency / treatment year, n (IQR) 3.1 [2.2-3.9] -
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Incidence rate of myelotoxicity and hepatotoxicity
Myelotoxicity
The overall incidence rate of myelotoxicity was 7.1% per treatment year, specifically 5.2% for 
mild myelotoxicity, 1.8 % for moderate myelotoxicity and 0.1% for severe myelotoxicity (Figure 
1A). In addition to 9% of patients (n=129) that showed myelotoxicity at baseline, cumulative 
incidence rates of myelotoxicity on maintenance thiopurine therapy were 12% at 1 year, 24% 
at 3 years, and 29% at 5 years of follow up. Median time to the development of myelotoxicity 
was 6 months from baseline [IQR 0-20]. The majority of detected myelotoxicity in laboratory 
assessments was classified as mild toxicity (945/1066 assessments, 89%) and comprised 
leukopenia in 97% (1032/1066 assessments).
Figure 1. Incidence rate of laboratory toxicity. Cumulative incidence of laboratory toxicity, stratified 
according to severity of myelotoxicity (A) or hepatotoxicity (B). A) Patients were categorized based on the 
most severe value of myelotoxicity detected during follow up, with time to event set at first event in the 
corresponding category of severity. The dark blue area represents severe myelotoxicity (n=6); the blue 
area represents moderate myelotoxicity (n=83); the light blue area represents mild myelotoxicity (n=282); 
the light grey area represents patients without myelotoxicity (n=761). B) Patients were categorized based 
on the most severe value of hepatotoxicity detected during follow up, with time to event set at first event 
in the corresponding category of severity. The dark green area represents severe hepatotoxicity (n=8); the 
green area represents moderate hepatotoxicity (n=38); the light green area represents mild hepatotoxicity 
(n=253); the light grey area represents patients without hepatotoxicity (n=833).
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Concomitant allopurinol treatment was a risk factor for myelotoxicity when compared to 
patients without laboratory toxicity (HR 1.59, 95% CI 1.04-2.43, P<0.034) (Table 3). A borderline 
significant interaction was observed between MP and allopurinol (p=0.08)
Hepatotoxicity
The overall incidence rate of hepatotoxicity was 5.1% per treatment year i.e. 3.8% for mild 
hepatotoxicity, 1.1 % for moderate hepatotoxicity and 0.2% for severe hepatotoxicity (Figure 
1B). In addition to the 8% of patients (n=91) that showed hepatotoxicity at baseline, cumulative 
incidence rates of patients that showed signs of hepatotoxicity were 6% at 1 year, 14% at 3 
years, and 21% at 5 years of follow up. Median onset of hepatotoxicity was 9 months from 
baseline [IQR 0-26]. In univariate and multivariate Cox regression analyses treatment with 
MP (HR 1.40 95% CI 1.10-1.78, P<0.006) and concomitant use of allopurinol (HR 2.73 95% CI 
1.56-4.79, P<0.0001) were associated with an increased risk of hepatotoxicity in long-term 
thiopurine treatment (Table 3). No interaction was observed between MP and allopurinol.
In univariate and multivariate Cox regression analyses, male gender (hazard ratio (HR) 1.302; 
95% confidence interval (CI) 1.10-1.54, P<0.009), treatment with MP (HR 1.56 95% CI 1.30-1.87, 
P<0.0001) and diagnosis of UC/IBDU (HR 1.27 95% CI 1.09-1.54, P<0.003) were associated 
with an increased risk of laboratory toxicity of any type in long-term thiopurine treatment 
(Table 3). No differences in overall toxicity, myelotoxicity and hepatotoxicity were observed 
in patients with TMPT abnormalities. Notably, thiopurine dose in patients with intermediate 
TPMT activity (0.78mg/kg +/- 0.27) was significantly lower than in patients with normal TPMT 
activity (0.90 mg/kg +/- 0.26) (P=0.027).
Clinical consequences of laboratory toxicity
Therapy adjustments for toxicity
After detection of laboratory toxicity, therapy adjustments were performed in 83 patients 
(7.3%) after a median follow-up time of 1.8 years [IQR 0.5-3.5]. Overall, 0.7% (83/12.391) 
of laboratory assessments in this cohort resulted in a therapy adjustment. These therapy 
adjustments comprised therapy cessation (n=28, 34%), dose reductions (n=46, 55%) and switch 
to LDTA therapy (n=9, 11%) (Table 4). Reasons for therapy cessation in these 28 patients were 
myelotoxicity (n=14), hepatotoxicity (n=9) and combined toxicity (n=5). Dose reductions were 
performed for myelotoxicity in 38/46 patients (83%), hepatotoxicity in 7/46 (15%) patients and 
combined toxicity in 1/46 patients (2%). Treatment with LDTA was initiated for hepatotoxicity 
in 6/9 (67%) patients and for myelotoxicity in 3/9 patients (33%). The overall incidence rate 
for treatment adjustment in patients on maintenance thiopurine treatment after detected 
laboratory toxicity was 1.9% per treatment year.
5
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Median time to adjustment, IQR 1.8 [0.5-3.5] -
Indication therapy adjustment, n (%)
Myelotoxicity
mild / moderate / severe
Hepatotoxicity
mild / moderate / severe
Myelotoxicity and hepatotoxicity
mild / moderate / severe
55 (3.0)
17 / 36 / 2
22 (3.9)
14 / 6 / 2
6 (0.4)









































IQR, interquartile range; MRI, magnetic resonance imaging; MRCP, Magnetic Resonance Cholangio- 
Pancreatography.
Complications included 6 grade 1 complications, 9 grade 2 complications and 11 grade 3 complications.
a13 patients received extra laboratory assessments and ultrasound. bperformed within a trial.
Cumulative incidence rate of therapy adjustments were 2.5% at 1 year, 6.2% at 3 years, 8.9% 
at 5 years, and 15.4% at 10 years of follow up (Figure 2). A higher thiopurine dose (HR 3.1 95% 
CI 1.5-6.4, P<0.004), higher annual monitoring frequency (HR 1.01 95% CI 1.00-1.01, P<0.0001) 
and higher number of aberrant assessments (HR 1.04 95% CI 1.04-1.05, P<0.0001) were 
independently associated with therapy adjustments. No correlation was observed between 
annual monitoring rate and the number of aberrant assessments (Spearman correlation 
R=0.09, p=0.762).
5
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Figure 2. Cumulative incidence of therapy adjustments during thiopurine treatment for laboratory tox-
icity.
Monitoring rate
The median monitoring frequency was 3.1 laboratory assessments per treatment year 
(IQR 2.2-3.9) with a slight decreasing trend in monitoring rate over time, ranging from 3.1 
assessments in the first year of follow-up (monitoring interval 3.9 months) to 2.0 assessments 
per year (monitoring interval 6.0 months) after 6 years of follow-up. The mean monitoring 
interval in patients receiving a therapy adjustment (3.3 months, SD 1.8) was shorter (i.e. more 
stringent) than in patients without an adjustment (4.1 months, SD 2.1, p<0.0001) . Also, the 
mean monitoring interval in patients receiving a therapy adjustment was shorter than in 
patients with laboratory toxicity but without an adjustment (4.2 months, SD 2.0, p<0.0001). 
No difference was observed in the mean monitoring interval in patients with laboratory toxicity 
(4.0, SD 2.0) and patients without toxicity (4.1, SD 2.2) (P=0.757). In patients receiving a therapy 
adjustment, the antecedent-monitoring interval was not significantly different from the mean 
monitoring interval (3.8 months (SD 3.7) vs. 3.3 months (SD 1.8), p=0.154). When comparing 
incidence rate of toxicity in patients on the most stringent monitoring regime (upper quartile, 
mean monitoring interval 2.3 months) with patients on the most liberal monitoring regime 
(lower quartile, mean monitoring interval 6.3 months)) no differences were observed in 
overall laboratory toxicity. However, the incidence rates of moderate leukopenia and severe 
hepatotoxicity were higher in patients on a stringent monitoring regimen than in patients 
on a liberal monitoring regimen (12% vs. 4.2%, p=0.001) (5% vs 0%, p=0.025). Details are 
depicted in Table 5. Cumulative incidence rate of therapy adjustments throughout follow up 
was higher in patients on a stringent monitoring regimen than on a liberal monitoring regimen 
(Supplementary Figure 1).
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Median monitoring rate/treatment yr, 
n (IQR) 3.1 [2.2-3.9] 1.8 [0.0-2.0] 4.8 [4.3 – 6.3]
Mean monitoring interval
(months), (SD)
4.1 (2.1) 6.3 (2.5) 2.3 (1.3) <0.0001
Detection of laboratory toxicity, 
n (%)









































Treatment related complications 12 (1.1) 1 (0.4) 8 (2.8) 0.019
IQR, interquartile range; SD, standard deviation. Liberal monitoring group comprises the lower quartile (lowest 
monitoring rate/treatment year) of the study population. Stringent monitoring group comprises the upper quartile 
(highest monitoring rate/treatment year) of the study population. P-values concern differences between liberal and 
stringent monitoring. Treatment-related complications comprised complications associated with concurrent laboratory 
toxicity.
Diagnostic procedures
Additional diagnostic procedures following established laboratory toxicity were performed 
in 154 aberrant laboratory assessments (7.6%) in 111 patients (9.8%). Overall, 1.2% of all 
assessments resulted in additional diagnostic procedures (Table 4). Most physicians 
followed up on detected toxicity through extra laboratory assessments (121 assessments 
in 86 patients), and 55% of these additional assessments were triggered by myelotoxicity. 
Ultrasound was performed after established hepatotoxicity in 27 patients (2.4%). No cases of 
nodular regenerative hyperplasia were reported.
Complications
Clinical treatment-related complications with concurrent laboratory toxicity were detected in 
12 patients (1.1%) in this cohort. The incidence rate of treatment-related complications with 
concurrent laboratory toxicity was 0.27% per treatment year (Table 4). Details on treatment-
related complications are depicted in Table 6.
5
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n (%) 6 (0.5) 0 (0.0) 5 (0.4) 1 (0.1)
Blood transfusiona
n (%) 2 (0.2) 2 (0.2) 0 (0.0) 0 (0.0)
Hospital admission for 
gastroenteritis
n (%)
2 (0.2) 2 (0.2) 0 (0.0) 0 (0.0)
Jaundiceb
n (%) 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0)
a Patients received a transfusion with packed red blood cells or iron for pancytopenia. 
b Patient at stable thiopurine dose presented with jaundice and hepatotoxicity after weight loss due to a sleeve 
gastrectomy.
Complications were more often observed in patients treated with MP than in AZA-treated 
patients (n=6, 2.1% versus n=6, 0.7%, P=0.015). Complication rate was higher in patients on a 
stringent monitoring regimen than in patients on a liberal monitoring regimen (2.8% vs 0.4%, 
P=0.019) (Table 5). Stringent monitoring remained associated with a higher complication 
rate when excluding all laboratory assessments after the onset of complications. Strikingly, 
3/12 patients (25%) developed mild myelotoxicity, 1/12 (13%) patients developed moderate 
myelotoxicity prior to complications and 8/12 patients (67%) presented with clinical symptoms 
and had no signs of toxicity in preceding laboratory assessments. Five of these 8 patients 
received stringent laboratory monitoring. No mortality was observed.
DISCUSSION
Frequent laboratory monitoring is advised throughout thiopurine maintenance treatment 
to detect myelotoxicity and hepatotoxicity. However, laboratory toxicity usually develops 
within the first few months of treatment and the reported incidence rate in maintenance 
treatment is low. This large cohort study has demonstrated that current laboratory monitoring 
regimen has limited value in patients on thiopurine maintenance monotherapy for at least 
1 year. Although the incidence of myelotoxicity was 7.1% and of hepatotoxicity 5.2% per 
treatment year, laboratory assessment had little impact on clinical decision making. Only 
0.7% of laboratory assessments resulted in therapy adjustments, and only 1.4% to further 
diagnostic procedures. Furthermore, severe treatment-related complications, such as 
infection and hospitalisation, attributed to concurrent laboratory toxicity are rare and these 
complications were not prevented with current monitoring regimen as the majority of cases 
were not preceded by laboratory toxicity in previous assessments.
The incidence of myelotoxicity and hepatotoxicity is line with previous studies, although there 
is no universal standard definition of laboratory toxicity, and small sample size and short 
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follow up in previous studies for comparison.20-22 Myelotoxicity incidence in our study of 7.1% 
per treatment year of follow up is based on stringent criteria and ranged from 5.1% for mild 
myelotoxicity, 1.8 % for moderate myelotoxicity to 0.1% for severe myelotoxicity. Myelotoxicity 
incidence was evaluated in a review of studies in which myelotoxicity definition varied from 
leukocyte count of <2.0 x 10e9/l to <4.5 x 10e9/L. As expected, a higher incidence rate of 11% 
in the first year of treatment was reported than in our study. Nevertheless, the overall range 
of myelotoxicity incidence of 3 to 8% per treatment year is compatible with our findings for 
maintenance treatment.9 In our study, hepatotoxicity incidence was 5.1% per treatment year. 
While incidence rates of 0 to 17% have been reported in other studies, possibly attributable 
to the heterogeneity of definitions, our findings are in line with large cohort studies that 
have reported incidence rates of 4 and 7%.8,20,23,24 Furthermore, the moderate to severe 
hepatotoxicity rate of 1.3% per treatment year in our cohort is in line with the rate of 1% per 
treatment year in other studies.8,10
In this study, the most stringent monitoring regimen was associated with increased incidence 
rates in moderate myelotoxicity and severe hepatotoxicity compared to the most liberal 
monitoring regimen. These results should be interpreted with caution, as the causal relation 
is unclear. The probability of detecting toxicity will increase with more frequent monitoring. 
Yet, abnormal laboratory values will urge physicians to increase the monitoring frequency to 
follow up on toxicity. Thus, it cannot be concluded that more frequent monitoring is more likely 
to pick up toxicity, or that previously established toxicity increases the monitoring frequency 
without direct clinical consequences.
In our study, fewer therapy adjustments were made to thiopurine treatment as a result 
of laboratory toxicity than were reported in other studies.25-28 Our study focused on the 
consequences of laboratory monitoring after 1 year of maintenance therapy in routine clinical 
practice and not the consequences of laboratory findings shortly after initiation of thiopurines. 
In our study, laboratory toxicity resulted in therapy adjustment in 7% of patients during 
follow up compared to reported rates of up to 15% in other studies. Furthermore, only 2.8% 
of patients in our cohort had to be withdrawn from therapy because of laboratory toxicity 
compared to 6 to 13% of patients in other studies.25-28 In line with the high risk of laboratory 
toxicity after start of thiopurines compared to maintenance treatment, these results indicate 
that therapy withdrawal due to laboratory toxicity usually occurs within the first months of 
treatment rather than during maintenance treatment.8,12,23
Our study has shown that mild toxicity is often disregarded in clinical practice with respect 
to additional diagnostic procedures. Laboratory results may have been disregarded because 
of a presumed low association between mild myelotoxicity and increased risk of infections, 
and possibly favourable outcome of mild leukopenia on therapeutic effectiveness of 
thiopurines.29
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A low risk of laboratory toxicity-associated complications was observed. Similarly, mild 
hepatotoxicity was often disregarded in our cohort probably because the association of 
transient hepatotoxicity with chronic liver disease is questionable. Laboratory toxicity-
associated complications were detected in 1% of patients in our cohort. Only 33% of patients 
had signs of laboratory toxicity in previous assessments. We observed that 67% of these 
patients received stringent laboratory monitoring (upper quartile (highest) annual monitoring 
rate of the study population). Treatment-related complications were more often observed 
in patients who received stringent monitoring than in those who received more liberal 
monitoring (lower quartile annual monitoring rate). As such, stringent monitoring does not 
prevent myelotoxicity-related or hepatotoxicity-related complications. These observations 
are of considerable significance as the clinical impact of detecting laboratory toxicity in 
maintenance therapy is low, and thus routine monitoring is of limited benefit.
Mercaptopurine was found to be associated with a higher risk of myelotoxicity than AZA.23,30 
This finding may be attributed to higher dosing of MP than AZA in IBD patients, because of 
little variation in pharmaceutical dosages in MP tablets and relatively higher recommended 
dose in official clinical guidelines than for AZA when correcting for bioavailability.30 This 
association was not confirmed in maintenance treatment in our cohort, presumably because 
of low dosing of thiopurines in general and MP in particular (lower dosing than recommended 
in guidelines). In line with previous studies, MP was associated with hepatotoxicity (HR 1.40) 
in our cohort. This may well be influenced by the percentage of MP users (15%) receiving 
concomitant therapy with allopurinol. Patients treated with LDTA showed higher detection 
rates of hepatotoxicity in multivariate analysis but this interaction was not confirmed by 
statistical analysis. However, the likelihood of detecting hepatotoxicity in patients on LDTA is 
higher because some patients possibly started on allopurinol shortly before inclusion in the 
study and hepatotoxicity had not (yet) normalised in the course of combination therapy.
To our knowledge, our study is the first to describe the consequences of laboratory monitoring 
throughout thiopurine maintenance monotherapy in a large cohort. Limitations relate mostly 
to the retrospective nature of this study. Firstly, we may have underestimated the incidence 
of laboratory toxicity because prospectively identified time points were not evaluated. 
True myelotoxicity can only be identified when a full blood count is completed. In addition, 
the absolute neutrophil count seems to be an important hematologic value in assessing 
susceptibility to infections.31 As neutrophils were not routinely measured, transient episodes 
of myelotoxicity may not have been recorded. On the other hand, all detected laboratory 
toxicity was attributed to thiopurine therapy but other medication or viral infections are also 
associated with myelotoxicity.32,33 Also, an increased risk of hepatotoxicity has been reported 
in IBD associated with other causal factors than thiopurine use, such as fatty liver disease.24 
Patients with a known history of liver disease were excluded in the analysis, but undiagnosed 
fatty liver disease in the patient population cannot be ruled out. High levels of the active 
thiopurine metabolite 6-thioguanine nucleotides are associated with myelotoxicity, and the 
byproducts 6-methyl mercaptopurine ribonucleotides are associated with both myelotoxicity 
binnenwerk_joany.indd   102 7-12-2020   13:27:32
| 103
Monitoring toxicity in IBD thiopurine maintenance therapy
and hepatotoxicity.34,35 Considerations of thiopurine metabolite levels and adverse events 
are hampered because thiopurine metabolites were not routinely measured and thus not 
included in the analysis. Secondly, data from 6 hospitals were included and both cessation 
and dose reductions were left to the discretion of the treating physician. Thus, the monitoring 
regimen and the clinical consequences after toxicity detection reflect the daily practice of 
these physicians. A clinician’s motivation to perform therapy adjustments or diagnostic 
procedures could be influenced by experience or patient-related factors. It is likely that 
repeated detection of laboratory abnormalities led the treating physician to adjust treatment. 
In addition, both patients and physicians influenced compliance to laboratory monitoring 
regimen. Thirdly, evaluation of clinical consequences of laboratory toxicity was hampered by 
the inability to discriminate between routine laboratory assessment for monitoring thiopurine 
therapy and laboratory assessments requested by other clinicians. This might also have led to 
overestimation of the monitoring frequency. Finally, almost 75% of patients were followed in a 
referral centre, and thus our population probably includes patients with a more complicated 
disease course or more comorbidity with a possible increased risk of laboratory toxicity. 
Our results apply to patients on thiopurine monotherapy. The risk of laboratory toxicity in 
patients on combination therapy with biologic agents was not investigated, and the risk in 
this population may be higher.36
As thiopurine-induced laboratory toxicity occurs more frequently in the first months of 
therapy, strict laboratory monitoring of the blood count and LTs in the first year of treatment 
as recommended in current guidelines seems justified.9,10 Regular laboratory monitoring is 
recommended at 2 to -3 month intervals during maintenance thiopurine treatment.16,22 These 
recommendations are largely based on concern about possible complications following late-
onset toxicity, especially leukopenia. However, the cost-effectiveness of this schedule is not 
evidence-based.15,16 Laboratory monitoring practices in this large real-life cohort were more 
liberal than recommended in the ECCO guideline; at 4-month intervals (our study) versus at 
2-3 month intervals (ECCO guideline). The results of our study demonstrate that after 1 year of 
thiopurine treatment, monitoring at 4-month intervals rarely leads to therapy adjustments and 
more importantly is rarely associated with treatment-related complications. Also, (frequent) 
monitoring after 1 year of treatment does not seem to prevent laboratory toxicity-related 
complications, as preceding laboratory assessments were unremarkable in 67% of cases. 
Therefore, the firm conclusion can be drawn that the recommended monitoring frequency 
may be reduced to an interval of less than 4 months. We speculate that a monitoring regimen at 
6-month intervals is sufficient in patients after 1 year of thiopurine treatment. This assumption 
is supported by the small number of complications in patients on the least frequent monitoring 
regimen (i.e. lower quartile based on annual in patients monitoring frequency). Also, we 
hypothesize that reducing laboratory monitoring to 6-month intervals could decrease patient 
burden and healthcare costs (Supplementary data 1). In order to confirm that laboratory 
monitoring at 6-month intervals is non-inferior to 4-month intervals, prospective evaluation 
in an impractically large study population with several years of follow-up would be required. 
Accurate risk stratification for complications, based on detected laboratory toxicity, is 
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hampered by the heterogeneity of data in this study. It is unlikely that this will be avoided 
by a prospective design, as the detection of laboratory toxicity is expected to influence both 
treatment and monitoring. Therefore, a prospective cohort study will probably not provide 
the required data to test this hypothesis.
In conclusion, this study has demonstrated a limited yield of current laboratory monitoring 
practices in maintenance thiopurine monotherapy in IBD patients. Firstly, laboratory 
monitoring in clinical practice was less frequent than advised in current guidelines. Secondly, 
severe myelotoxicity and hepatotoxicity are uncommonly detected. Thirdly, this study showed 
that treating physicians tend to disregard aberrant laboratory findings, and were not inclined to 
adjust therapy or perform additional diagnostic evaluation. Finally, complications associated 
with laboratory toxicity occurred rarely, and most complications developed unpredictably and 
could not be avoided by frequent monitoring. Reducing laboratory-monitoring in thiopurine 
maintenance therapy after 1 year of treatment to less than a 4-month interval seems sufficient 
and could result in reduced patient burden and health-care costs.
binnenwerk_joany.indd   104 7-12-2020   13:27:32
| 105
Monitoring toxicity in IBD thiopurine maintenance therapy
REFERENCES
1. Eriksson C, Rundquist S, Cao Y, Montgomery S, Halfvarson J. Impact of thiopurines on 
the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut. Apr 
2019;68(4):623-632.
2. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine 
for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. Sep 12 
2012(9):CD000478.
3. Zhu Z, Mei Z, Guo Y, et al. Reduced Risk of Inflammatory Bowel Disease-associated 
Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis. 
J Crohns Colitis. Apr 27 2018;12(5):546-558.
4. de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the 
treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl. 2003(239):69-72.
5. Saibeni S, Virgilio T, D’Inca R, et al. The use of thiopurines for the treatment of 
inflammatory bowel diseases in clinical practice. Dig Liver Dis. Oct 2008;40(10):814-820.
6. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel 
disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. Sep 
2010;16(9):1541-1549.
7. van Asseldonk DP, Sanderson J, de Boer NK, et al. Difficulties and possibilities with 
thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine 
Task Force meeting. Dig Liver Dis. Apr 2011;43(4):270-276.
8. Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-
induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol 
Ther. Nov 1 2005;22(9):775-782.
9. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory 
bowel disease: a review. Am J Gastroenterol. Jul 2008;103(7):1783-1800.
10. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients 
with inflammatory bowel disease: a systematic review. Am J Gastroenterol. Jul 
2007;102(7):1518-1527.
11. Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of Patients With Variants 
in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment 
of Inflammatory Bowel Disease. Gastroenterology. Oct 2015;149(4):907-917 e907.
12. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to 
modification of therapy in a large cohort of patients with inflammatory bowel disease. 
Aliment Pharmacol Ther. Jul 15 2006;24(2):331-342.
13. Meijer B, Seinen ML, van Egmond R, et al. Optimizing Thiopurine Therapy in Inflammatory 
Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication? 
Inflamm Bowel Dis. Nov 2017;23(11):2011-2017.
14. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel 
disease in adults. Gut. May 2011;60(5):571-607.
15. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused 
by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. Aug 
1993;34(8):1081-1085.
5
binnenwerk_joany.indd   105 7-12-2020   13:27:32
106 |
Chapter 5
16. Wallace TM, Veldhuyzen van Zanten SJ. Frequency of use and standards of care for the use 
of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: 
a systematic review of the literature and a survey of Canadian gastroenterologists. Can 
J Gastroenterol. Jan 2001;15(1):21-28.
17. 03_2010-06-14_QuickReference_5x7.pdf. CTCfAECvAfhenngfCC.
18. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization 
in drug-induced liver injury. Clin Pharmacol Ther. Jun 2011;89(6):806-815.
19. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 
6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment 
efficacy. Aliment Pharmacol Ther. Aug 2000;14(8):1009-1014.
20. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite 
measurement for 6-mercaptopurine therapy in inflammatory bowel disease. 
Gastroenterology. Apr 2000;118(4):705-713.
21. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s 
disease: correlation with efficacy and toxicity. Gut. Sep 1996;39(3):401-406.
22. de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn’s 
disease. Eur J Gastroenterol Hepatol. Feb 2004;16(2):207-212.
23. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory 
bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. Jun 
2013;19(7):1404-1410.
24. Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Liver injury in inflammatory bowel disease: 
long-term follow-up study of 786 patients. Inflamm Bowel Dis. Sep 2007;13(9):1106-1114.
25. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn’s disease 
treated with azathioprine or 6-mercaptopurine. Lancet. Jan 27 1996;347(8996):215-219.
26. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of 
inflammatory bowel disease: a 30 year review. Gut. Apr 2002;50(4):485-489.
27. Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 
6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 
Jan 2005;39(1):21-26.
28. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase 
enzyme activity is superior to genotype in predicting myelosuppression following 
azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol 
Ther. May 1 2007;25(9):1069-1077.
29. Park MS, Kim DH, Kim DH, et al. Leukopenia predicts remission in patients with 
inflammatory bowel disease and Behcet’s disease on thiopurine maintenance. Dig Dis 
Sci. Jan 2015;60(1):195-204.
30. Broekman M, Coenen MJH, van Marrewijk CJ, et al. More Dose-dependent Side Effects 
with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher 
Dosing. Inflamm Bowel Dis. Oct 2017;23(10):1873-1881.
31. Gisbert JP. Is less more: does leukopenia predict remission in patients with inflammatory 
bowel disease receiving thiopurine treatment? Dig Dis Sci. Jan 2015;60(1):4-6.
32. van Asseldonk DP, Kanis BM, de Boer NK, van Bodegraven AA. Leukopenia due to 
parvovirus B19 in a Crohn’s disease patient using azathioprine. Digestion. 2009;79(4):211-
214.
33. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine 
S-methyltransferase in patients with Crohn’s disease and severe myelosuppression 
during azathioprine therapy. Gastroenterology. Jun 2000;118(6):1025-1030.
binnenwerk_joany.indd   106 7-12-2020   13:27:32
| 107
Monitoring toxicity in IBD thiopurine maintenance therapy
34. Meijer B, Kreijne JE, van Moorsel SAW, et al. 6-methylmercaptopurine-induced 
leukocytopenia during thiopurine therapy in inflammatory bowel disease patients. J 
Gastroenterol Hepatol. Jun 2017;32(6):1183-1190.
35. Zaza G, Cheok M, Krynetskaia N, et al. Thiopurine pathway. Pharmacogenet Genomics. 
Sep 2010;20(9):573-574.
36. Wong DR, Pierik M, Seinen ML, et al. The pharmacokinetic effect of adalimumab on 
thiopurine metabolism in Crohn’s disease patients. J Crohns Colitis. Feb 2014;8(2):120-
128.
37. Tarieven ODV. http://www.erasmusmc.nl/47387/3056001/TARIEVEN_ODV.
38.  http://www.nfu.nl/umcmedewerkers/cao/.
39. van der Valk ME, Mangen MJ, Severs M, et al. Evolution of Costs of Inflammatory Bowel 
Disease over Two Years of Follow-Up. PLoS One. 2016;11(4):e0142481.
40. Rooks MG, Veiga P, Wardwell-Scott LH, et al. Gut microbiome composition and function 
in experimental colitis during active disease and treatment-induced remission. ISME J. 
Jul 2014;8(7):1403-1417.
41. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel 
disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: 
results from the COIN study. Gut. Jan 2014;63(1):72-79.
5




Supplementary data 1. Hypothesis of cost-effectiveness analysis
Patients: Number of patients in the Netherlands receiving long-term maintenance thiopurine 
therapy (>1 year) estimated at 18.500.
Direct health-care costs (i.e. costs for monitoring-related health care resource utilization 
such as laboratory assessments, analysis, evaluation by physician)
€70 per laboratory assessment 37-39
Indirect health-care costs (i.e. travel costs, productivity loss)
€77.50 per laboratory assessment 37-39
Costs associated with thiopurine-induced complications
Direct costs: €3000 per patient per event
Indirect costs: €1500 per patient per event
€4500 per patient per event 39-41
Hypothesis: routine laboratory monitoring at 3-month intervals will prevent 1% more events 
(complication) than monitoring a 6-month intervals.
Intervention (monitoring at 6-month intervals)
Direct costs:
monitoring( €70*2) + complication costs (1.3% * 18.500 patients * €4500) = €2.590.000 + 
€1.082.250 = €3.672.250/yr= €199/patient/year.
Indirect costs:
productivity loss: (2*2hours= 2 x €25,50) + travel costs (2*€26.5) = €155/patient/year.
Control (monitoring at 3-month intervals)
Direct costs:
monitoring( €70*4) + complication costs (0.3% * 18.500*€4500)= €5.180.000 + €249.750 = € 
5.429.750/yr = €294/patient/year.
Indirect costs:
productivity loss: (4*2hours= 2 x €25,50) + travel costs(4*€26.5) =€ 310/patient/year.
Anticipated point estimate for the difference in mean cost of intervention versus 
control:
(294+310) – (199+155) = € 250 per patient per treatment year.
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Supplementary Figure 1. Cumulative incidence of therapy adjustments during thiopurine treatment 
for laboratory toxicity stratified for monitoring frequency. The blue line represents the cumulative inci-
dence of therapy adjustments during thiopurine treatment in the entire cohort; i.e. overall (n=1132). The 
dotted dark blue line respresents the cumulative incidence of therapy adjustments during thiopurine 
treatment in the highest quartile monitoring frequency; i.e. stringent (n=283). The dotted light blue line 
respresents the cumulative incidence of therapy adjustments during thiopurine treatment in the lowest 
quartile monitoring frequency; i.e. liberal (n=283).
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CHAPTER 6
SEX IS ASSOCIATED WITH 
ADALIMUMAB SIDE-EFFECTS 
AND DRUG SURVIVAL IN 
CROHN’S DISEASE PATIENTS
Lie MRKL Lie, Kreijne JE, van der Woude CJ.
Inflammatory Bowel Disease. 2017 Jan;23(1):75-81.
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ABSTRACT
Background: Adalimumab (ADA) is an effective treatment for Crohn’s disease (CD). In 
rheumatology, sex differences concerning the response to ADA therapy have been described. 
However, such differences have not yet been reported for CD patients. As such, the aim of this 
study was to compare ADA treatment outcomes in male and female CD patients.
Methods: A clinical cohort was formed of consecutive CD patients starting ADA in a single 
tertiary center between March 2006 and February 2011. The cohort was followed up to August 
2015. Clinical outcomes were primary non-response, secondary non response and treatment 
success (ongoing ADA use). Reasons for stopping ADA were recorded. Kaplan-Meier analysis 
and Cox regression were used to assess treatment success.
Results: The cohort consisted of 107 female and 81 male patients. Median follow-up was 6.0 
years (range 0.3-9.2). Treatment success was higher in male than female patients (48.1% vs 
30.8%, P=0.016). Side-effects were reported more often by female patients (81.3% vs 64.2%, 
P=0.008) and female patients ceased ADA more often due to side-effects (35.4% vs 18.4%, 
P=0.017). In survival analysis, female sex was associated with higher cessation rates (P=0.006). 
Cox regression also identified female sex (P=0.020), along with higher baseline CD activity 
index (P=0.003), as predictors of ADA cessation.
Conclusions: Female sex is negatively associated with ADA treatment success. Female patients 
report more side-effects and cease ADA due to side effects more often. A more personalized 
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INTRODUCTION
The treatment of inflammatory bowel disease (IBD), with its relapsing and remitting nature, 
has benefitted greatly from the introduction of antibodies against tumor necrosis factor alpha 
(TNF-a).1,2 Adalimumab (ADA) is a recombinant human IgG1 monoclonal antibody against 
TNF-a and is an established treatment for both anti-TNF-naïve and exposed patients.3-6 When 
offered the choice, a substantial proportion of the patients with Crohn’s disease (CD) prefer 
subcutaneously administered anti-TNF, such as adalimumab, over intravenous anti-TNF.7 The 
now widespread use of anti-TNF agents has shifted the bulk of IBD healthcare costs from 
hospitalization and surgery to anti-TNF agents, with ADA making up 33.9% of all costs in CD 
patients.8 Thus, it appears that ADA is commonly prescribed to CD patients, regardless of the 
sex of the patient.
However, it has previously been shown that the sex of the patient can have profound influences 
on drug metabolism and efficacy. For instance, in cardiovascular disease, the commonly 
used beta-blocker metoprolol has significantly higher drug concentrations in women than in 
men.9 These differences are likely caused by sex specific differences in body composition (e.g. 
proportion of body fat) and drug metabolism (e.g. cytochrome P450 (CYP) enzyme activity). 
Though a biological agent such as ADA is not metabolized by CYP enzymes, sex-specific 
differences have been seen with biological drugs in other fields of medicine. Specifically, on 
a pharmacokinetic level several oncological biological agents such as bevacizumab, cetuximab 
and rituximab are cleared at different speeds between men and women.10 Though the clinical 
implication of these pharmacokinetic differences are unclear, these differences again probably 
result from differences in body composition.11
Of greater clinical relevance are observations in rheumatology, where female sex was found 
to be a significant negative predictor for longer ADA drug survival (i.e. the continued use of 
ADA). Particularly, lower drug survival was seen in women compared to men with arthritic 
psoriasis12 and rheumatoid arthritis.13 As such, the aim of this study was to investigate drug 
survival of ADA and possible other sex differences in a cohort of 188 CD patients.
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A prospective clinical cohort was formed, consisting of 188 consecutive CD patients that 
started ADA between March 2006 and February 2011 at the Erasmus University Medical Center 
Rotterdam, The Netherlands. Patients with evidence of tuberculosis, chronic hepatitis B and/or 
C, or patients with immunodeficiency syndromes did not start ADA and thus were not part of 
the cohort. Of all patients in the cohort, the following parameters were documented: sex, age 
at diagnosis, age at start of ADA , Montreal disease classification, smoking behavior, body mass 
index (BMI), previous CD related medical history (i.e. CD related surgical history, previous CD 
related drug therapies) and ADA start and stop date. Where available, clinical disease activity 
via the Crohn’s disease activity index (CDAI) at start of ADA therapy, C-reactive protein (CRP) at 
start of therapy and ADA serum levels after 12 weeks of treatment were recorded. ADA serum 
levels were measured with ELISA, as described previously14. Patient reported side-effects 
were also recorded.
All patients received a loading dose of 160mg and 80mg subcutaneously (sc) at week 0 and 
2 respectively, followed by a maintenance dose of 40mg sc every other week thereafter. ADA 
dose escalation occurred at the decision of the treating physician. Patients were evaluated 
at the outpatient clinic at start of ADA therapy and at least every 4 months thereafter. In 
cases where ADA therapy was ceased, further follow-up and treatment at the outpatient clinic 
occurred according to treatment guidelines. CD related therapies initiated during and after 
ADA therapy were also recorded. Data was recorded up to the last outpatient visit preceding 
01 August 2015.
The primary outcomes of interest was the ADA drug survival rate. Other outcomes of interest 
were sex specific differences in drug survival and adverse events. Drug survival was evaluated 
by determining maintained clinical response, primary non-response and secondary non-
response. Primary non-response was defined as cessation of ADA therapy within 6 months 
due to lack of clinical improvement. Secondary non-response was defined as cessation of 
ADA therapy after at least 6 months of treatment (and thus, after an initial response), due to 
subsequent loss of response. Maintained response was defined as continued ADA therapy up to 
the end of follow-up. ADA cessation due to other reasons, such as side-effects, was registered 
separately. Other outcomes of interest were the occurrence and outcome of dose escalation, 
reasons for stopping ADA and adverse events to ADA.
Statistics
For all of the statistical analysis the SPSS 21.0 software package was used. Descriptive 
statistics were used to summarize the data. Medians with range or means with standard 
deviations (SD) were calculated for continuous data as appropriate, and percentages were 
calculated for categorical data. Variables were log-transformed as necessary and normality 
was assessed using Kolmogorov-Smirnov’s test. Categorical data was compared via the χ2 test 
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or Fisher’s exact test. The Mann-Whitney test was used to compare continuous data. For all 
tests, one or two-sided (as appropriate) P-values <0.05 were considered significant. Ongoing 
ADA therapy was assessed using Kaplan-Meier analysis, with additional log-rank analyses 
to compare survival curves. Univariable Cox proportional hazard models were employed to 
assess associations between ongoing ADA therapy and patient factors. The assumption of 
proportional hazards was assessed visually, using a log(-log(survival)) versus log of survival 
graph. Additionally, a multivariable Cox proportional hazard model was constructed, using 
the predictors with a P value of <0.20 in the univariable models, using stepwise backward 
elimination (probability of F to remove >0.10). To address potential sex-specific effects, 
interactions between sex and significantly different baseline characteristics were also 
assessed in this model. The number of predictors entered in the multivariable model were 
limited to the number of events divided by 10.
Ethical considerations
The study was approved by the institutional review board and ethics committee of the Erasmus 
MC, University Medical Center Rotterdam, the Netherlands.
Access to Study Data




Of the 188 patients included in this study, BMI values were missing in 4 patients, baseline 
CRP values in 24 patients, ADA serum levels in 58 patients and baseline CDAI values in 63 
patients.
Patient characteristics
Between March 2006 and February 2011, 188 CD patients were started on ADA treatment (see 
Table 1 for patient details). Median follow up was 6.0 years (range 0.3 – 9.2 years). The total 
cohort consisted of 81 male and 107 female patients. At baseline, several sex differences were 
observed. Firstly, more peri-anal involvement was seen in male patients (48.1% vs 33.6%, 
χ2 P=0.044), whereas higher median CDAI values were found in females (174 vs 154, Mann-
Whitney-U P=0.036), with a trend for higher median CRP values in females as well (4.0mg/L vs 
3.0mg/L, Mann-Whitney-U P=0.079).
6
binnenwerk_joany.indd   115 7-12-2020   13:27:33
116 |
Chapter 6








Median age at diagnosis (years, range) 24 (5-74) 24 (10-74) 23 (5-63) 0.931
Median age at start of ADA (years, range) 36 (18-81) 36 (18-81) 36 (18-66) 0.201
Median disease duration at start of ADA 
(years, range)
9 (0-49) 10 (1-44) 8 (0-49) 0.532
































Perianal involvement, n (%) 75 (39.9) 39 (48.1) 36 (33.6) 0.044
Current smokers, n (%) 45 (23.9) 20 (24.7) 25 (23.4) 0.833
Drug use prior to start of ADA, n (%)
None, 5-ASA and/or steroids
5-ASA, steroids and 
immunosuppressives


























Previous intestinal surgery, n (%) 73 (38.8) 31 (38.3) 42 (39.3) 0.891





CRP mg/L, median (range) 3.0 (1-99) 3.0 (1-89) 4.0 (1-99) 0.079





ADA, adalimumab; 5-ASA, 5-Aminosalicylic acid; BMI, body mass index; CRP, C-reactive protein; CDAI, Crohn’s disease 
activity index.
* azathioprine, tioguanine or methotrexate; † P-value for comparison between male and female patients.
Reasons for starting ADA therapy (Table 2) included active luminal CD, maintaining a steroid 
induced remission, step-up therapy due to intolerance or inefficacy of immunosuppressive 
therapy, fistulas, extra-intestinal manifestations and other reasons. Steroid intolerance was 
significantly more often a starting reason for males than females (9.9% vs 1.9%, Fisher’s exact 
test P=0.021).
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Reason for initiating adalimumab therapy
Disease flare 141 (75.0) 58 (71.6) 83 (77.6) 0.350
Intolerance to previous therapy 20 (10.6) 7 (8.6) 13 (12.1) 0.440
Steroid dependent disease 10 (5.3) 8 (9.9) 2 (1.9) 0.021
Patient wish* 8 (4.3) 5 (6.2) 3 (2.8) 0.294
Fistula 6 (3.2) 2 (2.5) 4 (3.7) 0.701
Wish to conceive child† 3 (1.6) 1 (1.2) 2 (1.9) 0.999
* patients in remission with infliximab who chose to switch to adalimumab; † females in remission with methotrexate; 
‡ P-value for comparison between male and female patients.
Clinical outcomes to ADA therapy
Figure 1 displays the clinical outcomes to ADA therapy in this cohort, divided by male and 
female patients. In the first 6 months of treatment 31 patients stopped ADA therapy, with a 
significantly greater proportion of female patients than male patients stopping ADAA (21.5% 
vs 9.9%, χ2 P=0.034). Reasons for stopping were primary non-response in 13 patients, side 
effects in 15 patients and other reasons in 3 patients (1x chemotherapy for testis carcinoma; 2x 
physician decision due to ongoing systemic infection). There were no statistically significant sex 
differences concerning the reason for stopping ADA in the first 6 months of treatment. Finally, 
2 patients were lost to follow-up within the first 6 months of treatment. The remaining 72 male 
and 83 female patients achieved an initial clinical response. During follow-up, 83 patients of 
the initial responders stopped ADA therapy. A trend for the proportional difference in female 
and male patients stopping ADA was seen (60.2% vs 45.8%, χ2 P=0.073). Reasons for stopping 
were secondary non-response in 39 patients, intolerance in 32 patients and other reasons in 
12 patients (5x patient decision, 4x malignancy, 2x pregnancy, 1x suspected malignancy). No 
statistically significant sex differences in the reason for stopping ADA were observed amongst 
the patients with an initial response. At the end of follow-up, 39 male and 33 female patients 
still had a clinical response, which translates into a significantly greater maintained clinical 
response rate in male than female patients (48.1% vs 30.8%, χ2 P=0.016).
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Figure 1. Flowchart depicting outcomes in the cohort, divided by male and female patients.
Similarly, in Kaplan-Meier analysis a difference was seen in male and female ADA continuation 
rates (Figure 2, log-rank P=0.006). Additionally, in univariable and multivariable Cox 
proportional hazard models (Table 3), male sex (beta = 0.591, hazard ratio = 1.807, P = 0.020) 
predicted longer ADA treatment duration. A lower CDAI at start (beta = 0.003, hazard 
ratio = 1.003, P = 0.003) was also predictive of longer ADA treatment duration. Previous anti-
TNF exposure and steroid use at start of ADA therapy were removed from the multivariable 
model during the backward stepwise elimination. Of note, no interactions were seen between 
CDAI and sex or between peri-anal involvement and sex, despite the baseline sex differences 
in these two variables.
ADA dose escalation
In total, 106 patients (56.4%) in the cohort had at least one episode of ADA dose escalation, 
including patients with escalation after ADA re-treatment. In total, 140 ADA dose escalations 
occurred in these 106 patients. The proportion of female and male patients receiving dose 
escalation was not significantly different (57.0% vs 44.4%, χ2 P=0.842). The median ADA 
treatment duration prior to escalation was 13 months (range 1-95 months), with a median 
escalation duration of 7 months (range 1 – 105 months). Dose escalation led to recapture of 
response in 99 of 140 escalations (70.7%), with a significantly greatersuccess percentage in 
male than female patients (83.7% vs 60.7%, χ2 P=0.011).
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Table 3. Univariable and multivariable Cox proportional hazard regression model.
Univariable Multivariable
Beta P-value Beta P-value Hazard ratio
Gender .533 .007 .591 .020 1.807
BMI* -.004 .827
Age at baseline -.009 .231
Active smoker -.039 .853
CRP at start* .005 .412
CDAI at start* .004 <.001 .003 .003 1.003
Previous anti-TNF exposure -.316 .101
Presence of peri-anal disease -.045 .817
Steroid use at start .073 .189
Immunomodulator use at start -.014 .944
Week 12 adalimumab serum level * .019 .381
anti-TNF = anti tumor necrosis factor; BMI = body mass index; CDAI = Crohn’s disease activity index; CRP = C-reactive 
protein. * missing data for BMI (4), CRP (24), ADA level (58) and CDAI (63).
Figure 2. Kaplan-Meier survival curve, displaying ongoing adalimumab treatment in males and females, 
over 7 years. The difference between ongoing treatment in males and females is significant (log-rank 
P=0.006).
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The majority of patients reported side effects to ADA. Only 50 patients (26.6%) did not report 
any side-effects. In total, 254 adverse events were reported by 138 patients (Supplementary 
Table 1). Most commonly reported were injection site skin reactions such as erythema, bullae 
or hematomas (30), followed by respiratory tract infections (27), arthralgia (24) and generalized 
skin rash (23). Hair loss (16), fatigue (14), skin infection (14), nausea (13), dry skin (13) and 
headache (11) were also reported frequently. Side-effects were more often reported in females 
than males (81.3% vs 64.2% respectively, χ2 P=0.008). Additionally the median amount of 
reported side-effects was greater in females than males (2 vs 1, Mann-Whitney-U P < 0.001). 
During the whole follow-up period, female patients stopped ADA more often due to side-effects 
than male patients (35.4% vs 18.4%, χ2 P=0.017), whereas no significant differences were seen 
regarding stopping due to non-response or other reasons.
Regarding laboratory values, though mild liver enzyme abnormalities were seen in 123 
patients, either these disturbances did not persist (n=69), were present prior to ADA therapy 
(n=42), or were clearly not caused by ADA (n=12; e.g. due to thiopurine use, symptomatic 
cholelithiasis or post-surgery).
DISCUSSION
In this clinical Crohn’s disease cohort, we studied possible sex differences in the outcome to 
adalimumab treatment. At baseline, several differences already exist, chief amongst them 
a difference in prior therapies. Additionally, we observe several sex differences concerning 
response, primarily a greater proportion of treatment in male than female patients, of 48.1% 
and 30.8% respectively. Survival analysis in this cohort also underscores the effect of sex 
on ongoing ADA treatment, along with baseline disease activity. Furthermore, we find that 
female patients report more side-effects and also cease ADA treatment more often due to 
side-effects than male patients.
As this study was a prospective cohort, several baseline differences exist between male and 
female patients. Importantly, there is a difference in therapies preceding start of ADA therapy. 
A significantly greater proportion of female patients were not treated with immunosuppressive 
drugs prior to the start of ADA. Though the reasons for not starting an immunosuppressive 
agent are unknown, possible explanations are a patient’s fear of side-effects and the 
preference of the treating physician for top-down anti-TNF treatment.
To our knowledge, our observed sex difference concerning response to ADA therapy has 
not been previously described in CD patients, though it is in line with studies performed in 
rheumatology patients. One study in patients with psoriatic arthritis found that female sex was 
the strongest predictor of anti-TNF interruption in long-term anti-TNF treatment11. Similarly, 
a meta-analysis concerning patients with rheumatoid arthritis also reported that female 
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sex predicts higher anti-TNF drug discontinuation rates.12 In our study, the sex difference 
concerning response appears to be caused by differences in side-effects. In our whole cohort, 
25.0% of the whole cohort stopped ADA due to side-effects, which is similar to previous 
studies.15-17 However unlike the aforementioned studies, we find that the distribution of 
patients stopping due to side-effects is skewed toward female patients. However, a similar 
sex difference was seen in a study in 1009 IBD patients, of which 344 used anti-TNF (and 99 
used ADA). In the whole anti-TNF subgroup, adverse reactions were seen more often in females 
than males, and females stopped anti-TNF treatment more often due to adverse reactions than 
males, but no statistically significant difference was seen within the subgroup of 77 patients 
using ADA.18
A possible explanation for the sex differences in side-effects may lie in sex specific physiological 
differences. On average, women have a smaller organ size and a higher proportion of body fat 
than men. Additionally, in pre-menopausal women, the menstrual cycle results in fluctuations 
in the percentage of tissue-water. These physiological differences result in different 
drug distribution volumes, and could thus lead to different responses to drug therapy.19 
Additionally, modulation of CYP3A4 enzyme activity may also play a role. In general, women 
show higher CYP3A4 enzyme activity than men20, probably due to sex related differences 
in sex hormone levels. However, CYP3A4 has been shown to be influenced by TNF-a21, thus 
the use of an anti-TNF agent such as ADA may influence CYP3A4 activity. Via this route, ADA 
may influence the metabolism of other commonly used drugs, possibly causing patients to 
experience side-effects to these drugs, which in turn are attributed to ADA use. These effects 
may be further compounded by differences in perception of pain and adverse events in male 
and female patients.22
Also, the clearance of ADA may differ between male and female patients. Mathematical 
modelling using data from ulcerative colitis patients receiving infliximab showed a 33% lower 
drug clearance in females than males.23 Another modelling study amongst both CD and UC 
patients showed approximately 50% lower drug clearance in females than males.24 However, 
it is unclear how this mathematical difference in infliximab clearance affects ADA serum levels, 
as previous reports did not find sex to significantly influence ADA serum level.25
Furthermore, the difference in disease activity and previous at the start of ADA therapy suggests 
that female patients were slightly more ill at start of therapy, possibly reflecting reluctance to 
start anti-TNF therapy in female patients. Also, the sex difference in previous drug exposure is 
also suggestive of some form of bias against the prescription of immunosuppressive agents 
in general to female patients. However, the possibility of female patients being more ill at 
the start of ADA therapy does not readily explain the observed sex difference in side-effects 
occurring during the course of treatment.
Given the differences observed between men and women, it is conceivable that providing 
female patients with additional personalized information prior to the start of ADA therapy 
6
binnenwerk_joany.indd   121 7-12-2020   13:27:34
122 |
Chapter 6
could reduce the observed sex-difference in reported adverse reactions. Specifically, 
providing more information concerning the possible side-effects may result in different patient 
expectations, which subsequently could reduce the high amount of drop-outs due to side-
effects, as observed in our study.
The efficacy of ADA in our whole cohort was similar to the efficacy reported in previous studies. 
Our 6.9% primary non-response rate is comparable to the 9% lack of response rate reported 
in the open-label arm of the CLASSIC-II trial.26 Similarly, the 27% discontinuation rate (for 
reasons other than lack of response) is comparable to the findings from our cohort.
In this cohort dose escalation to 40mg every week occurred in 56.4% of patients, with some 
patients receiving multiple periods of dose escalation. This proportion is similar to the 
reported escalation rates in other studies, which vary from 13.2% to 63.4%.27,28 In our cohort, 
dose escalation was successful in 70.7% of attempts, similar to the reported success rate in 
other studies, which ranges from 36% to 86% in smaller studies27,29, to 70 to 80%30-32 as 
reported in larger studies.
Of note, we did not observe a sex difference in the need to dose escalate. This is similar to a 
study in 75 CD patients requiring dose escalation, though this study did find that male patients 
required dose escalation earlier than female patients.33
This real-life tertiary referral cohort has several limitations. Though our cohort is certainly not 
the largest ADA cohort to be reported on, though our follow-up duration is relatively long. Also, 
the missing data at baseline may have influenced the results of the Cox analysis. Furthermore, 
the influence of CRP levels and CDAI scores during treatment could not be assessed, as these 
values were not regularly available during follow-up. Additionally, due to the tertiary nature of 
our hospital, the patients enrolled in this cohort may not accurately reflect clinical practice in 
smaller regional hospitals. Finally, we were unable to gauge the efficacy of ADA via an objective 
endpoint such as mucosal healing.
In summary, in this clinical cohort of CD patients treated with ADA, we reconfirm the overall 
efficacy of ADA for CD patients. Moreover, we show several gender differences in response to 
ADA therapy. Chiefly, the success rate of ADA therapy is higher in males than females, both for 
initial treatment, but also for dose escalation. The greater proportion of side-effects in females 
appears to be the major cause to the difference in treatment success. This suggests that a 
personalized approach to female patients starting ADA could positively influence the incidence 
and severity of side-effects and thus reduce the high drop-out rate seen in female patients.
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SUPPLEMENTARY DATA
Supplementary Table 1. Adverse events reported during adalimumab use, ordered by frequency.
Adverse event N (%)
Injection site skin reaction 30





















Urinary tract infection 2
Other‡ 18
Total 254
* e.g. cough, sore throat rhinitis, pneumonia; † e.g. conjunctivitis, episcleritis, blurred vision; ‡ Adverse events reported 
once (ordered alphabetically): alcohol intolerance, anemia, back pain, bloated feeling, constipation, dyspnea, ear 
infection, epilepsia, epistaxis, hypermenorrhea, hypertension, general malaise, migraine, peripheral edema, 
tendinopathy, thrombopenia, urticaria, vasculitis.
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Background: Ulcerative proctitis (UP) refractory to 5-aminosalicylic acid (5-ASA) suppositories 
is a challenge to treat, often requiring step up to immunomodulator or biological therapy. 
Topical tacrolimus is effective and safe in patients with refractory UP. However, it is not clear 
how tacrolimus suppositories fit into in the treatment algorithm of UP.
Methods: We performed a randomized controlled, double-blind study at 8 hospitals in The 
Netherlands and Belgium from 2014 through 2017. Eighty-five patients with refractory UP 
(65% women) were randomly assigned to groups given once daily tacrolimus suppositories 
(2mg, n=43) or beclomethasone (3mg, n=42) for 4 weeks. The primary outcome was clinical 
response (decrease in Mayo score of 3 or more). Secondary outcomes included clinical 
remission, endoscopic response and remission, adverse events and quality of life. Outcomes 
were compared using Fisher’s exact test and Mann-Whitney U test.
Results: Proportions of patients with clinical responses were 63% in the tacrolimus group and 
59% in the beclomethasone group (p=0.812); proportions of patients in clinical remission were 
46% and 38%, respectively (p=0.638). Proportions of patients with an endoscopic response 
were 68% and 60% in the tacrolimus group and in the beclomethasone group (p=0.636); 
proportions in endoscopic remission rates were 30% and 13%, respectively (p=-0.092) Median 
increases in the inflammatory bowel disease questionnaire score were 18.0 in the tacrolimus 
group and 20.5 in the beclomethasone group (P=0.395). Adverse event rates did not differ 
significantly between groups.
Conclusions: In a 4-week randomized controlled trial, tacrolimus and beclomethasone 
suppositories induce comparable clinical and endoscopic responses in patients with UP 
refractory to 5-ASA. There were no significant differences in adverse events rates. Tacrolimus 
and beclomethasone suppositories are therefore each safe and effective treatment options 
for 5-ASA refractory disease.
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INTRODUCTION
Up to 40% of newly diagnosed ulcerative colitis patients have disease limited to the rectum 
and are considered incident cases of ulcerative proctitis (UP).1 Adequate therapy for UP may 
not only be important for symptom control and quality of life but may also reduce the risk of 
progression of disease extent.2 Epidemiological and retrospective studies have shown that 
in patients with UP progression of disease extent occurs in up to 50% of patients3,4, whilst in 
retrospective studies the risk of progression appears to be higher in patients with persistent 
or recurrent disease activity.5
The first step in the current treatment scheme for UP consists of topical 5-ASA therapy, usually 
in suppository form. Though 5-ASA has a remission induction rate of 65%, maintenance of 
remission occurs in only 50% of patients.6 Current guidelines advise locally administered 
corticosteroids in these refractory patients7, though this therapy induces remission in only 
46% of patients8 and comes with risks of systemic side effects such as suppression of the 
hypothalamic-pituitary-adrenal axis.9
When UP is refractory to both 5-ASA and corticosteroids, step-up to systemically administered 
immunosuppressive drugs such as thiopurines and biologicals is recommended in the 
guidelines.7 However, robust data regarding these drugs in UP is lacking, as patients with 
UP are usually excluded from clinical trials. Furthermore the use of these systemically 
administered drugs might be associated with side effects and higher costs, particularly in 
the case of biological therapies.10 Therefore, a proven effective topical therapy will expand 
the current therapeutic possibilities.
Systemically applied calcineurin inhibitors such as ciclosporin and tacrolimus are already 
established therapeutic options for steroid refractory UC.7 Several pilot studies have shown 
that topical tacrolimus is a safe and effective induction therapy in refractory UP, with clinical 
response rates up to 80%.11,12 Recently the results of a double-blind, randomized controlled 
trial were published, showing highly significant differences between rectal tacrolimus and 
placebo at the interim analysis.13 The response and remission rates were similar to the pilot 
studies, further reinforcing the basis of this study. These studies formed the basis for this 
randomized controlled trial comparing tacrolimus suppositories with beclomethasone 
suppositories for the treatment of patients with 5-ASA refractory UP.
METHODS
Study Design
A randomized controlled, double-blind multicenter study was performed in 8 hospitals in 
Belgium and the Netherlands from 2014 to 2017. The study protocol was approved by the 
institutional review board and ethics committee of the Erasmus MC University Medical Center 
9
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(MEC-2013-300) and by the institutional review boards and ethics committees from each 
participating site, and all enrolled patients provided written informed consent. Patients were 
treated with suppositories for 4 weeks and were randomly assigned to either beclomethasone 
3mg once daily or tacrolimus 2mg once daily. All study procedures were conducted in 
accordance to the Declaration of Helsinki. This trial was registered at the Netherlands Trial 
Register (NL4205, NTR4416). All authors had access to the study data and reviewed and 
approved the final manuscript.
Patients
Patients aged >= 18 years with endoscopically proven active UP, with disease activity up to 20 
cm beyond the anal verge. Active disease was defined as either a Mayo endoscopic severity 
subscore [14] of at least 2, or a histological inflammation grade (Geboes score15) of at least 2, 
regardless of total Mayo score. Additional inclusion criteria were either 5-ASA refractory UP 
(defined as a failure to at least the use of 5-ASA suppositories of a maximum of 1 gram for at 
least 21 days) or recurring UP (defined as a relapse within 3 months after stopping adequate 
local 5-ASA therapy). Concomitant treatment with oral 5-ASA, thiopurines, methotrexate or 
biologicals was allowed if used at a stable dose for at least 12 weeks prior to enrollment.
Key exclusion criteria were: Signs of bacterial pathogens in a stool sample (i.e. Clostridium 
difficile, Salmonella species, Shigella species, Yersinia species, Campylobacter jejuni), local IBD 
therapy with 5-ASA enemas within 14 days prior to randomization, any previous tacrolimus 
treatment, treatment with topical beclomethasone 12 weeks prior to randomization or any 
other steroid use 4 weeks prior to randomization. Additionally, other significant medical 
issues such as poor renal function (eGFR < 30 mL/min), poor liver function, leucopenia and 
thrombopenia were reasons for ineligibility. Finally, pregnant or lactating women were 
excluded.
Randomization and blinding
Randomization was performed centrally by an independent clinical research bureau. 
Participating sites were to fax or e-mail a request for randomization, which would then be 
provided within 24 hours of the request. Randomization occurred per study site, using a 1 : 1 
randomization schedule with various block sizes. To ensure blinding, the investigational drugs 
were custom made for this trial and were of identical in appearance and weight (Tiofarma 
BV, Oud-Beijerland, the Netherlands). Patients, treating physicians, endoscopists and 
investigators remained blinded throughout the study. Tacrolimus serum levels were centrally 
measured during the study and were thus unavailable to the investigators.
Study procedures
After providing written informed consent, a screening period of up to two weeks prior to 
randomization started. During this period the index endoscopy had to be performed, 
confirming the key inclusion criterion of active proctitis as described above. Additionally, 
baseline laboratory tests and stool cultures were performed to ensure eligibility. Upon 
binnenwerk_joany.indd   180 7-12-2020   13:27:40
| 181
Tacrolimus vs Beclomethasone Suppositories for ulcerative proctitis
eligibility, patients visited the study site for baseline clinical activity measurements and 
subsequently the study drugs were provided to the patients. Follow-up visits occurred after 
two and four weeks of treatment. During these visits adverse events were registered, drug 
accountability was performed and blood samples were acquired. Additionally a second clinical 
and endoscopic evaluation was scheduled after four weeks of treatment.
Outcome measures
Clinical activity was measured using the Mayo score14 (see Supplemental data), which consists 
of 3 clinical variables and 1 endoscopic variable, all rated from 0 to 3. The total score therefore 
varies between 0 to 12, with a higher score indicating more severe disease. Additionally, 
histological inflammation was graded using the Geboes score, which ranges from 0 (structural 
changes only) to 5 (erosions or ulcers).15 Grades 0 and 1 are considered remission whereas 
grades 2 to 5 are considered active disease.
The primary outcome of this study was clinical response after 4 weeks of treatment, defined 
as a an absolute decrease in Mayo score of ≥ 3 points, with a relative decrease of ≥ 30% of the 
total score and at least ≥ 1 point decrease in the rectal bleeding subscore or an absolute rectal 
bleeding subscore of 0 or 1. Secondary outcomes were combined clinical and endoscopic 
remission. Clinical remission was defined as a Mayo score ≤ 2, and endoscopic remission as no 
visible inflammation (i.e. Mayo sub-score 0). Additional secondary outcomes were endoscopic 
response, defined as a decrease in Mayo sub-score of ≥ 1 and/or a decrease in extent of 
inflammation of ≥ 5 cm, changes in histological inflammation grade, changes in C-reactive 
protein (CRP) and leucocyte counts, adverse events and quality of life using the Dutch version 
of the inflammatory bowel disease questionnaire (IBDQ).16
Statistical analyses
A power analysis was performed using Pearson Chi-squared test for two proportions. Under 
the assumptions of a 50% response rate for topical steroids and 80% response rate for topical 
tacrolimus, and with a one-sided alpha of 0.025, >80% power could be achieved with 40 
patients in each arm. To account for possible loss to follow-up, it was decided to include an 
additional 10% of patients, resulting in a total of 88 study patients. For the statistical analysis 
the SPSS 24.0 software package was used. Descriptive statistics were used to summarize the 
data. Medians with the range were calculated for continuous data and percentages were 
calculated for categorical data.
Apart from missing data, no adjustment for confounders was performed. Categorical data in 
unrelated groups were compared by the Fisher’s exact test, categorical data in related groups 
were analyzed by McNemar̀ s test. The Mann-Whitney test was used to compare continuous 
data. For paired test, the paired sample t-test was utilized. Correlations were assessed using 
Spearman’s rho. For all these results, one or two-sided (as appropriate) P-values <0.05 were 
considered significant. Analyses were performed according to both intention to treat and per 
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protocol principles. As there were no meaningful differences between these analyses, the per 
protocol results were reported in this manuscript.
As for missing data, only missing data in the IBDQ was imputed. At baseline, imputation was 
only performed if up to 3 missing sub-scores were present and no more than 1 sub-score was 
missing from the “systemic symptoms” or “social functioning” domains, as these domains 
consist of only 5 questions. In case of a missing sub-score, the lowest possible score (1 point) 
was imputed. For the IBDQ at week 4, missing values were carried forward from baseline where 
available, or similarly imputed.
RESULTS
Patient characteristics
Between February 2014 and November 2017, a total of 88 patients were enrolled in this study. 
However, one patient was subsequently excluded because of protocol violations (upon 
monitoring, concomitant use of corticosteroids was discovered). Additionally, 2 patients were 
excluded because of low Mayo scores at baseline, resulting in 85 patients for per protocol 
analysis (Figure 1). In total, 43 patients received tacrolimus and 42 received beclomethasone 
(Table 1). Fifty-seven patients were female (64.7%), median age was 42.3 years (range 18.3 – 
76.4 years) and median disease duration was 7.0 years (range 0.25 – 47.83 years). Concomitant 
medication included oral 5-ASA in 39 patients (45.9%), immunomodulators in 16 patients 
(18.8%) and biologicals in 9 patients (10.6%). The available data are also summarized in Figure 
1. The study ended after the last follow-up visit from the last patient, in December 2017.
Clinical response
In the tacrolimus group, the median baseline Mayo score was 7 (range 3 – 12), in the 
beclomethasone group the median baseline Mayo score was also 7 (range 3 – 12).
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Figure 1. CONSORT flow diagram of screened and included patients, and available study data per time-
point.
After 4 weeks of treatment, in the tacrolimus group 22 out of 35 patients (62.9%) achieved 
the primary outcome of clinical response, compared to 22 out of 37 (59.5%) patients in the 
beclomethasone group, a non-significant difference (p = 0.812, Figure 2A). At the end of the 
study, in the tacrolimus group the median Mayo score decreased to 3 (range 0 – 12, median 
change -3.0 points) and in the beclomethasone to 3 (range 0 – 11, median change -3.5 points, 
p = 0.638). The secondary outcome of clinical remission was achieved in 16 of 35 patients 
(45.7%) in the tacrolimus group and 15 of 39 patients (38.5%) in the beclomethasone group, 
which was not a statistically significant difference (p = 0.638, Figure 2B).
9
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Female (n, %) 27 (62.8%) 28 (66.7%)
Age in years (median, range) 39.6 (18.3 - 75.1) 43.2 (18.6 - 76.4)
Disease duration in years (median, range) 5.8 (0.3 - 36,7) 7.4 (0.3 - 47.8)
Concomitant medication use (n, %)
Oral 5-ASA 15 (34.9%) 24 (57.1%)
Immunomodulators 10 (23.3%) 6 (14.3%)
Biologicals (anti-TNF n 8, vedolizumab n = 1) 4 (9.3%) 5 (11.9%)
Smoking status (n, %)
Current 4 (9.3%) 5 (11.9%)
Former 17 (39.5%) 19 (45.2%)
Never smoked 21 (48.8%) 17 (40.5%)
Total Mayo score (median, range) 7 (3 - 12) 7 (3 - 12)
Mayo endoscopic subscore (n, %)
 0 0 (0%) 0 (0%)
 1 4 (9.3%) 2 (4.8%)
 2 26 (60.5%) 29 (69.0%)
 3 13 (30.2%) 11 (26.2%)
Disease extent in cm (median, range) 10 (2 - 20) 13 (1 - 20)
C-reactive protein (median, range) 2,5 (0.3 - 248,0) 2,0 (0.0 -44.0)
IBDQ (median, range) 146 (91- 211) 145 (87 - 210)
Endoscopic response
At baseline, 39 patients (90.7%) in the tacrolimus group and 40 patients (95.3%) in the 
beclomethasone group had moderate or severe disease activity. The remaining patients 
had mild endoscopic disease activity, but were included because of severe histological 
inflammation. Median baseline disease extent was 10cm (2 – 20) in the tacrolimus group and 
12cm (1 – 20) in the beclomethasone group. At the end of the study, endoscopic response was 
achieved in 25 of 37 patients (67.6%) in the tacrolimus group and 24 of 40 (60.0%) patients in 
the beclomethasone. This difference was not statistically significant (p = 0.636, Figure 2C). 
The difference in endoscopic remission rate was not significantly different (p = 0.092), with 
remission occurring in 11 of 37 patients (29.7%) in the tacrolimus group and in 5 of 40 patients 
(12.5%) in the beclomethasone group (Figure 2D). The change in length of inflamed colon was 
also not significantly different between both groups (p = 0.139).
Histological response
The baseline biopsies showed a median inflammation grade of 3 (range 1 – 5) in the tacrolimus 
group and 4 (range 0 – 5) in the beclomethasone group. At the end of the study, the median 
inflammation grade decreased to 2 (range 0 – 5) for both groups. Histological remission was 
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seen in 11 tacrolimus patients (40.7%) and 8 beclomethasone patients (27.6%), which was not 
a statistically significant difference (p = 0.299).
Figure 2. Main study results. All panels show tacrolimus as white and beclomethasone as gray. Panel A 
shows the proportion of patients with a clinical response, panel B shows the proportion of patients with 
clinical remission. In panel C the proportion of patients with endoscopic response is shown and panel D 
shows the proportion of patients with endoscopic remission.
Biochemical parameters
At the start of the study, the median CRP levels in the tacrolimus and beclomethasone groups 
respectively were 2.5 (range 0.3 – 248.0) and 2.0 (range 0.0 – 44). At the end of the study the 
medians were respectively 2.0 (range 0.3 – 31.0) and 1.6 (range 0.0 – 17.0), which was not 
significantly different (p = 0.554).
Median leucocyte counts at baseline in the tacrolimus and beclomethasone groups 
respectively were 7.2 (range 2.7 – 13.5) and 6.9 (range 3.0 – 10.2). After 4 weeks, the medians 
respectively changed to 7.5 (range 2.8 – 13.4) and 7.3 (range 3.0 – 11.7), which was also not 
significantly different (p = 0.476).
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At the start of the study, the median IBDQ scores for the tacrolimus and beclomethasone 
groups were 147 (range 91 – 211) and 145 (range 87 – 210) respectively. After treatment, the 
median increases in IBDQ scores were 18 (range -18 – 93) and 20.5 (range -13 – 71), leading 
to median IBDQ scores of 175 (range 57 – 214) and 165 (range 80 – 214), for the tacrolimus 
and beclomethasone groups respectively, which was not significantly different (p = 0.733). 
Additionally, changes in the IBDQ were significantly correlated with changes in the total 
Mayo score (R2 0.151, P < 0.001), endoscopic severity (R2 0.104, p = 0.007) and endoscopic 
disease extent (R2 0.164, P < 0.001), but not to changes in CRP, leucocyte count or histologic 
inflammation grade (p = 0.766, 0.575 and 0.108 respectively).
Tacrolimus levels and adverse events
Sixty-two tacrolimus levels were available from 37 of tacrolimus treated patients. The mean 
tacrolimus level was 4.2 ± 3.4μg/L (range 0.0 – 13.6) at week 2 and 2.7 ± 2.8μg/L (range 0.0 – 
12.8) at week 4. Although tacrolimus levels did not represent trough levels, 46 of the levels 
(74.2%) were undetectable or subtherapeutic (<5 µg/L). The remainders were within the low 
therapeutic range (5-20μg/L). There was no correlation between tacrolimus levels and clinical 
and endoscopic outcome. Forty-eight adverse events were reported that were judged to be 
at least possibly related to the study drugs (see Table 2 for details). Eighteen adverse events 
occurred in 14 patients (33.3%) of the beclomethasone group whereas 29 events were seen in 
21 patients (48.8%) in the tacrolimus group, which was not significantly different (p = 0.188). 
Within the tacrolimus group, serum tacrolimus levels were not associated with the occurrence 
of adverse events (p = 0.611). No serious adverse events were reported, nevertheless, one 
patient discontinued the study due to an adverse event possibly related to the study drug. 
Specifically, this patient was randomized to tacrolimus and developed a clostridium infection 
after two weeks.
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Table 2. Overview of adverse events
Tacrolimus Beclomethasone Total
Abdominal pain / worsening of symptoms 3 3 6
Arthritis 0 1 1
Peri-anal effects (burning/itching/hemorrhoid/
fissure) 9 3 12
Clostridium infection 1 0 1
CMV 1 0 1
Nausea/dizziness/weakness 2 1 3
Skin (flushing, erythema, itchiness) 3 4 7
Flatulence 5 2 7
Headache 2 1 3
Rectal urgency 1 0 1
Night sweats 1 0 1
Palpitations 1 1 2
Upper airway infection 0 2 2
Total 29 18 47
DISCUSSION
In this randomized controlled trial comparing tacrolimus suppositories with beclomethasone 
suppositories as induction therapy for 5-ASA refractory ulcerative proctitis, no superiority 
of tacrolimus was shown over beclomethasone. After 4 weeks of treatment, clinical and 
endoscopic response (62.9% versus 59.9% and 67.6% versus 60%) and clinical and endoscopic 
remission (45.7% versus 38.5% and 29.7% versus 14.5%) were equal. Thus, both study drugs 
managed to induce clinical and endoscopic response in the majority of patients. Furthermore, 
both treatments resulted in improvements in histological inflammation and quality of life. 
Adverse event rates were similar in both groups.
To our knowledge, this is the first head to head controlled trial examining the effects of 
tacrolimus and beclomethasone suppositories in ulcerative colitis patients. The clinical 
response and remission rates of 60% and 40% respectively are comparable to the rates of 
other topical corticosteroids17, though some of these studies examined a combination of UP 
patients and patients with left-sided disease.18,19
Topical tacrolimus has been investigated in only few studies. When comparing our study to the 
randomized controlled trial of Lawrance et al, certain differences in the reported outcomes 
warrant consideration.13 In their 8-week trial comparing rectal tacrolimus with placebo in 
patients with therapy refractory UP, they observed a clinical response rate of 73%. Our 4 week 
study finds a somewhat lower clinical response rate of 62.9% in the tacrolimus group, and finds 
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no statistically significant difference when compared with another active drug. The clinical 
remission rates are more similar, with Lawrance et al reporting 45% and our study finding 
45.7%. However, mucosal healing (defined in their study as an endoscopic Mayo score of 0 or 
1) was reported in 73% of their patients, whereas using this criterion it was seen in only 58% 
of tacrolimus treated patients in our study.
Possible explanations for the differences in clinical response rate and mucosal healing 
are the differences in baseline characteristics between the patients of these two studies. 
Specifically, we had a greater proportion of female patients, had more current smokers and 
patients used more concomitant immunosuppressive and biological drugs. This may reflect 
more refractory disease in the patients enrolled in our trial, as current guidelines recommend 
the use of these agents only for refractory UP. A notable difference between our study and 
Lawrance et al is a shorter treatment duration (4 weeks compared to 8 weeks). Additionally, 
Lawrance et al used a different treatment regimen, consisting of twice-daily rectally applied 
ointment with a total daily dose of 3mg tacrolimus. In our study we decided to use once daily 
suppositories containing only 2 mg of tacrolimus, based on our previous Phase 1 study.11 In 
that study, low but measurable serum levels of tacrolimus were found with the use of once 
daily 2mg tacrolimus suppositories. Thus in order to prevent systemic exposure to higher 
tacrolimus levels, the same dose was used in our current study. Concerning serum tacrolimus 
levels, Lawrance et al also find measurable serum levels, and similar to our study, they find 
no correlation between serum levels and efficacy or adverse events. Of note, the tacrolimus 
serum levels in our study do not represent true trough levels, nevertheless the majority of 
tacrolimus levels were sub-therapeutic. Therefore, the true tacrolimus trough levels would 
probably be even lower than currently measured. These differences in treatment duration, 
regimen and patient characteristics may partly explain the differences seen between these 
studies in the reported in clinical response and mucosal healing rates.
No serious adverse events were reported during the study period, and only a single adverse 
event, possibly related to the study drugs, caused patients to discontinue the study. 
Nevertheless, mild adverse events, particularly peri-anal itching and burning, were frequently 
reported, more often in patients treated with tacrolimus.
Systemically applied calcineurin inhibitors are already approved for use in steroid refractory 
acute severe ulcerative colitis.7 The optimal position of topical tacrolimus within the step-up 
scheme for treatment of UP is currently unclear. Topical 5-ASA is the first line therapy for UP 
patients because of the robustly proven efficacy and side effect profile. Given the results of 
our study and of previous studies, using either topical tacrolimus or topical corticosteroids as 
the second step in UP therapy both seem safe and viable options, and both therapies should 
be considered prior to step-up to immunomodulators or biologicals.
Despite the randomized controlled and triple blinded design, there are limitations to this 
study. Firstly, patients were mostly enrolled in tertiary centers. This may have resulted in the 
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inclusion of patients with more severe disease than seen in general clinical practice. Secondly, 
the inclusion criteria of our study were primarily based on the presence of endoscopic 
disease activity. Though this was intended to ensure objective disease activity at the start 
of the study, some of the included patients had surprisingly low Mayo scores at inclusion. 
These low baseline scores may have reduced the amount of patients who could achieve the 
predefined 3 point decrease in the Mayo score to achieve the primary outcome of clinical 
response, thus resulting in a study with less power than initially designed. Thirdly, this study 
only examined an induction treatment period of 4 weeks, thus the value of a longer induction 
period or (intermittent) maintenance therapy remains unclear. Initially, a study period of 8 
weeks was considered, but due to concerns regarding side effects related to long-term rectal 
corticosteroid therapy a 4-week study period was chosen.
In summary, among 5-ASA refractory ulcerative proctitis patients, the use 4 weeks of 
tacrolimus suppositories was not superior to treatment with beclomethasone suppositories. 
Furthermore, no significant differences between tacrolimus and beclomethasone were seen 
regarding the secondary outcomes and both treatments appear to be safe. Therefore, both 
tacrolimus suppositories and beclomethasone suppositories appear to be viable treatment 
options for 5-ASA refractory disease. Topical treatment with tacrolimus should be considered 
prior to step-up to thiopurines or biologicals in 5-ASA refractory ulcerative proctitis.
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Supplementary data 1. Mayo score exactly as described by Schroeder KW, Tremaine WJ and 
Ilstrup DM (N Engl J Med. 1987 Dec 24;317(26):1625-9.).
Stool frequency*
0 = Normal no. of stools fort his patient
1 = 1-2 stools more than normal
2 = 3-4 stools more than normal
3 = 5 or more stools than normal
Rectal bleeding¥
0 = No blood seen
1 = Streaks of blood with stool less than half the time
2 = Obvious blood with stool most of the time
3 = Blood alone passed
Findings of flexible proctosigmoidoscopy
0 = Normal or inactive disease
1 = Mild disease (erythema, decreased vascular pattern, mild friability)
2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions)
3 = Severe disease (spontaneous bleeding, ulceration)
Physician’s global assessment ‡
0 = Normal
1 = Mild disease
2 = Moderate disease
3 = Severe disease
* Each patient served as his or her own control to establish the degree of abnormality of the 
stool frequency.
¥ The daily bleeding score represented the most severe bleeding of the day.
‡ The physician’s global assessment acknowledged the three other criteria, the patient’s daily 
record of abdominal discomfort and general sense of well-being, and other observations, 
such as physical findings and the patient’s performance status.
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CHAPTER 10
SUMMARY, GENERAL DISCUSSION 
AND FUTURE PERSPECTIVES




This thesis aimed at providing more insight into several safety aspects, efficacy and 
opportunities with current immunosuppressive treatment in inflammatory bowel disease 
(IBD). First we explored risk factors for therapy withdrawal due to ineffectiveness or adverse 
events. Second, we focussed on the risk of cervical dysplasia and cervical cancer in IBD and 
the role of immunosuppressive therapy in these extra-intestinal complications. Finally, we 
explored opportunities in treatment and monitoring of IBD patients. In this chapter, we 
summarize and discuss these aspects and provide possible directions for future research.
GENERAL DISCUSSION
Risk factors for therapy failure
Difficulties in thiopurine treatment
Although thiopurine treatment for IBD has been introduced several decades ago, the 
balance between optimization of treatment effect and avoidance of toxicity remains an 
important challenge in clinical practice.1-3 Strategies to monitor this balance include genetic 
testing of polymorphisms associated with risk of toxicity (e.g. TPMT, NUDT15), therapeutic 
drug monitoring (TDM) of thiopurine metabolites 6-thio guanine nucleotides (6-TGN) and 
6-methylmercaptopurine ribonucleotides (6-MMPR), and laboratory monitoring of toxicity.
In Chapter 2 we have studied treatment failure within a cohort of 49 IBD patients with a 
routinely established skewed metabolism, i.e. a drug metabolism variation that results in 
excessive amounts of cytotoxic 6-MMPR at the expense of immunosuppressive 6-TGN levels 
that usually remain below the therapeutic range. In this cohort, 84% of patients discontinued 
thiopurine therapy in the first 3 months of treatment, mainly for adverse events (55%) and 
nonresponse (12%). This proportion of early failure of thiopurine therapy was substantially 
higher than the 15-35% reported in literature on early failure.4,5 We concluded that a skewed 
metabolism of thiopurines is a major risk factor for future thiopurine failure. TDM is usually 
applied as a reactive strategy when a patient does not adequately respond to treatment 
or experiences intolerable adverse events and therefore a skewed metabolism is generally 
detected upon signs of toxicity or treatment failure.6-8 Our observations imply that routine 
thiopurine metabolite measurements early after the start of thiopurines may be considered to 
identify patients with an aberrant-skewed metabolism at an early stage, possibly benefitting 
from therapy adjustments, to prevent thiopurine therapy failure. This is supported by the 
observation by Wong et al that assessment of 6-TGN and 6-MMPR metabolites as early as 1 
week after thiopurine initiation (i.e. before steady-state) was correlated with the development 
of leukopenia and hepatotoxicity.9,10
Since up to 37% of IBD patients harbour thiopurine metabolism variations, early (pre-
emptive) TDM-guided thiopurine therapy deserves further study in a prospective cohort 
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study, with a detailed analysis of (long-term) efficacy, toxicity and cost-effectiveness. For the 
development of this monitor strategy the importance of genetic polymorphisms in thiopurine 
S-methyltransferase (TPMT) and NUDT15 associated with therapy withdrawal because of 
myelotoxicity need to be taken into account. Genetic variants in NUDT15 is particularly present 
in patients of Asian descent and to a much lesser extent in patients of non-Asian descent.11,12 
However, it should be noted that both of these genetic variations only explain a proportion of 
myelotoxicity cases and myelotoxicity is not the only reason for therapy withdrawal. In TDM 
the outcome of genetic variations and inadequate dosing is detected and it is uncertain if 
extensive pre-treatment pharmacogenetic screening will replace TDM in the future. Based on 
current literature and the findings in our study, a monitor strategy combining pre-treatment 
TPMT and NUDT15 testing, and early TDM at week 8 seems advocated to prevent patients from 
discontinuing thiopurine treatment.
In Chapter 3 we demonstrated that patients with a skewed thiopurine metabolism are at 
increased risk of myelotoxicity. Although myelotoxicity, in particular leukopenia, during 
thiopurine treatment is most commonly attributed to (extremely) high 6-TGN levels, we 
have shown in this study of 24 patients that myelotoxicity also occurs because of (extremely) 
high 6-MMPR concentrations in patients with a skewed thiopurine metabolism. Leukopenia 
improved in 17% and resolved in 83% of patients within 4 weeks of adjusting treatment (i.e. 
discontinuation, LDTA or switch to thioguanine (TG)). These data confirm the value of TDM 
after detection of laboratory toxicity, c.q. leukopenia. Myelotoxicity, especially leukopenia, 
is usually attributed to high bioavailability of 6-TGN levels as a result of overdosing or genetic 
variation resulting in low TPMT enzyme activity.13,14 Pre-treatment genetic testing of TPMT 
is performed to identify patients with absent or low TPMT enzyme activity that are prone to 
development of myelotoxicity and would benefit from reduced thiopurine dose or treatment 
with a different drug. Because 6-MMPR formation is mainly driven by TPMT activity (i.e. normal 
to high activity), pre-treatment genetic testing would not have prevented myelotoxicity in 
these patients. These study findings confirm previous publications that TDM is particularly 
useful in the management of patients with inadequate response to thiopurines or adverse 
events.15 In addition, reactive TDM has been shown to optimize treatment response and is 
cost-effective compared with standard weight-based dosing.16,17
Optimizing thiopurine treatment
Several strategies have been proposed to optimize thiopurine treatment in patients with 
inadequate response or adverse events (AEs). Low dose thiopurine combined with allopurinol 
(LDTA) therapy is a beneficial optimization strategy in patients with a skewed thiopurine 
metabolism but data on continued maintenance LDTA treatment and incidence of renewed 
laboratory toxicity are scarce.18 19-21 In Chapter 4 we demonstrated that maintenance LDTA 
is a safe and beneficial optimization strategy in a cohort of 221 IBD patients with treatment 
continued in 51% of patients beyond 5-years. Treatment withdrawal was most commonly the 
result of ineffectiveness of LDTA rather than LDTA-attributed laboratory toxicity. Importantly, 
we showed that LDTA is most advantageous in patients failing thiopurine monotherapy due 
10
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to AEs with high rates of continued treatment and rapid recovery of thiopurine monotherapy 
associated hepatotoxicity and also myelotoxicity. In addition, none of these patients stopped 
treatment for LDTA-induced laboratory toxicity. Given the favourable effects of allopurinol 
on thiopurine metabolism and long-term therapeutic benefit and safety, one could argue 
that LDTA should not be restricted to patients with a skewed metabolism. In the presence of 
pre-treatment genetic screening and/or pre-emptive TDM, LDTA could possibly be considered 
as a first-line therapy. These predictions await confirmation by the on-going multicentre 
randomised controlled DECIDER trial (ACTRN12613001347752), evaluating response and 
tolerability of thiopurine monotherapy compared to LDTA in thiopurine naïve patients.
The advantage of tioguanine is that only one pill has to be administered which may improve 
treatment adherence and avoids the toxicity of a second drug such as allopurinol. In contrast, 
therapy with LDTA is supported by more clinical evidence that may guide the interpretation of 
the levels of metabolites associated with effectiveness and safetye advantage of tioguanine is 
that only one pill has to be administered which may improve treatment adherence and avoids 
the toxicity of a second drug such as allopurinol. In contrast, therapy with LDTA is supported by 
more clinical evidence that may guide the interpretation of the levels of metabolites associated 
with effectiveness and safety.
Improving thiopurine monitoring
As hepatotoxicity and myelotoxicity often result in thiopurine withdrawal, frequent monitoring 
of laboratory parameters including a full blood count (FBC) and serum liver enzyme tests 
(LTs) is performed to guide possible therapy modification.22-25 The risk of laboratory toxicity 
is highest in the first months of treatment, but after this induction period it is unclear if the 
potential benefit of laboratory monitoring at 2-3 month in maintenance therapy outweighs 
the burden for patients and associated direct and indirect healthcare costs.26 In Chapter 5 
we assessed incidence rates and clinical consequences of myelotoxicity and hepatotoxicity 
within current laboratory regimen in thiopurine maintenance therapy after at least 1 year of 
treatment in a cohort of 1132 IBD patients. Although mild myelotoxicity and hepatotoxicity 
were present (5% and 7% per treatment year), severe laboratory toxicity was uncommon after 
1 year of thiopurine monotherapy (0.1% and 0.2%). Our results demonstrated that laboratory 
monitoring rarely leads to therapy adjustments or additional diagnostic procedures such as 
additional laboratory assessments. The most relevant observation was that severe toxicity-
related complications, such as infection and hospitalisation, were rare (1% in the total 
cohort) and not prevented by (stringent) monitoring, as preceding laboratory assessments 
were unremarkable in the majority of cases. Since the clinical impact of detecting laboratory 
toxicity in maintenance therapy was low, and complications rare, routine monitoring is of 
limited benefit. Laboratory monitoring practices in our large real-life cohort were more 
liberal than recommended in the ECCO guideline; at 4-month intervals (our study) versus 
at 2-3 month intervals (ECCO guideline).27 Therefore, we conclude that the recommended 
monitoring frequency may be reduced to less than every 4 months. The rate of thiopurine-
induced myelotoxicity has been reduced after the introduction of TPMT genotype testing.26,28 
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In addition, Broekman et al showed that patients with non-TPMT mediated thiopurine-induced 
leukopenia had no increased infection risk compared to patients without leukopenia.29 These 
results also support that monitoring frequency in maintenance thiopurine treatment could 
be reduced.
We speculate that a monitoring regimen at 6-month intervals is sufficient in patients after 1 
year of thiopurine treatment and will decrease patient burden and healthcare costs. To confirm 
these speculations, prospective evaluation in an impractically large study population with 
several years of follow-up would be required. In addition, detection of laboratory toxicity 
is expected to influence both treatment and monitoring and this will not be avoided by a 
prospective design. Therefore, a prospective cohort study will probably not provide the 
required data to test this hypothesis. Our results apply to patients on thiopurine monotherapy 
and it would be interesting to study the clinical relevance of laboratory toxicity in patients on 
combination therapy with biologic agents.
Difficulties in adalimumab treatment
Biologic agents are increasingly used to treat IBD patients, but drug efficacy and tolerability 
are often different in real-life clinical practice than reported in randomised controlled trials 
performed under strict conditions in a selected patient population. To allow optimal drug use 
in a personalized fashion, factors that predict treatment failure, safety and tolerability need 
to be studied in clinical cohorts. In Chapter 6 we described a prospective real-life cohort 
study of 188 CD patients treated with adalimumab and assessed efficacy and tolerability. In 
particular we studied possible sex differences in the outcome to adalimumab treatment and 
we noticed that that female sex negatively affects treatment success of adalimumab. First, 
female patients were less likely to achieve or maintain clinical response than male patients 
(31% vs 48%). Second, female patients reported more side effects such as skin reactions and 
infections, but more importantly stopped ADA treatment more often than males due to side 
effects. This suggests that a personalized approach to female patients starting ADA could 
positively influence treatment success. In other fields of medicine it has been shown that 
the sex of the patient can have profound influences on drug metabolism and efficacy, also 
in biological treatment.30,31 Although the exact mechanism is unknown, our results could be 
explained by sex specific physiological differences in drug metabolism, body composition or 
sex hormones, 32-41 Apart from physiological explanations, perception of adverse events and 
health care seeking behaviour also differs between males and females. In a recent systematic 
review performed by Lie et al, no evidence was found for sex differences in efficacy of biological 
therapies using objectively measured endoscopic disease outcomes.42 This finding strongly 
suggests that the greater proportion of side effects and subsequent therapy withdrawal is the 
major cause for a decreased success rate of ADA in females. Providing tailored information and 
education concerning the possible side effects may result in different patient expectations, 
which could subsequently reduce the high drop out rate due to side effects, as observed in 
our study.
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Cervical neoplasia in IBD
Cervical neoplasia in IBD
Although several studies suggest that IBD women are at increased risk of cervical 
neoplasia caused by human papilloma virus (HPV), the role of disease characteristics and 
immunosuppression in the pathogenesis is unclear.43-47 Due to conflicting evidence and lack 
of longitudinal follow-up in the majority of studies it is unclear whether cervical screening in 
IBD needs to be intensified. In Chapter 7, we studied the risk of high-grade cervical dysplasia 
and cancer (CIN2+) in a large cohort of IBD women compared to a matched cohort from the 
Dutch general female population with longitudinal follow up. We found that CIN2+ detection 
rate was higher in the IBD cohort than in the matched cohort, even after correcting for their 
more frequent screening behaviour (standardised detection rate 1.27). This risk was highest 
in women within the age group of 35 to 39 years (standardised detection rate 1.80). In line 
with previous findings we found that smoking was a strong risk factor for CIN2+, but CIN2+ 
risk associated with smoking was higher in IBD than in the general population.46,48-51 Therefore, 
one may suggest a combined effect of IBD and exposure to cigarette smoke on CIN2+ risk 
which provides a further strong motivation to encourage patients to stop smoking. Exposure 
to immunomodulators and biologics, studied as trichotomous variables (never, <1 year, > 
1 year), was not associated with CIN2+ development. Importantly, we show that the risk of 
progression from normal cervical smear towards CIN2+ was increased in IBD women, and IBD 
women were also at increased risk for persistent or recurrent CIN than women in the general 
population. Reduced high-risk HPV (hrHPV) clearance due to impaired detection of oncogenic 
signals (immunosurveillance) caused by chronic systemic inflammation could explain these 
findings.52-55 This is supported by the fact that we did not establish a difference in transient low-
grade CIN1 between both groups. Therefore, vaccination for HPV and adherence to cervical 
cancer screening programs should be strongly encouraged in all IBD women, regardless of 
immunosuppressant use. This is supported by the fact that normal immunogenic response 
to HPV vaccination has been reported in patients on immunosuppressive medication.56
In Chapter 8 we further explored the effect of exposure to immunosuppressive drugs 
(immunomodulators and/or biologics) and CIN 2+ development in the IBD cohort. Although 
exposure to immunosuppressive drugs expressed as dichotomous variables (ever/never) 
did not seem to impact CIN2+ development, we demonstrated that each year of exposure 
to immunomodulators (HR 1.15 per treatment year) or biologics (HR 1.15 per treatment 
year) was associated with an increased risk of CIN2+ development. Lag-time of 6 and 12 
months taking latency time of drug exposure and CIN2+ development into account, did not 
meaningfully change these results. The influence of immunosuppressive medication on CIN2+ 
development could again be explained by a decreased clearance of hrHPV infections caused 
by an (iatrogenic) immune-compromised state. Physicians should stress the importance of 
HPV vaccination and cervical cancer screening for all IBD women. These results imply that 
further investigation is required to assess the benefit of intensified screening IBD women on 
long-term immunosuppressive treatment.
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Local treatment of ulcerative proctitis
Topical therapies are an attractive treatment option in ulcerative proctitis because of their 
local activity and minimal systemic toxicity. Unfortunately, the arsenal of topical therapies is 
small and patients with 5-ASA refractory proctitis often require step up treatment to (local) 
corticosteroids, immunomodulators or biological agents that might be associated with 
adverse events and higher costs. Previous studies reported promising results of tacrolimus 
as a treatment for proctitis compared to placebo.57,58 Chapter 9 describes a multicentre 
double-blinded randomized controlled trial aimed to evaluate tacrolimus suppositories 
2mg OD compared to beclomethasone 3mg OD suppositories for 4 weeks in patients with 
5-ASA refractory UP. We demonstrated that tacrolimus and beclomethasone suppositories 
display comparable clinical and endoscopic response. Both drugs managed to induce clinical 
response (60%) and endoscopic response (60%) in the majority of patients. Furthermore, 
both treatments resulted in improvements in histological inflammation and quality of life. 
We did not observe significant differences in adverse events rates between tacrolimus and 
beclomethasone. Our findings imply that both tacrolimus and beclomethasone suppositories 
are viable treatment options for 5-ASA refractory ulcerative proctitis. Adequate treatment of 
UP is not only important for symptom control and quality of life, but also to reduce disease 
progression.59-62 Topical treatment with tacrolimus or beclomethasone should be considered 
in 5-ASA refractory UP prior to step-up to systemic treatment with thiopurines or biologic 
agents. It would be interesting to study real-life effectiveness and tolerability of continued 
(maintenance) treatment with tacrolimus in UP in the future.63
FUTURE PERSPECTIVES
Selecting the right drug for the right patient in the expanding maze of IBD treatment is a true 
challenge. Appropriate treatment of IBD is essential to avoid long-term disease complications. 
Despite significant efforts, a cure for IBD has not been identified. Although there is a definite 
need for novel and improved treatment options to maximise remission rates and quality of 
life, there is a lot of room for improvement with the currently available treatments.
Apart from effectively targeting the perpetuating inflammatory response in IBD with 
medication, efforts should be made to further optimize monitoring of treatment response and 
adverse events and adequate optimization strategies to prevent treatment failure and improve 
clinical outcome. Early (pre-emptive) TDM-guided thiopurine therapy seems promising to 
prevent thiopurine failure and future prospective studies should focus on (long-term) efficacy, 
toxicity and cost-effectiveness of this strategy, possibly combined with pre-treatment genetic 
testing. Ideally, genotyping of all patients is performed prior to thiopurine exposure to reveal 
genetic variations that influence thiopurine drug metabolism to ultimately prevent patients 
from being exposed to drugs that are not effective or harmful due to severe toxicity and would 
therefore benefit from alternative therapies. However, as TDM essentially comprises the 
outcome of all genetic variations and inadequate dosing, it is questionable if pre-treatment 
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pharmacogenetic testing will eventually alleviate the burden of routine monitoring for toxicity 
in the future.
Optimization strategies with LDTA and TG show similar benefit in patients failing conventional 
thiopurines, but because of their favourable properties in thiopurine metabolism, the efficacy 
of first-line treatment with LDTA of TG should be further studied, preferably in a head-to-head 
trial.
Another aspect to explore is thiopurine-analogues that specifically target the Rac1 signalling 
pathway to increase T-cell apopotosis and bypassing enzymatic pathways associated with 
toxicity. Optimised immunosuppressive agents might offer relevant therapy implications if 
confirmed in clinical studies. Although the vast majority of new immunosuppressive drugs 
are systemic therapies, rectal therapies that clearly offer a number of advantages remain 
underdeveloped. To allow for personalized medicine in patients with distal forms of IBD, (new) 
local therapies should be explored.
In (severely) active IBD the risks of medical treatment generally outweigh possible disease-
related complications, but the risks of long-term immunosuppressive treatment need to 
be noted. Since cervical neoplasia is increased in IBD women, future studies should aim at 
exploring persistence of hrHPV and the role in cervical carcinogenesis as this may lead to 
strategies of (temporal) reduction of immunosuppressant use to clear the virus and halt or 
even reverse cervical carcinogenesis, before passing a point of no return. Oncogenic HPV-
infections are also associated with head, neck and anogenital cancers besides cervical cancer. 
Current estimates indicate that 5.2% of all cancers are HPV associated and the risk of infection 
is equal among men and women, therefore future studies should also investigate the impact 
of immunosuppressive exposure in other HPV-associated cancers and the efficacy of HPV 
vaccination in male IBD patients.
An important step in the translation of our results in to clinical practice would be the 
development of a prediction tool allowing for personalized medicine. The inherent complexity 
of IBD introduces a large number of confounding factors that hamper development of a 
personalized treatment strategy. It is unlikely that RCTs will yield the evidence for such a 
strategy as these studies use strict in- and exclusion patient criteria and therefore do not 
represent clinical practice. Consistent longitudinal collection of clinical data and biomaterials 
in nationwide databases, such as the Dutch IBD biobank (PSI) described in this thesis, could 
allow for development of a therapeutic strategy for each individual IBD patient. Future 
research should explore further development of personalized treatment strategies, preferably 
in the setting of international collaboration. A new high-potential field of research to analyse 
complex clinical data combined with data from biomaterials is system dynamics analysis, 
which allows for real-time individualized prediction of disease and treatment outcomes.64
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To conclude, IBD is a complex disease with large inter-individual variance in disease behaviour 
and treatment response. Overall, this thesis adds to the current data regarding safety aspects 
of current medical immunosuppressive treatment in IBD and provides several opportunities 
to improve IBD care. Combining these findings together with clinical data and biomaterials 
could guide development of more tailored treatment strategies will hopefully become reality 
in the near future.
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Inflammatoire darmziekten (IBD) zijn chronische inflammatoire aandoeningen die 
voornamelijk het maagdarmkanaal aantasten. IBD wordt gekenmerkt door terugkerende 
chronische ontsteking met periodes van actieve ziekte afgewisseld met perioden waarin de 
ziekte rustig is. De belangrijkste ziektebeelden zijn de ziekte van Crohn (CD), colitis ulcerosa 
(UC) en IBD-niet-geclassificeerd (IBDU). Deze ziekten hebben deels overlappende kenmerken, 
maar onderscheiden zich in verschil in de locatie en het gedrag van de ontsteking. IBD is 
een complexe, multifactoriële ziekte en ondanks aanzienlijke inspanningen is er nog geen 
manier gevonden om de ziekte te genezen. Aangezien IBD een chronische ziekte is en gepaard 
gaat met invaliderende symptomen is langdurige behandeling met ontstekingsremmende 
geneesmiddelen in de meeste patiënten noodzakelijk, soms zelfs levenslang. Het doel van deze 
behandeling is om opvlamming te behandelen zodat de ziekte tot rust kan komen (remissie) en 
een nieuwe opvlamming te voorkomen. Wanneer de ziekte niet voldoende wordt behandeld 
kan dit leiden tot onomkeerbare schade aan het maag-darm stelsel, verminderde kwaliteit 
van leven en werkproductiviteit, en hoge zorgkosten. Anderzijds hebben medicijnen ook 
bijwerkingen en kunnen behandelings-gerelateerde complicaties zoals infecties of kanker 
voorkomen. Het is een uitdaging om de juiste behandeling voor de juiste patiënt te selecteren 
in de klinische praktijk, waarbij een balans gezocht moet worden tussen de effectiviteit van 
het medicijn, de bijwerkingen en de kosten.
Met dit proefschrift hebben we getracht om meer inzicht te geven in verschillende 
veiligheidsaspecten, effectiviteit en mogelijkheden binnen huidige behandelingen voor 
IBD. In deel I hebben we risicofactoren onderzocht voor het staken van behandeling 
vanwege ineffectiviteit of bijwerkingen. Ten tweede hebben we ons gericht op het risico van 
baarmoederhalskanker en voorloperstadia bij IBD en de rol van immunosuppressieve therapie. 
Ten slotte hebben we mogelijkheden van lokale therapie onderzocht bij patiënten met colitis 
ulcerosa waarbij het laatste gedeelte van de dikke darm is aangetast. In dit hoofdstuk vatten 
we deze aspecten samen en bespreken we suggesties voor toekomstig onderzoek.
Risicofactoren voor therapiefalen
Uitdagingen in thiopurine therapie
Hoewel thiopurines al decennia lang worden toegepast in de behandeling van IBD, blijft 
het in de klinische praktijk een uitdaging om de balans te vinden tussen enerzijds het 
optimaliseren van het behandelefect en anderzijds het vermijden van toxiciteit. Strategieën 
om deze balans te bewaken omvatten genetische testen op polymorfismen die verband 
houden met het risico op toxiciteit (bijv. TPMT, NUDT15), therapeutic drug monitoring (TDM) 
van thiopurinemetabolieten 6-thioguaninenucleotiden (6-TGN, werkzame metabolieten) en 
6-methylmercaptopurine-ribonucleotiden (6-MMPR, toxische metabolieten), en monitoren 
van toxiciteit in het bloedonderzoek (lab monitoring).
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In Hoofdstuk 2 is de voorspellende waarde van een afwijkend ‘skewed’ thiopurine metabolisme 
bestudeerd, vastgesteld bij routinematige metingen in bloedonderzoek, in een cohort van 49 
IBD patiënten. Een skewed thiopurine metabolisme is een variatie die resulteert in overmatige 
hoeveelheden toxische 6-MMPR ten koste van immuunsuppressieve 6-TGN-niveaus die 
vaak geen therapeutische waarde bereiken. In dit cohort stopte 84% van de patiënten met 
thiopurine therapie binnen de eerste 3 maanden van de behandeling, voornamelijk vanwege 
bijwerkingen (55%) en uitblijvende respons (12%). Dit percentage van vroegtijdig falen van 
thiopurinetherapie was substantieel hoger dan 15-35% zoals in de literatuur gerapporteerd. 
We concludeerden dat een skewed metabolisme een belangrijke risicofactor is voor toekomstig 
falen van thiopurines. TDM wordt gewoonlijk toegepast als een reactieve strategie wanneer 
een patiënt niet adequaat reageert op de behandeling of ondraaglijke bijwerkingen ervaart. 
Hierdoor wordt een skewed metabolisme over het algemeen pas gedetecteerd bij tekenen 
van toxiciteit of falen van de behandeling. Deze resultaten impliceren dat overwogen kan 
worden om thiopurinemetabolieten routinematig te bepalen, vroegtijdig na het starten van 
de thiopurinebehandeling om zo patiënten met een skewed metabolisme in een vroeg stadium 
te identificeren. Deze patiënten hebben mogelijk baat bij aanpassing van de thiopurine 
therapie, waardoor voorkomen kan worden dat de behandeling faalt. Dit advies wordt 
ondersteund door de resultaten van een studie van Wong et al, waarin 6-TGN- en 6-MMPR-
metabolieten een week na aanvang van de thiopurine behandeling gecorreleerd waren met 
de ontwikkeling van leukopenie en levertoxiciteit. Aangezien tot 37% van de IBD-patiënten 
variaties in het thiopurinemetabolisme herbergen, is het zinvol om vroege (preventieve) TDM-
geleide thiopurine therapie nader te onderzoeken in een prospectieve cohortstudie, met een 
gedetailleerde analyse naar (lange termijn) werkzaamheid, toxiciteit en kosteneffectiviteit. 
Voor de ontwikkeling van deze nieuwe monitorstrategie moet rekening worden gehouden 
met het belang van genetische polymorfismen in thiopurine S-methyltransferase (TPMT) 
en NUDT15 die vanwege beenmergtoxiciteit geassocieerd met het stoppen van therapie. 
Genetische varianten in NUDT15 zijn vooral aanwezig bij patiënten van Aziatische afkomst 
en in veel mindere mate bij patiënten van niet-Aziatische afkomst. Het feit dat deze twee 
genetische variaties slechts een deel van de beenmergtoxiciteit verklaren en toxiciteit van 
het beenmerg niet de enige reden is van therapie falen verdiend de aandacht. Bij TDM komen 
in principe de uitkomsten van zowel genetische variaties en inadequate dosering aan het 
licht en het is nog niet duidelijk of uitgebreide genetische screening voorafgaand aan de 
behandeling, TDM in de toekomst volledig zal vervangen. Op basis van de huidige literatuur 
en de bevindingen in onze studie lijkt screening naar TPMT- en NUDT15 polymorfismen 
voorafgaand aan de behandeling combineert met vroege TDM 8 weken na aanvang van de 
behandeling de aanbevolen monitorstrategie om te voorkomen dat patiënten de thiopurine 
behandeling staken.
In Hoofdstuk 3 hebben we aangetoond dat patiënten met een skewed thiopurine 
metabolisme een verhoogd risico hebben op beenmergtoxiciteit. Hoewel beenmergtoxiciteit, 
in het bijzonder leukopenie, tijdens thiopurine therapie meestal wordt toegeschreven aan 
(extreem) hoge 6-TGN-spiegels, hebben we in deze studie onder 24 patiënten met een skewed 
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metabolisme aangetoond dat beenmergtoxiciteit ook optreedt in aanwezigheid van (extreem) 
hoge 6-MMPR-concentraties. Leukopenie verbeterde bij 17% en verdween bij 83% van de 
patiënten binnen 4 weken na aanpassing van de behandeling (d.w.z. staken van thiopurine, lage 
dosis thiopurine in combinatie met allopurinol (LDTA) of switch naar thioguanine therapie (TG)). 
Deze resultaten bevestigen de waarde van TDM ook na detectie van laboratoriumtoxiciteit, c.q. 
leukopenie. Beenmergtoxiciteit, met name leukopenie, wordt gewoonlijk toegeschreven aan 
een hoge biologische beschikbaarheid van 6-TGN-metabolieten als gevolg van overdosering 
of genetische variatie die leidt tot verminderde of afwezige enzym activiteit van thiopurine-
S-methyltransferase (TPMT). Genetische screening naar TPMT mutaties wordt voorafgaand 
aan therapie verricht om patiënten te identificeren die door lage of afwezige enzymactiviteit 
vatbaar zijn voor de ontwikkeling van beenmergtoxiciteit en baat zouden kunnen hebben bij 
het verlagen van de dosis of behandeling met een ander geneesmiddel. Omdat de vorming 
van 6-MMPR voornamelijk wordt veroorzaakt door TPMT-activiteit (d.w.z. normale tot hoge 
activiteit), zou beenmergtoxicteit bij deze patienten niet voorkomen zijn door een genetische 
test voorafgaand aan de behandeling. Deze onderzoeksresultaten bevestigen dat TDM 
bijzonder nuttig is bij de behandeling van patiënten met onvoldoende respons op thiopurines 
of bijwerkingen. Bovendien is aangetoond dat reactieve TDM de respons op de behandeling 
optimaliseert en kosteneffectief is vergeleken met standaard dosering gebaseerd op het 
gewicht.
Optimaliseren van thiopurinetherapie
Er zijn verschillende strategieën om de thiopurinebehandeling te optimaliseren bij 
patiënten met onvoldoende respons of bijwerkingen (AEs). Behandeling met een lage dosis 
thiopurine gecombineerd met allopurinol (LDTA) is een gunstige optimalisatiestrategie 
bij patiënten met een skewed thiopurine metabolisme, maar gegevens over voortgezette 
onderhoudsbehandeling met LDTA en het voorkomen van hernieuwde laboratoriumtoxiciteit 
zijn schaars. In hoofdstuk 4 hebben we aangetoond dat onderhoudsbehandeling met LDTA 
een veilige en gunstige optimalisatiestrategie in een cohort van 221 IBD-patiënten, waarbij 
de behandeling bij 51% van de patiënten na 5 jaar nog werd gebruikt. Daarbij zagen we dat 
de het staken van de behandeling meestal het gevolg was van onvoldoende effectiviteit van 
LDTA en niet door laboratoriumtoxiciteit toegeschreven aan LDTA. Belangrijk is dat we hebben 
aangetoond dat patiënten die vanwege bijwerkingen falen op thiopurine monotherapie het 
meeste baat hebben bij LDTA. In die groep wordt de behandeling grotendeels voortgezet 
en treedt er snel herstel op van de lever- en beenmergtoxiciteit geassocieerd met eerdere 
thiopurine monotherapie. Bovendien stopte geen van deze patiënten de behandeling vanwege 
LDTA-geassocieerde laboratoriumtoxiciteit. Gezien de gunstige effecten van allopurinol op 
het thiopurine metabolisme, therapeutische voordeel en de veiligheid op lange termijn, zou 
men kunnen stellen dat behandeling met LDTA niet beperkt zou moeten worden tot patiënten 
met een skewed metabolisme. In aanwezigheid van genetische screening voorafgaand aan 
de behandeling en / of preventieve TDM, zou LDTA mogelijk ook als eerstelijnsbehandeling 
kunnen worden beschouwd. Echter, onze voorspellingen zijn nog in afwachting van klinische 
bevestiging in de lopende multicenter gerandomiseerde gecontroleerde DECIDER-studie 
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(ACTRN12613001347752), waarin de respons en tolerantie van thiopurine monotherapie wordt 
vergeleken met LDTA in thiopurine-naïeve patiënten.
Verbeteren van thiopurine monitoring
Aangezien beenmergtoxiciteit en levertoxiciteit vaak leiden tot het staken van thiopurine 
therapie, wordt laboratoriumparameters, waaronder een volledig bloedbeeld en serum 
leverenzymtesten, frequent gecontroleerd om zo richting te geven aan eventuele 
therapiewijzigingen. Het risico op deze laboratoriumtoxiciteit is het grootste tijdens de 
eerste maanden van behandeling (inductieperiode), maar het is onduidelijk of het potentiële 
voordeel van het bepalen van deze laboratoriumparameters elke 2-3 maanden tijdens 
onderhoudsbehandeling opweegt tegen de belasting voor patiënten en de bijbehorende 
directe en indirecte zorgkosten. Hoofdstuk 5 beschrijft de incidentie en klinische gevolgen van 
beenmergtoxiciteit en levertoxiciteit binnen het huidige regime van laboratoriummonitoring 
tijdens thiopurine onderhoudstherapie ten minste 1 jaar na het starten van de behandeling 
in een cohort van 1132 IBD patiënten. Hoewel we milde beenmergtoxiciteit en levertoxiciteit 
zagen (5% en 7% resp. per behandeljaar), werd ernstige laboratoriumtoxiciteit maar 
zelden gezien (0,1%). Onze resultaten toonden aan dat laboratoriummonitoring zelden 
leidt tot aanpassingen in therapie of aanvullende diagnostische procedures zoals extra 
laboratoriumbeoordelingen. De meest relevante observatie was dat ernstige toxiciteit-
gerelateerde complicaties, zoals infecties en ziekenhuisopname, zeldzaam waren (1% 
van het totale cohort) en dat (strikte) monitoring deze complicaties niet kon voorkomen 
aangezien voorafgaande laboratoriumbeoordelingen in de meeste gevallen niet afwijkend 
waren. Aangezien de klinische impact van het detecteren van laboratoriumtoxiciteit tijdens 
onderhoudsbehandeling laag was en complicaties zeldzaam waren, is het voordeel van 
routinematige monitoring beperkt. Opvallend genoeg zagen we dat de frequentie van 
laboratoriummonitoring in ons grote real-life cohort liberaler was dan werd aanbevolen 
in de ECCO-richtlijn; met een interval van 4 maanden (onze studie) versus met een interval 
van 2-3 maanden (ECCO-richtlijn). Daarom concluderen we dat de monitoring frequentie 
van laboratoriumparameters verlaagd kan worden naar minder dan elke 4 maanden. Na de 
introductie van genetische testen voor TMPT, is het voorkomen van thiopurine geïnduceerde 
beenmergtoxiciteit verminderd.
We speculeren dat een monitoringstrategie met controle van laboratoriumparameters 
per 6 maanden voldoende is na 1 jaar thiopurine behandeling en dat dit de belasting voor 
de patiënt en de zorgkosten zal verminderen. Een prospectieve studie in een onpraktisch 
grote studiepopulatie en meerdere jaren follow-up zou vereist zijn om deze speculaties te 
bevestigen. Daarnaast is de verwachting dat het vaststellen van laboratoriumtoxiciteit zowel 
de behandeling als de monitoringfrequentie zal beïnvloeden en dat een prospectief design dit 
niet zal voorkomen en derhalve niet de vereiste gegevens op zal leveren om deze hypothese 
te testen. In deze studie zijn patiënten met thiopurine monotherapie bestudeerd, maar het 
zou ook interessant zijn om de klinische relevantie van laboratoriumtoxiciteit te bestuderen 
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in patiënten die worden met behandeld met combinatietherapie met een thiopurine en een 
biological.
Uitdagingen in adalimumab behandeling
Biologicals worden in toenemende mate toegepast in de behandeling van IBD-patiënten, 
maar de werkzaamheid en tolerantie van deze medicijnen in de dagelijkse klinische praktijk 
verschillen van de gerapporteerde cijfers uit gerandomiseerde gecontroleerde onderzoeken 
die vaak onder strikte voorwaarden zijn uitgevoerd in een geselecteerde patiëntenpopulatie. 
Om gepersonaliseerde behandeling mogelijk te maken is het noodzakelijk om factoren die 
verband kunnen houden met de effectiviteit, veiligheid en tolerantie van een behandeling 
te bestuderen in een cohort afkomstig uit de dagelijks klinische praktijk. In Hoofdstuk 6 
beschreven we een prospectieve real-life cohortstudie van 188 CD-patiënten die werden 
behandeld met de biological adalimumab (ADA) waarbij we de werkzaamheid en tolerantie 
beoordeelden. In het bijzonder hebben we ons verdiept in mogelijke sekse verschillen in de 
effectiviteit van de behandeling. Het bleek dat het vrouwelijk geslacht het behandelingssucces 
van ADA negatief beïnvloedt. Ten eerste hadden vrouwelijke patiënten minder kans op 
klinische respons of het behouden van respons dan mannelijke patiënten (31% versus 48%). 
Ten tweede rapporteerden vrouwelijke patiënten meer bijwerkingen zoals huidreacties en 
infecties en zagen we dat vrouwen vaker de behandeling stopten vanwege bijwerkingen dan 
mannen. Dit suggereert dat een gepersonaliseerde benadering van vrouwelijke patiënten 
die starten met ADA een positieve invloed zou kunnen hebben op het behandelsucces. Op 
andere gebieden binnen de geneeskunde is aangetoond dat het geslacht van de patiënt grote 
invloed kan hebben op zowel het metabolisme als de werkzaamheid van geneesmiddelen, 
ook bij behandelingen met biologicals. Hoewel het exacte mechanisme onbekend is, zouden 
onze resultaten kunnen worden verklaard door geslacht-specifieke fysiologische verschillen 
in geneesmiddelmetabolisme, lichaamssamenstelling of geslachtshormonen. Behalve 
fysiologische verklaringen, zijn er ook verschillen tussen mannen en vrouwen in de perceptie 
van bijwerkingen en de mate waarmee de toegang tot gezondheidszorg wordt gezocht. In 
een recente systematische review, uitgevoerd door Lie et al, werd geen bewijs gevonden 
voor sekseverschillen in de werkzaamheid van behandeling met biologicals wanneer werd 
gekeken naar objectieve metingen zoals uitkomsten van endoscopie. Deze bevinding wekt 
sterkt de suggestie dat het lagere succespercentage van ADA bij vrouwen grotendeels wordt 
veroorzaakt door het staken van de therapie als gevolg van bijwerkingen. Het verstrekken van 
informatie en voorlichting op maat over de mogelijke bijwerkingen zou kunnen inspelen op 
de verwachtingen van de patiënt over het medicijn en mogelijk het uitvalspercentage door 
bijwerkingen kunnen verminderen.
Cervicale neoplasie en IBD
Hoewel verschillende onderzoeken suggereren dat IBD-vrouwen een verhoogd risico 
lopen op cervicale neoplasie, dat wordt veroorzaakt door humaan papillomavirus (HPV), is 
de rol van IBD ziektekarakteristieken en gebruik van immunosuppressieve therapie in de 
pathogenese onduidelijk. Vanwege tegenstrijdig bewijs en gebrek aan longitudinale follow-
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up in de meeste onderzoeken is het onduidelijk of cervicale screening bij IBD moet worden 
geïntensiveerd. In Hoofdstuk 7 hebben we het risico op hooggradige cervicale dysplasie en 
baarmoederhalskanker (CIN2+) bestudeerd in een groot cohort met longitudinale follow-up 
waarin we IBD vrouwen hebben vergeleken met een gematcht cohort bestaande uit vrouwen 
afkomstig uit de algemene Nederlandse populatie. We ontdekten dat de mate waarin CIN2+ 
werd vastgesteld (detectiepercentage) hoger was in het IBD cohort dan in het gematchte 
controles, zelfs na correctie voor hun frequentere screeningsgedrag. Dit risico was het 
hoogst bij vrouwen in de leeftijdsgroep van 35 tot 39 jaar. Roken werd in eerdere studies 
reeds beschreven als risicofactor, en ook in onze studie was dit een sterke voorspeller voor 
CIN2+. Echter, het risico van roken op CIN2+ was hoger in IBD vrouwen dan vrouwen van de 
algemene bevolking wat een gecombineerd effect van IBD en roken zou suggereren op het 
ontwikkelen van CIN2+. Dit zou patiënten verder moeten aanmoedigen om te stoppen met 
roken. Blootstelling aan immunomodulatoren en biologicals, geanalyseerd als trichotome 
variabelen (nooit, <1 jaar blootstelling,> 1 jaar blootstelling), was niet geassocieerd met het 
ontwikkelen van CIN2+. Belangrijk is dat we aantoonden dat het risico op progressie van een 
normaal uitstrijkje naar CIN2+ verhoogd was bij IBD vrouwen, en dat IBD vrouwen ook een 
verhoogd risico liepen op aanhoudende of recidiverende CIN afwijkingen vergelijken met 
vrouwen uit het gematchte cohort. Deze bevindingen zouden kunnen worden verklaard door 
een verminderde klaring van hoog-risico HPV infecties, als gevolg van verminderde detectie 
van oncogene signalen (immunosurveillance) veroorzaakt door chronische systemische 
inflammatie. Dit wordt ondersteund door het feit dat we geen verschil in voorbijgaande 
laaggradige CIN1 afwijkingen tussen beide groepen konden vaststellen. Deze bevindingen 
benadrukken het belang van HPV-vaccinatie en deelname aan het bevolkingsonderzoek 
baarmoederhalskanker bij alle IBD-vrouwen, ongeacht het gebruik van immunosuppressieve 
medicatie. Dit wordt ondersteund door het feit dat een HPV-vaccinatie in patienten die 
immunosuppressieve medicatie gebruiken een normale immuunrespons veroorzaakt.
In Hoofdstuk 8 hebben we het effect van blootstelling aan immunosuppressiva 
(immunomodulatoren en / of biologische geneesmiddelen) en CIN 2+ ontwikkeling in het 
IBD-cohort nader onderzocht. Hoewel blootstelling aan immunosuppressiva, uitgedrukt 
als dichotome variabelen (ooit / nooit blootstelling) geen invloed leek te hebben op de 
ontwikkeling van CIN2+, toonden we aan dat het risico op CIN2+ wordt verhoogd met elk 
jaar blootstelling aan immunomodulatoren (HR 1.15 per behandeljaar) of biologicals (HR 
1.15 per behandeljaar). Om rekening te houden met het uitgestelde effect van blootstelling 
aan medicatie en het ontwikkelen van CIN2+ (latentietijd) werden de analyses herhaald met 
een vertraginsperiode van 6 en 12 maanden, echter dit gaf geen belangrijke verandering in 
resultaten. De invloed van immunosuppressieve medicatie op de ontwikkeling van CIN2+ 
zou opnieuw verklaard kunnen worden door een verminderde klaring van hrHPV-infecties 
veroorzaakt door de (iatrogeen) immuungecompromitteerde status van patiënten. Het is 
belangrijk dat artsen het belang van HPV-vaccinatie en deelname aan het bevolkingsonderzoek 
naar baarmoederhalskanker benadrukken in alle IBD-vrouwen. Deze resultaten benadrukken 
A
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dat vervolgonderzoek nodig is om te beoordelen of intensievere screening gunstig is voor IBD 
vrouwen die langdurig worden blootgesteld aan behandeling met immunosuppressiva.
Lokale behandeling van proctitis ulcerosa
Lokale behandeling verdiend de voorkeur in proctitis ulcerosa (UP), een vorm van UC waarbij 
het laatste gedeelte van de dikke darm ontstoken is, omdat er weinig systemische bijwerkingen 
zijn. Helaas is het arsenaal aan lokale therapieën beperkt en hebben patiënten met een 5-ASA-
refractaire proctitis vaak intensievere behandeling nodig met (lokale) corticosteroïden, 
immunomodulatoren of biologials die mogelijk gepaard gaan met bijwerkingen en hogere 
kosten. Vanwege veelbelovende resultaten in eerdere onderzoeken hebben we de effectiviteit 
van het medicijn tacrolimus onderzocht in zetpilvorm. Hoofdstuk 9 beschrijft deze multicenter 
dubbelblinde gerandomiseerde gecontroleerde studie in patiënten met 5-ASA refractaire UP, 
waarin de helft van de patiënten werd behandeld met tacrolimus zetpillen en de andere helft 
van de patiënten met beclometason (corticosteroïd) zetpillen, gedurende 4 weken. Uiteindelijk 
zijn 85 patiënten in de studie geïncludeerd en na 4 weken behandeling toonden tacrolimus- en 
beclomethason-zetpillen een vergelijkbare klinische respons (60%) en endoscopische respons 
(40%). Bovendien resulteerden beide behandelingen in histologische genezing van ontsteking 
en verbeterde kwaliteit van leven. In deze studie werden geen significante verschillen 
waargenomen in het aantal bijwerkingen tussen tacrolimus en beclometason behandeling. 
Onze bevindingen impliceren dat zowel tacrolimus- als beclometason zetpillen geschikt zijn 
als behandeling voor patiënten met 5-ASA refractaire UP. Adequate behandeling van UP is 
niet alleen belangrijk voor controle van symptomen en behoud van kwaliteit van leven, maar 
ook om ziekteprogressie te verminderen/voorkomen. Lokale behandeling met tacrolimus 
of beclometason zou overwogen moeten worden bij 5-ASA-refractaire UP voorafgaand aan 
step-up naar systemische behandeling met thiopurines of biologials. Voor de toekomst zou het 
interessant zijn om de effectiviteit en tolerantie van onderhoudsbehandeling met tacrolimus 
in UP in de praktijk te onderzoeken.
Aanbevelingen voor toekomstig onderzoek
Het is een uitdaging om het juiste medicijn voor de juiste patiënt te selecteren in het groeiende 
doolhof van IBD behandelingen. Adequate behandeling van IBD is essentieel om complicaties 
van de ziekte op de lange termijn te voorkomen. Ondanks aanzienlijke inspanningen is er nog 
geen behandeling die tot genezing van IBD leidt. Onderzoek naar nieuwe behandelstrategieën 
voor IBD is van belang, maar er is zeker nog ruimte voor verbetering met de huidige beschikbare 
behandelingen.
Naast het effectief behandelen van de ontstekingsreactie, dienen ook inspanningen geleverd 
te worden om de monitoring van respons en bijwerkingen te verbeteren en adequate 
optimalisatiestrategieën toe te passen om therapie falen te voorkomen en zo de klinische 
uitkomsten te verbeteren.
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Vroege (preventieve) TDM-geleide thiopurinetherapie lijkt veelbelovend om falen van 
thiopurine therapie te voorkomen en toekomstige prospectieve studies zouden zich moeten 
richten op de (lange termijn) effectiviteit, toxiciteit en kosteneffectiviteit van deze strategie, 
al dan niet gecombineerd met genetische testen voorafgaand aan de behandeling. Idealiter 
wordt volledige genotypering van alle patiënten verricht voorafgaand aan behandeling met 
thiopurines om zo genetische variaties aan het licht te brengen die het metabolisme van 
thiopurine beïnvloeden. Op deze manier zou uiteindelijk voorkomen kunnen worden dat 
patiënten worden blootgesteld aan geneesmiddelen die niet effectief of schadelijk voor hen 
zijn vanwege ernstige toxiciteit en daarom baat zouden hebben bij alternatieve therapieën. 
Aangezien TDM in wezen het effect van alle genetische variaties en inadequate dosering 
omvat, is het de vraag of uitgebreid farmacogenetische testen voorafgaand aan behandeling 
uiteindelijk zal voorkomen dat patiënten nog routinematige monitoring voor toxiciteit moeten 
ondergaan.
Er wordt een vergelijkbaar voordeel gezien van optimalisatiestrategieën met LDTA en TG bij 
patiënten bij wie conventionele thiopurines falen. Vanwege hun gunstige eigenschappen op 
het thiopurine metabolisme zou de werkzaamheid van eerstelijnsbehandeling met LDTA of 
TG verder moeten worden bestudeerd, bij voorkeur in een head-to-head trial.
Een ander aspect om te onderzoeken zijn thiopurine-analogen die zich specifiek richten 
op de Rac1-signaleringsroute om T-cel apopotose te stimuleren waarbij de enzymatische 
routes geassocieerd met toxiciteit worden omzeilt. Geoptimaliseerde immunosuppressieve 
medicijnen kunnen relevante therapeutische implicaties bieden indien dit wordt bevestigd in 
klinische onderzoeken. Hoewel de overgrote meerderheid van nieuwe immunosuppressieve 
medicijnen systemische therapieën zijn, blijven lokale therapieën onderontwikkeld. Om 
gepersonaliseerde behandeling mogelijk te maken voor patiënten met distale vormen van 
IBD, is het aanbevolen om ook (nieuwe) lokale therapieën te onderzoeken.
Bij (ernstig) actieve IBD wegen de risico’s van medische behandeling over het algemeen 
op tegen mogelijke ziekte-gerelateerde complicaties, maar de risico’s van langdurige 
immunosuppressieve behandeling mogen niet naar de achtergrond verdwijnen. Aangezien 
cervicale neoplasie bij IBD-vrouwen toeneemt, moeten toekomstige studies gericht zijn op 
het onderzoeken van de persistentie van hrHPV infecties en de rol bij cervicale carcinogenese. 
Dit zou kunnen leiden tot strategieën waarbij het gebruik van immunosuppressieve medicatie 
(tijdelijke) wordt verminderd om zodat het virus geklaard kan worden en de cervicale 
carcinogenese wellicht te onderbreken of zelfs om te keren, voordat de laesies niet meer 
reversibel zijn. Naast baarmoederhalskanker zijn oncogene HPV-infecties ook geassocieerd 
met hoofd-, nek- en anogenitale kankers. De huidige schattingen geven aan dat 5,2% van alle 
kankers HPV-geassocieerd zijn, en het risico op HPV-infectie gelijk is voor mannen en vrouwen. 
Derhalve zouden toekomstige studies ook de impact van immunosuppressieve blootstelling 
bij andere HPV-gerelateerde kankers en de werkzaamheid van HPV-vaccinatie bij mannelijke 
IBD patiënten moeten onderzoeken.
A
binnenwerk_joany.indd   221 7-12-2020   13:27:43
222 |
Appendices
Een belangrijke stap in de vertaling van onze resultaten naar de klinische praktijk is de 
ontwikkeling van een ‘voorspellingstool’ die gepersonaliseerde behandeling mogelijk 
maakt. Vanwege de complexiteit van IBD zijn er verschillende factoren die de ontwikkeling 
van een gepersonaliseerde behandelstrategie belemmeren. Het is onwaarschijnlijk dat 
gerandomiseerde studies het bewijs zullen leveren voor een dergelijke strategie, aangezien 
deze onderzoeken strikte in- en exclusiecriteria voor patiënten hanteren en daarmee niet de 
klinische praktijk vertegenwoordigen. Het consistent verzamelen van longitudinale klinische 
gegevens en biomaterialen in landelijke databases, waaronder de Nederlandse IBD biobank 
(PSI) zoals beschreven in dit proefschrift, zou de ontwikkeling van een therapeutische strategie 
voor de individuele IBD-patiënt mogelijk kunnen maken. Toekomstig onderzoek zou de verdere 
ontwikkeling van gepersonaliseerde behandelstrategieën moeten onderzoeken, bij voorkeur 
in het kader van internationale samenwerking. Een veelbelovend nieuw onderzoeksgebied om 
complexe klinische gegevens te analyseren in combinatie met gegevens van biomaterialen is 
dynamische systeemanalyse, waarmee ‘realtime’ geïndividualiseerde voorspelling van ziekte 
en behandelingsresultaten mogelijk is.
Conclusies
IBD blijft een complexe ziekte met een grote interindividuele variantie in ziektegedrag en 
behandelingsrespons. Dit proefschrift draagt bij aan de huidige inzichten op het gebied van 
immunosuppressieve behandeling en biedt het verschillende mogelijkheden om IBD zorg te 
verbeteren. Het combineren van deze bevindingen met klinische gegevens en biomaterialen 
zou kunnen leiden tot de ontwikkeling van meer op maat gemaakte behandelstrategieën en 
zal hopelijk in de nabije toekomst ook realiteit worden.
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5-ASA  5-aminosalicylic acid
6-MP  6-mercaptopurine
6-MMPR  6-methylmercaptopurine ribonucleotides
6-TG  6-thioguanine
6-TGN  6-thio guanine nucleotides
6-TGTP  6-thioguanosine 5’ triphosphate
ADA  adalimumab
AE  adverse event
ALT  alanine aminotransferase
AST  aspartate aminotransferase
AP  alkaline phosphatase
AZA  azathioprine
BIO  biologics
BMI  body mass index
CD  Crohn’s disease
CDAI  Crohn’s disease activity index
CI  confidence interval
CIN  cervical intraepithelial neoplasia
CRP  C-reactive protein
CRC  colorectal cancer
CTCAE  Common Terminology Criteria for Adverse Events
CYP  cytochrome P450
FBC  full blood count
γ-GT  gamma-glutamyltransferase
Hb  haemoglobin
HR  hazard ratio
HGPRT  hypoxantine-guanine phosphoribosyl transferase
HPV  human papillomavirus
hrHPV  high-risk types of human papillomavirus
IBD  inflammatory bowel disease
IBDI  inflammatory bowel disease indeterminate
IBDQ  inflammatory bowel disease questionnaire
IBDU  inflammatory bowel disease unclassified
IRR  incidence rate ratios
IQR  interquartile range
LDTA  low dose thiopurine allopurinol combination therapy
LTs  liver tests
MCV  mean corpuscular volume
IM  immunomodulators
IS  immunosuppressive drugs




MRCP  magnetic resonance cholangio- pancreatography
MRI  magnetic resonance imaging
N  number
OR  odds ratios
PC  platelet count
PSI  Parelsnoer Insitute, Dutch IBD biobank
RBC  red blood cells
RCT  randomized controlled trial
SC  subcutaneously
SD  standard deviation
SDR  standardized detection rates
TDM  therapeutic drug monitoring
TNF-a  tumor necrosis factor alpha
TPMT  thiopurine S-methyltransferase
TG  tioguanine
UC  ulcerative colitis
ULN  upper limit of normal
UP  ulcerative proctitis
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